
<html lang="en"     class="pb-page"  data-request-id="4fa4a6a7-40f0-469a-bdec-64d2c65e29f2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01625"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema" /></meta><meta name="dc.Creator" content="Daniel&#xA;P.  Teufel" /></meta><meta name="dc.Creator" content="Gavin  Bennett" /></meta><meta name="dc.Creator" content="Helen  Harrison" /></meta><meta name="dc.Creator" content="Katerine  van Rietschoten" /></meta><meta name="dc.Creator" content="Silvia  Pavan" /></meta><meta name="dc.Creator" content="Catherine  Stace" /></meta><meta name="dc.Creator" content="François  Le Floch" /></meta><meta name="dc.Creator" content="Tine  Van Bergen" /></meta><meta name="dc.Creator" content="Elke  Vermassen" /></meta><meta name="dc.Creator" content="Philippe  Barbeaux" /></meta><meta name="dc.Creator" content="Tjing-Tjing  Hu" /></meta><meta name="dc.Creator" content="Jean H. M.  Feyen" /></meta><meta name="dc.Creator" content="Marc  Vanhove" /></meta><meta name="dc.Description" content="Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Precl..." /></meta><meta name="Description" content="Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Precl..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 8, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01625" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01625" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01625" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01625" /></link>
        
    
    

<title>Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01625" /></meta><meta property="og:title" content="Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0009.jpeg" /></meta><meta property="og:description" content="Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Preclinical evidence implicates the activity of plasma kallikrein in diabetic retinopathy, which is a leading cause of visual loss in patients suffering from diabetes mellitus. Employing a technology based on phage-display combined with chemical cyclization, we have identified highly selective bicyclic peptide inhibitors with nano- and picomolar potencies toward plasma kallikrein. Stability in biological matrices was either intrinsic to the peptide or engineered via the introduction of non-natural amino acids and nonpeptidic bonds. The peptides prevented bradykinin release in vitro, and in vivo efficacy was demonstrated in both a rat paw edema model and in rodent models of diabetes-induced retinal permeability. With a highly extended half-life of ∼40 h in rabbit eyes following intravitreal administration, the bicyclic peptides are promising novel agents for the treatment of diabetic retinopathy and diabetic macular edema." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01625"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01625">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01625&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01625&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01625&amp;href=/doi/10.1021/acs.jmedchem.7b01625" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2823-2836</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01622" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01682" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Daniel P. Teufel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel P. Teufel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel%0AP.++Teufel">Daniel P. Teufel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gavin Bennett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gavin Bennett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gavin++Bennett">Gavin Bennett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Helen Harrison</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Helen Harrison</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Harrison">Helen Harrison</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katerine van Rietschoten</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katerine van Rietschoten</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katerine++van+Rietschoten">Katerine van Rietschoten</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Silvia Pavan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Silvia Pavan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Pavan">Silvia Pavan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine Stace</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine Stace</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bicycle Therapeutics Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Stace">Catherine Stace</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">François Le Floch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">François Le Floch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fran%C3%A7ois++Le+Floch">François Le Floch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tine Van Bergen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tine Van Bergen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tine++Van+Bergen">Tine Van Bergen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elke Vermassen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elke Vermassen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elke++Vermassen">Elke Vermassen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philippe Barbeaux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philippe Barbeaux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Barbeaux">Philippe Barbeaux</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tjing-Tjing Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tjing-Tjing Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tjing-Tjing++Hu">Tjing-Tjing Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean H. M. Feyen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean H. M. Feyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +32 16 751 340. E-mail: <a href="/cdn-cgi/l/email-protection#3f555a5e5111595a465a517f4b574d50525d50585a51565c4c115c5052"><span class="__cf_email__" data-cfemail="fc96999d92d29a99859992bc88948e93919e939b9992959f8fd29f9391">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean+H.+M.++Feyen">Jean H. M. Feyen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marc Vanhove</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marc Vanhove</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Thrombogenics N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marc++Vanhove">Marc Vanhove</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4144-7688" title="Orcid link">http://orcid.org/0000-0003-4144-7688</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01625&amp;href=/doi/10.1021%2Facs.jmedchem.7b01625" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2823–2836</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 8, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 November 2017</li><li><span class="item_label"><b>Published</b> online</span>8 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 April 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01625" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01625</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2823%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDaniel%250AP.%2BTeufel%252C%2BGavin%2BBennett%252C%2BHelen%2BHarrison%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D7%26contentID%3Dacs.jmedchem.7b01625%26title%3DStable%2Band%2BLong-Lasting%252C%2BNovel%2BBicyclic%2BPeptide%2BPlasma%2BKallikrein%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BDiabetic%2BMacular%2BEdema%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2836%26publicationDate%3DApril%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01625"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2022</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">17</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01625" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Daniel\nP.&quot;,&quot;last_name&quot;:&quot;Teufel&quot;},{&quot;first_name&quot;:&quot;Gavin&quot;,&quot;last_name&quot;:&quot;Bennett&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Harrison&quot;},{&quot;first_name&quot;:&quot;Katerine&quot;,&quot;last_name&quot;:&quot;van Rietschoten&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Pavan&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Stace&quot;},{&quot;first_name&quot;:&quot;François&quot;,&quot;last_name&quot;:&quot;Le Floch&quot;},{&quot;first_name&quot;:&quot;Tine&quot;,&quot;last_name&quot;:&quot;Van Bergen&quot;},{&quot;first_name&quot;:&quot;Elke&quot;,&quot;last_name&quot;:&quot;Vermassen&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Barbeaux&quot;},{&quot;first_name&quot;:&quot;Tjing-Tjing&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Jean&quot;,&quot;last_name&quot;:&quot;H. M. Feyen&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;Vanhove&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2823-2836&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01625&quot;},&quot;abstract&quot;:&quot;Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Preclinical evidence implicates the activity of plasma kallikrein in diabetic retinopathy, which is a leading cause of visual loss in patients suffering from diabetes mellitus. Employing a technology based on phage-display combined with chemical cyclization, we have identified highly selective bicyclic peptide inhibitors with nano- and picomolar potencies toward plasma kallikrein. Stability in biological matrices was either intrinsic to the peptide or engineered via the introduction of non-natural amino acids and nonpeptidic bonds. The peptides prevented bradykinin release in vitro, and in vivo efficacy was demonstrated in both a rat paw edema model and in rodent models of diabetes-induced retinal permeability. With a highly extended half-life of ∼40 h in rabbit eyes following intravitreal administration, the bicyclic pe&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01625&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01625" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01625&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01625" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01625&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01625" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01625&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01625&amp;href=/doi/10.1021/acs.jmedchem.7b01625" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01625" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01625" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01625%26sid%3Dliteratum%253Aachs%26pmid%3D29517911%26genre%3Darticle%26aulast%3DTeufel%26date%3D2018%26atitle%3DStable%2Band%2BLong-Lasting%252C%2BNovel%2BBicyclic%2BPeptide%2BPlasma%2BKallikrein%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BDiabetic%2BMacular%2BEdema%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D7%26spage%3D2823%26epage%3D2836%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/jmcmar.2018.61.issue-7/20180412/jmcmar.2018.61.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Plasma kallikrein, a member of the kallikrein-kinin system, catalyzes the release of the bioactive peptide bradykinin, which induces inflammation, vasodilation, vessel permeability, and pain. Preclinical evidence implicates the activity of plasma kallikrein in diabetic retinopathy, which is a leading cause of visual loss in patients suffering from diabetes mellitus. Employing a technology based on phage-display combined with chemical cyclization, we have identified highly selective bicyclic peptide inhibitors with nano- and picomolar potencies toward plasma kallikrein. Stability in biological matrices was either intrinsic to the peptide or engineered via the introduction of non-natural amino acids and nonpeptidic bonds. The peptides prevented bradykinin release <i>in vitro</i>, and <i>in vivo</i> efficacy was demonstrated in both a rat paw edema model and in rodent models of diabetes-induced retinal permeability. With a highly extended half-life of ∼40 h in rabbit eyes following intravitreal administration, the bicyclic peptides are promising novel agents for the treatment of diabetic retinopathy and diabetic macular edema.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Plasma kallikrein (PKal) is a serine protease present in blood plasma at a relatively high concentration (30–50 μg/mL)<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> in the form of the inactive zymogen prekallikrein. PKal is positioned at the interface between the contact activation system (CAS) and the kallikrein-kinin system (KKS). Within the CAS, PKal is involved in a reciprocal activation loop with the coagulation factor XII (Factor XII) leading to activation of the coagulation factor XI (Factor XI) and eventually activation of the intrinsic blood coagulation pathway. Within the KKS, PKal activity releases the nonapeptide bradykinin (BK) from the high molecular weight kininogen (HMWK). BK then signals through the constitutive bradykinin B2 G-protein-coupled receptor and, via its des-Arg<sub>9</sub> metabolite, through the inducible bradykinin B1 G-protein-coupled receptor, leading to the production of mediators of inflammation, angiogenesis, vasodilation, increased vessel permeability, and pain.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Unlike in the CAS, where conversion of the inactive zymogen prekallikrein into active PKal is mediated by Factor XIIa, conversion of the zymogen in the KKS system can occur both in a Factor XIIa-dependent and -independent manner.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><div class="NLM_p"><i>In vivo,</i> active PKal is mostly controlled by the serpin family derived C1 inhibitor (C1-INH), whose genetic deficiency or dysfunction causes hereditary angioedema (HAE). HAE is a rare, autosomal dominant disorder that clinically manifests as episodic attacks of subcutaneous or mucosal edema of the face, upper respiratory and gastrointestinal tracts, limbs, or genitalia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therapies to treat and prevent HAE attacks include treatment with plasma-derived or recombinant C1-INH, the PKal inhibitor drug Ecallantide, or the B2 receptor antagonist Icatibant.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a></div><div class="NLM_p">Diabetic retinopathy (DR) is one of the most prevalent complications of diabetes mellitus and a leading cause of vision loss in industrialized countries.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> Clinical manifestations of DR represent different stages that can be classified as nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). Diabetic macular edema (DME) represents the major cause of moderate to severe visual loss in NPDR or PDR.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It is estimated that the population of diabetic patients worldwide will grow from 285 million in 2010 to 439 million by 2030, and the DR patient population is expected to grow in parallel.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> By 2030, the number of DR patients and of patients with vision-threatening DR has been projected to rise to 191 million and 56.3 million, respectively.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Current treatments for DR or DME include laser photocoagulation, steroidal or nonsteroidal anti-inflammatory drugs, anti-VEGF agents, and vitrectomy.<a onclick="showRef(event, 'ref14 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref17">(14,17)</a></div><div class="NLM_p">More recently, experimental and clinical data have also implicated the KKS in DR development.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> For example, the level of components of the KKS system, including PKal, was shown to be increased both in diabetic animal models and in the vitreous of diabetic patients.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22">(19−22)</a> Furthermore, both PKal and BK have been reported to induce retinal vascular permeability (RVP) in animal models,<a onclick="showRef(event, 'ref19 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref23">(19,23)</a> while inhibition by either PKal inhibitors or B1/B2 receptors antagonists improved diabetes-induced retinal dysfunction in rat models.<a onclick="showRef(event, 'ref19 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref19 ref23 ref24 ref25">(19,23−25)</a> Finally, RVP in diabetic, PKal knockout mice was observed to be reduced compared to diabetic wild-type animals.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This prompted the investigation of alternative therapeutic approaches, one of which is using direct PKal inhibition with the small molecule inhibitor KVD001 (Kalvista Pharmaceuticals), which has completed its first-in-human study in patients with DME and is being prepared for Phase 2.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">In light of the strong evidence for the involvement of PKal in the development of DR and DME, we sought to develop new therapeutic modalities for its effective treatment. Here, we describe the identification, molecular optimization, and <i>in vitro/in vivo</i> characterization of a series of highly potent, stable, and long-lasting PKal inhibitory bicyclic peptides. Bicyclic peptides (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) are more constrained than either conventional linear or monocyclic peptides, allowing them to exhibit properties (e.g., affinity and target specificity) that are more generally associated with antibodies.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> PKal inhibitory activity of these peptides was demonstrated in a variety of <i>in vitro</i> assays and in a variety of biological matrices, and <i>in vivo</i> efficacy was demonstrated in both a rat paw edema model and in rodent models of diabetes-induced retinal permeability. The data presented here demonstrate that bicyclic constrained peptides act as potent and highly specific PKal inhibitors with therapeutic potential to targeting plasma kallikrein-mediated conditions of edema.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of bicyclic peptides. (A) Canonical structure of bicyclic peptides containing 5 AA in each loop (5 × 5). Any loop format is possible, referred to in text as 6 × 6 and 5 × 6 bicyclic peptides. Cysteine residues and the 1,3,5-trismethylbenzene scaffold are indicated in red. Loop 1 is located between Cys<sub>i</sub> and Cys<sub>ii</sub>, Loop 2 is located between Cys<sub>ii</sub> and Cys<sub>iii</sub>. Residue numbering begins following the N-terminal first Cys<sub>i</sub>. (B) Rat and human plasma protease activity on <b>2b</b>. Rat and human cleavage sites and successive excision of peptide segments are indicated in blue and green, respectively. (C) Chemical structure of <b>2d</b>. The central scaffold is shown in red, with non-natural modifications (Aze, HArg, pseudopeptide bond) indicated in blue. All amino acids are in their <span class="smallcaps smallerCapital">l</span>-configuration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Discovery of Anti-plasma Kallikrein Bicyclic Peptides by Phage Display and Chemical Optimization</h3><div class="NLM_p">Bicyclic peptides consist of a peptide sequence containing 3 cysteine residues, which are covalently linked to a thiol-reactive molecular scaffold. A number of thiol-reactive scaffolds are available,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and in this instance, we chose 1,3,5-tris(bromomethyl)benzene (TBMB) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Using large phage libraries of linear peptides containing 3 invariant cysteines that are cyclized <i>in situ</i> to form thioether-bonded bicyclic peptide libraries, selections and subsequent affinity maturation selections were performed against PKal using methodology described previously.<a onclick="showRef(event, 'ref26 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref29">(26,29)</a> Rat and human PKal orthologous enzymes were alternated as baits during each selection round in order to identify bicyclic peptides with good cross-reactivity that would facilitate their study in preclinical animal models.</div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> Bicyclic Peptide <b>1b</b></h4><div class="NLM_p">A promising sequence output was peptide <b>1a</b>, of sequence AC<sub>i</sub>NTWNPWC<sub>ii</sub>PWDAPLC<sub>iii</sub>A. Using enzyme inhibition assays, this peptide showed strong inhibitory activity to both human and rat PKal (<i>K</i><sub>i</sub> = 2.3 ± 2.7 and 0.40 ± 0.24 nM, respectively). Qualitative stability assessment using a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) assay in rat plasma revealed rapid removal of the N/C-terminal alanine residues which are situated outside the loop structures. Furthermore, the peptide displayed poor solubility in aqueous buffers, and consequently a derivative, termed <b>1b</b>, was synthesized that replaced the N-terminal Ala with an acetyl group and that contained a C-terminal extension following the C-terminal alanine composed of 3 sarcosines and 2 <span class="smallcaps smallerCapital">d</span>-arginine residues (sequence Ac-C<sub>i</sub>NTWNPWC<sub>ii</sub>PWDAPLC<sub>iii</sub>A-Sar<sub>3</sub>-[<span class="smallcaps smallerCapital">d</span>-Arg]<sub>2</sub>). The former is a benign molecular spacer with good aqueous solubility properties,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and the latter imparts higher aqueous solubility to the molecule due to the strongly ionic, water-complexing nature of the guanidinyl groups at physiological pH. <span class="smallcaps smallerCapital">d</span>-Arginine residues were chosen rather than <span class="smallcaps smallerCapital">l</span>-arginine residues to render these amino acids (AA) resistant to proteolytic removal.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p"><b>1b</b> showed adequate solubility in aqueous buffers and retained overall potency and good cross-reactivity to both rat and human PKal (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Furthermore, the peptide was stable in blood plasma derived from three species (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), with no measurable degradation occurring over 24 h.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>K</i><sub>i</sub> Values (nM) against PKal from Various Species<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PKal species</th><th class="colsep0 rowsep0" align="center"><b>1b</b></th><th class="colsep0 rowsep0" align="center"><b>2b</b></th><th class="colsep0 rowsep0" align="center"><b>2c</b></th><th class="colsep0 rowsep0" align="center"><b>2d</b></th><th class="colsep0 rowsep0" align="center"><b>4b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="center">3.0 ± 0.3</td><td class="colsep0 rowsep0" align="center">0.15 ± 0.18</td><td class="colsep0 rowsep0" align="center">0.39 ± 0.17</td><td class="colsep0 rowsep0" align="center">0.36 ± 0.07</td><td class="colsep0 rowsep0" align="center">0.25 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus</td><td class="colsep0 rowsep0" align="center">3.1 ± 0.1</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">2.7 ± 0.5</td><td class="colsep0 rowsep0" align="center">0.86 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="center">54 ± 4</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">120 ± 20</td><td class="colsep0 rowsep0" align="center">45 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">3.4 ± 1.1</td><td class="colsep0 rowsep0" align="center">2.0 ± 0.9</td><td class="colsep0 rowsep0" align="center">11 ± 4</td><td class="colsep0 rowsep0" align="center">30 ± 9</td><td class="colsep0 rowsep0" align="center">5.5 ± 3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rabbit</td><td class="colsep0 rowsep0" align="center">∼1,450</td><td class="colsep0 rowsep0" align="center">10 ± 2</td><td class="colsep0 rowsep0" align="center">84 ± 24</td><td class="colsep0 rowsep0" align="center">3,400 ± 200</td><td class="colsep0 rowsep0" align="center">∼2,650</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pig</td><td class="colsep0 rowsep0" align="center">410 ± 30</td><td class="colsep0 rowsep0" align="center">3.6 ± 0.6</td><td class="colsep0 rowsep0" align="center">22 ± 3</td><td class="colsep0 rowsep0" align="center">510 ± 60</td><td class="colsep0 rowsep0" align="center">300 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">500 ± 90</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">80 ± 10</td><td class="colsep0 rowsep0" align="center">22 ± 3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">n.d. not determined. Errors are expressed as standard deviation.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Stability (Expressed As Half-Life) of Bicyclic Peptides in Vitreous Humor and Plasma</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">matrix</th><th class="colsep0 rowsep0" align="center"><b>1b</b></th><th class="colsep0 rowsep0" align="center"><b>2d</b></th><th class="colsep0 rowsep0" align="center"><b>2b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">vitreous</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">>24 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">1.5 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">2.8 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">>24 h</td><td class="colsep0 rowsep0" align="left">7 h</td></tr></tbody></table></div></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> <b>2b</b> and Chemically Optimized <b>2d</b></h4><div class="NLM_p">Using 5 × 5 phage libraries, one of the sequence outputs termed <b>2a</b> (sequence: AC<sub>i</sub>SWPARC<sub>ii</sub>LHQDLC<sub>iii</sub>A) showed high potency to human and rat PKal (<i>K</i><sub>i</sub> = 0.07 ± 0.02 and 0.90 ± 0.33 nM, respectively). A variant was synthesized lacking the protease labile terminal alanine residues (<b>2b</b>, sequence Acetyl-C<sub>i</sub>S<sub>1</sub>W<sub>2</sub>P<sub>3</sub>A<sub>4</sub>R<sub>5</sub>C<sub>ii</sub>L<sub>6</sub>H<sub>7</sub>Q<sub>8</sub>D<sub>9</sub>L<sub>10</sub>C<sub>iii</sub>), and its potency toward both rat and human PKal was retained (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, the plasma stability of <b>2b</b> was poor, with a half-life of 1.5 h, 2.8 h, and 7 h in mouse, rat, and human plasma, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). MALDI-TOF analysis of the peptide exposed to rat plasma revealed endoproteolytic loop opening and exoproteolytic removal of Arg<sub>5</sub> in Loop 1, followed by removal of all residues in Loop 1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). By contrast, exposure to human plasma revealed Loop 2 opening followed by removal of 3 fragments (L<sub>6</sub>H<sub>7</sub>Q<sub>8</sub>, H<sub>7</sub>Q<sub>8</sub>, L<sub>6</sub>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The initial endoproteolytic event appeared to occur on the N- or C-terminal side of His<sub>7</sub>. Thus, <b>2b</b> appears to contain two sites (Arg<sub>5</sub> and His<sub>7</sub>) that render the molecule sensitive to proteolytic attack by rat and human plasma proteases (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), respectively, with the consequence that this molecule is likely not sufficiently stable for <i>in vivo</i> studies.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Degradation of bicyclic peptide <b>2b</b> in plasma. (A) MALDI-TOF derived ion chromatograms of <b>2b</b> exposed to rat plasma. Removal of Arg<sub>5</sub> in Loop 1 is observed, with larger fragments being excised subsequently. Note the low signal for intact parent peptide following 18 h of incubation. (B) MALDI-TOF derived ion chromatograms of <b>2b</b> exposed to human plasma. Removal of 3 fragments in Loop 2 is observed, centering on His<sub>7</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We undertook a campaign of chemical derivatization of <b>2b</b> to identify variants with enhanced stability toward plasma proteases, while maintaining the potency and specificity profile. Structure activity relationships were assessed by performing partial alanine and <span class="smallcaps smallerCapital">d</span>-AA scans in each loop to assess the energetic role of each AA side chain in binding, and to assess the steric requirement of side chain projection on binding, respectively. Furthermore, the derivatives were assessed for changes in proteolytic cleavage patterns in rat/human plasma using MALDI-TOF.</div><div class="NLM_p">In Loop 1, <span class="smallcaps smallerCapital">d</span>-amino acid replacement reduced affinities to 50 nM and beyond. However, it is of interest that <span class="smallcaps smallerCapital">d</span>-AA replacement at positions 4 and 5 markedly reduced Loop1 degradation by rat plasma, in that no des-Arg fragments could be detected. Consequently, a variety of arginine isosteres were tested at position 5 in Loop 1 (including citrulline, α-<i>N</i>-methyl arginine, 4-guanidino-phenylalanine, Arg side chain length variants homoarginine (C4), beta-homoarginine, and the shorter side chain derivatives 2-amino-4-guanidinobutyric (C2) and 2-amino-3-guanidinopropionic acid (C1)). Strikingly, all isosteres reduced Loop 1 degradation by rat plasma. Homoarginine at position 5 (HArg<sub>5</sub>) and α-<i>N</i>-methyl Arg<sub>5</sub> derivatives retained potencies at 2.1 and 3.5 nM (however still 10–20-fold lower than the parent molecule, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Summary of Chemical Modifications and Comparative <i>K</i><sub>i</sub> Values (nM) for Human PKal during the Optimization Campaign of <b>2b</b> To Produce the Highly Stabilized Derivative <b>2d</b><a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">family</th><th class="colsep0 rowsep0" align="center">substitutions</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center">protection of Loop 1 and/or Loop 2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="left">parent compound, no modifications</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.18</td><td class="colsep0 rowsep0" align="left">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Arg<sub>5</sub> → HArg<sub>5</sub></td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 2.6</td><td class="colsep0 rowsep0" align="left">Loop 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Pro<sub>3</sub> → Aze<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.01</td><td class="colsep0 rowsep0" align="left">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Pro<sub>3</sub> → Aze<sub>3</sub>, Arg<sub>5</sub> → HArg<sub>5</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.02</td><td class="colsep0 rowsep0" align="left">Loop 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="left">Trp<sub>2</sub> → Phe<sub>2</sub>, Ala<sub>4</sub> → Tyr<sub>4</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.39 ± 0.17</td><td class="colsep0 rowsep0" align="left">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp<sub>2</sub> → Phe<sub>2</sub>, Pro<sub>3</sub> → Aze<sub>3</sub>, Ala<sub>4</sub> → Tyr<sub>4</sub>, Arg<sub>5</sub> → HArg<sub>5</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.15</td><td class="colsep0 rowsep0" align="left">Loop 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Trp<sub>2</sub> → Phe<sub>2</sub>, Ala<sub>4</sub> → Tyr<sub>4</sub>, Leu<sub>6</sub> → Ala(ψCH<sub>2</sub>NH)<sub>6</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">Loop 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">Trp<sub>2</sub> → Phe<sub>2</sub>, Pro<sub>3</sub> → Aze<sub>3</sub>, Ala<sub>4</sub> → Tyr<sub>4</sub>, Arg<sub>5</sub> → HArg<sub>5</sub>, Leu<sub>6</sub> → Ala(ψCH<sub>2</sub>NH)<sub>6</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.07</td><td class="colsep0 rowsep0" align="left">Loop 1 and Loop 2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Errors are expressed as standard deviation.</p></div></div></div><div class="NLM_p">Further isostere substitution was conducted at proline 3. Proline is a secondary AA, containing the alpha nitrogen within a 5-membered ring structure. The isosteres azetidine-carboxylic acid (4-membered ring, Aze) and pipecolic acid (6-membered ring structure, Pip) were incorporated and tested for potency. Unexpectedly, replacement with Aze increased the potency to <i>K</i><sub>i</sub> = 0.06 nM (compared to 0.15 nM for parent), while Pip lowered the potency slightly (<i>K</i><sub>i</sub> = 0.26 nM). The fragmentation of Loop 1 in the presence of rat plasma remained unchanged. Taking the two modifications together, i.e. the affinity enhancing Pro<sub>3</sub> → Aze<sub>3</sub> and stability enhancing Arg<sub>5</sub> → HArg<sub>5</sub> replacements, produced a bicyclic peptide with fully retained potency to human PKal at <i>K</i><sub>i</sub> = 0.14 nM (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and with enhanced stability of Loop 1 in rat plasma.</div><div class="NLM_p">Next, we returned to a derivative of <b>2b</b> containing two changes (W<sub>2</sub> → F<sub>2</sub> and A<sub>4</sub>→ Y<sub>4</sub>, termed <b>2c</b>, of sequence Ac-C<sub>i</sub>S<sub>1</sub>F<sub>2</sub>P<sub>3</sub>Y<sub>4</sub>R<sub>5</sub>C<sub>ii</sub>L<sub>6</sub>H<sub>7</sub>Q<sub>8</sub>D<sub>9</sub>L<sub>10</sub>C<sub>iii</sub>). This sequence, which was derived from phage selections, was of interest due to the replacement of the oxidation-liable Trp<sub>2</sub> with tyrosine. The affinity of this derivative was virtually unchanged, and likewise, incorporating Pro<sub>3</sub> → Aze<sub>3</sub> and Arg<sub>5</sub> → HArg<sub>5</sub> substitutions yielded a fully potent, but Loop 1-stabilized, tryptophan-deficient Bicycle (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p last">Finally, efforts focused on the stabilization of Loop 2, where His<sub>7</sub> is the recognition point for human plasma proteases. The alanine scan in Loop 2 (using <b>2c</b>) did not dramatically lower potencies, with <i>K</i><sub>i</sub>’s not increasing beyond 23.4 nM for H<sub>7</sub> → A<sub>7</sub>. Interestingly, removal of the His<sub>7</sub> side chain reduced Loop 2 degradation in human plasma, confirming the role of this residue in providing a recognition point for human plasma proteases. Both <span class="smallcaps smallerCapital">d</span>-AA and <span class="smallcaps smallerCapital">d</span>-alanine replacement in Loop 2 at or near His<sub>7</sub> produced peptide derivatives with enhanced stability, however at the cost of markedly reduced affinity (data not shown). A range of histidine isosteres, probing requirement of charge, molecular shape, and/or aromaticity of the histidine side chain, invariably produced molecules with lower potency. Consequently, we investigated whether AA backbone changes, which potentially render the molecule stable to proteolytic hydrolysis, were tolerated. α-<i>N</i>-Methylation of Leu<sub>6</sub>, His<sub>7</sub>, or Gln<sub>8</sub>, rendered the molecule stable to human plasma, but <i>K</i><sub>i</sub>’s were >50 nM. In an attempt to modify the peptide backbone itself, a reduced form of the peptide bond was introduced between Leu<sub>6</sub> and His<sub>7</sub>. Here, Leu<sub>6</sub> was replaced by Ala<sub>6</sub>, and the carbonyl on this residue was reduced to methylene, yielding a pseudo peptide bond (ψCH<sub>2</sub>–NH versus CO-NH). Due to the absence of the hydrolyzable peptide bond, the peptide was stable in human plasma as Loop 2 fragmentation could not be observed, and potency was high (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Introduction of Ala(ψCH<sub>2</sub>–NH)<sub>6</sub> in the context of the previously described stability and potency-enhancing modifications in Loop 1 (Phe<sub>2</sub>, Aze<sub>3</sub>, Tyr<sub>4</sub>, HArg<sub>5</sub>) produced a candidate molecule (<b>2d,</b><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) which showed, using quantitative stability measurement in human, rat, or mouse plasma, no measurable degradation (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf" class="ext-link">Supporting Information Figure 1 and Table 1</a>). With a potency of 0.36 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), <b>2d</b> presents an attractive molecule for further study and demonstrates a stark improvement over the original parent compound <b>2b</b> in terms of stability.</div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Bicyclic Peptide <b>4b</b></h4><div class="NLM_p last">Phage selections further identified a 6 × 6 peptide of sequence AC<sub>i</sub>NN<u class="uu">FPFR</u>C<sub>ii</sub>VYYPDIC<sub>iii</sub>A (termed <b>3</b>) that had a high potency (<i>K</i><sub>i</sub> = 0.44 ± 0.07 nM) to human PKal. Of note, this peptide comprises the FPFR motif in Loop 1, which is similar to the WPAR and FPYR motif described previously for the peptide <b>2</b> family. Importantly, the equivalent His<sub>7</sub> proteolytic recognition site in Loop 2 is absent, rendering this loop potentially stable without chemical modification. Given the similarity of Loop 1 of <b>3</b> with Loop 1 of the peptide <b>2</b> family, we reasoned that <b>2c</b> could be used as a template where its His<sub>7</sub>-containing Loop 2 is replaced with Loop 2 from <b>3</b>, generating a chimeric bicyclic peptide of sequence AC<sub>i</sub>SFPYRC<sub>ii</sub>VYYPDIC<sub>iii</sub>A (termed <b>4a</b>). Note the asymmetry of the loop sizes: 5 AA in Loop 1 and 6 AA in Loop 2. <b>4a</b> still contains the Arg<sub>5</sub> protease recognition point, thus the chemically stabilized variant containing Aze<sub>3</sub> and HArg<sub>5</sub> was generated, following findings described above. This bicyclic peptide however displayed poor aqueous solubility, and consequently the final derivative <b>4b</b> (sequence Ac-C<sub>i</sub>SF[Aze]Y[HArg]C<sub>ii</sub>VYYPDIC<sub>iii</sub>A-Sar<sub>3</sub>-[<span class="smallcaps smallerCapital">d</span>-Arg]<sub>2</sub>) was generated containing the solubilizing Sar<sub>3</sub>-[<span class="smallcaps smallerCapital">d</span>-Arg]<sub>2</sub> extension described earlier. The potency was high, at <i>K</i><sub>i</sub> = 0.27 ± 0.22 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibitory Properties and Species Cross-Reactivity</h3><div class="NLM_p">The inhibitory activity of the bicyclic peptides was assessed via <i>K</i><sub>i</sub> determination in enzyme inhibition assays. Control measurements using aprotinin, an antifibrinolytic proteinaceous drug with well-characterized inhibitory activity toward PKal, trypsin, chymotrypsin, plasmin, thrombin, and activated protein C,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> were performed with the objective of validating the potencies of the PKal-inhibiting bicyclic peptides. Our assay using aprotinin (<i>K</i><sub>i</sub> at 27 nM to human PKal) showed excellent correlation with published data (30 nM to human PKal).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">All tested peptides proved to be highly potent (single-digit nanomolar or subnanomolar) inhibitors of human PKal (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), with a representative example shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Robust cross-reactivity toward cynomolgus PKal was observed, at least for the three tested peptides (namely <b>1b</b>, <b>2d</b>, and <b>4b</b>), which was expected given the high degree of identity (95%) between the human and cynomolgus PKal sequences. The cross-reactivity of the same three peptides was also found to be relatively strong against rat PKal, but weaker against the mouse, dog, or pig enzymes, and poor against the rabbit enzyme (identity between the human PKal sequence and the sequences of rat, mouse, dog, pig, and rabbit PKal is 75, 76, 82, 80, and 82%, respectively).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of human PKal activity by the bicyclic peptide <b>2d</b>. Each data point represents the mean ± SD of duplicate measurements. The solid line represents the best fit obtained using <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Specificity against a Panel of Proteases</h3><div class="NLM_p">The specificity of the <b>1b</b>, <b>2d</b>, and <b>4b</b> peptides, which represent the most stable, soluble, and potent members of peptide sequence families <b>1</b>, <b>2</b>, and <b>4</b>, was assessed by measuring their ability to inhibit a variety of serine proteases (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). We found that <b>1b</b> and <b>2d</b> are highly specific, none of the tested proteases being inhibited with a <i>K</i><sub>i</sub> value lower than 10 μM. The selectivity profile of <b>4b</b> was slightly less specific, with four proteases inhibited with <i>K</i><sub>i</sub> values in the 1–2 μM range (KLK5, KLK13, KLK14, and Factor XIa). Of note, none of the tested peptides was able to inhibit Factor XIIa, which is the main physiological activator of prekallikrein, and therefore these peptides are not expected to interfere with prekallikrein activation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>K</i><sub>i</sub> for the <b>1b</b>, <b>2d</b>, and <b>4b</b> Peptides against a Panel of Human Serine Proteases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">protease</th><th class="colsep0 rowsep0" align="center"><b>1b</b></th><th class="colsep0 rowsep0" align="center"><b>2d</b></th><th class="colsep0 rowsep0" align="center"><b>4b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK1</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">∼50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK2</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">∼10 μM</td><td class="colsep0 rowsep0" align="left">∼10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK5</td><td class="colsep0 rowsep0" align="left">∼50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">0.8 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK6</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK12</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK13</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">0.82 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KLK14</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">∼2 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Plasmin</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha thrombin (Factor IIa)</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Factor VIIa</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Factor Xa</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">∼23 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Factor XIa</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">0.5 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Factor XIIa</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Activated protein C</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Matriptase</td><td class="colsep0 rowsep0" align="left">∼40 μM</td><td class="colsep0 rowsep0" align="left">∼50 μM</td><td class="colsep0 rowsep0" align="left">∼15 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Complement component C 1s</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Granzyme B</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cathepsin G</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td><td class="colsep0 rowsep0" align="left">>50 μM</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Activity in aPTT Assay</h3><div class="NLM_p">Prekallikrein, together with the HMWK, Factor XI, and Factor XII, is part of the contact activation system, a group of circulating proteins that responds to the presence of (patho)physiological materials and invasion pathogens. Factor XII, once activated by surface contact to active Factor XIIa, catalyzes the conversion of prekallikrein into active PKal which in turn catalyzes further Factor XII to XIIa conversion (where the latter activates Factor XI). This generates an activation feedback loop that overcomes inactivation of PKal and Factor XIIa by their natural inhibitors<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> that subsequently leads to onset of coagulation.</div><div class="NLM_p">Previous work demonstrated that kunitz-domain inhibitors of PKal were able to reduce clotting times 3.5-fold, using the activated partial thromboplastin time (aPTT) assay that measures the activity of the intrinsic and common pathways of coagulation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> For this reason, we were interested in testing the most promising PKal targeting peptides <b>1b</b>, <b>2d</b>, and <b>4b</b> in the aPTT assay using human plasma (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Surprisingly, <b>1b</b> and <b>2d</b> induced only a limited increase in coagulation time in this assay (less than 5% and ∼15% for <b>1b</b> and <b>2d</b>, respectively, at 10 μM). By contrast, although remaining close to the normal range of 26 to 40 s,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> the coagulation time increased ∼1.5-fold in the presence of 10 μM of <b>4b</b>, which may reflect the slightly lower selective profile of the molecule, in particular for Factor XIa (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Together, these data led us to select <b>1b</b> and <b>2d</b> for further characterization.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>1b</b>, <b>2d</b>, and <b>4b</b> on the coagulation time in the aPTT assay. Each data point represents the mean ± SD of triplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Stability in Vitreous Humor</h3><div class="NLM_p last">Both <b>1b</b> and <b>2d</b> were tested for stability in human vitreous in addition to nonstabilized <b>2b</b> as a comparator. All three tested peptides were highly stable (half-lives >24 h) in human vitreous, including the plasma-sensitive <b>2b</b> peptide (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The latter finding is likely to reflect the relatively low protein/protease content in vitreous (<1%).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Inhibition of Bradykinin Release in Plasma</h3><div class="NLM_p"><i>K</i><sub>i</sub> measurements as those described above are important to determine the intrinsic potency (i.e., the affinity) of inhibitory peptides toward PKal. However, they do not demonstrate the ability of such peptides to block the activity of PKal against its natural substrate, i.e. HMWK. We therefore developed an assay in plasma where active PKal is generated from the endogenous pool of prekallikrein upon addition of kaolin, and where activity on HMWK is monitored through the quantification of released BK using ELISA. Kaolin, also known as kaolinite, is a clay mineral of chemical composition Al<sub>2</sub>Si<sub>2</sub>O<sub>5</sub>(OH)<sub>4</sub> which here acts as an activator of the contact phase of the coagulation pathway. <b>2d</b> was able to inhibit BK release in a dose-dependent manner, with an IC<sub>50</sub> of 120 ± 60 nM. A typical example of inhibition of BK production in human plasma is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. <b>1b</b>, also tested in the same assay, proved slightly less potent (IC<sub>50</sub> = 790 ± 220 nM). It should be noted here that the difference between the <i>K</i><sub>i</sub> values reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and the IC<sub>50</sub> values measured here is most likely due to the fact that the PKal concentration produced by kaolin-induced conversion from prekallikrein is very high (prekallikrein concentration in blood plasma is 30–50 μg/mL),<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> which requires at least several times this concentration of inhibitory peptides to effectively inhibit all PKal activity and associated BK production.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of bradykinin release in plasma and vitreous by <b>2d</b>. Each data point represents a single measurement. The solid lines represent the best fits obtained using <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>. The left and right <i>Y</i>-axes represent the bradykinin concentration in the vitreous and in plasma, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In a similar assay performed in rabbit plasma instead of human plasma, <b>2d</b> was unable to block BK release even at a concentration of 2 μM (data not shown), which is explained by its poor cross-reactivity toward the rabbit enzyme (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Together, provided cross-reactivity to PKal is maintained, both peptides can effectively block PKal in blood plasma, leading to concomitant suppression of downstream BK production.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Inhibition of Bradykinin Release in Vitreous</h3><div class="NLM_p last">Given that intravitreal (IVT) injection is a potential route of administration for therapeutic PKal inhibitory peptides in the context of diabetic eye diseases, we also tested the ability of the peptides to block PKal activity on HMWK in vitreous. Unlike plasma, vitreous does not contain PKal or HMWK at high concentrations, and therefore an assay where purified reagents were spiked into vitreous was used (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Both <b>2d</b> and <b>1b</b> were shown to block BK release in this assay, although here <b>2d</b> also proved slightly superior to <b>1b</b> (IC<sub>50</sub> = 6.0 ± 0.9 and 27 ± 18 nM, respectively). A representative data set is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Due to the lower, defined concentration of PKal (10 nM) that was spiked into vitreous, the resulting IC<sub>50</sub>s for both peptides are lower than those observed in plasma above.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacokinetics Following Intravenous Administration</h3><div class="NLM_p">Evaluation of plasma pharmacokinetics following intravenous dosing in rats showed a profile consistent with that expected of a small peptide construct and with the plasma stabilities shown above. For both <b>2d</b> and <b>1b</b>, clearances were moderate, consistent with renal clearance at glomerular filtration rate.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Peptide <b>2d</b> showed a low volume of distribution (0.44 L/kg), with <b>1b</b> having a slightly higher volume (0.93 L/kg). This led to plasma half-lives of ∼48 min (<b>2d</b>) and ∼78 min (<b>1b</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters Following Intravenous Dosing in Rat<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>1b</b></th><th class="colsep0 rowsep0" align="center"><b>2d</b></th><th class="colsep0 rowsep0" align="center"><b>2b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Clp (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">156</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vdss (L/kg)</td><td class="colsep0 rowsep0" align="left">0.93</td><td class="colsep0 rowsep0" align="left">0.44</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">n.d. not determined.</p></div></div></div><div class="NLM_p last">For peptide <b>2b</b>, a markedly higher clearance was observed in the <i>in vivo</i> rat. Plasma exposure was measurable during infusion but not following the end of infusion. Clearance was very high (estimated ∼150 mL/min/kg) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The high clearance rate is likely due to the fast degradation of the peptide by plasma proteases <i>in vivo</i> and is not unexpected given the poor stability of the peptide in <i>ex vivo</i> blood plasma (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pharmacokinetics Following Intravitreal Administration</h3><div class="NLM_p">Rabbit was selected as an animal model for intravitreal pharmacokinetics because of its relevance and predictability for translation into intravitreal pharmacokinetics in human.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Following IVT administration to rabbits, <b>2d</b> showed a long residence time in the eye, with a half-life of 39 ± 2 h (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In a similar study, <b>4b</b> showed a slightly faster clearance, with a half-life of ∼22 h (data not shown). Furthermore, when either of these two peptides was injected in only one eye, the peptide levels in the contralateral eye as well as in plasma were found to be below the lower limit of detection of the LC-MS/MS method described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, i.e. 1 ng/mL in vitreous and 2.8 ng/mL in plasma.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Vitreous concentrations of the <b>2d</b> peptide following intravitreal administration in rabbit. Calculated half-life is 39 ± 2 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The concentration of peptide <b>2d</b> as reported in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> decreased from ∼45 μM (∼76 μg/mL) at the earliest time points down to ∼8 μM (∼14 μg/mL) at the latest time point. Despite the poor potency of <b>2d</b> against rabbit PKal (<i>K</i><sub>i</sub> = 3400 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), endogenous PKal inhibition would be predicted to exceed 90% at the earliest time points and would still be ∼70% at the latest time point. Importantly, similar peptide concentrations in the human eye would result in a virtually complete inhibition of human PKal.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Efficacy in a Rat Paw Edema Model</h3><div class="NLM_p">The <i>in vivo</i> efficacy of <b>2d</b> and <b>1b</b> was investigated in a rat model of carrageenan-induced paw edema. This animal model is often used to study acute inflammation-induced edema formation and exhibits a pronounced therapeutic window, which enables dose response profiling. In response to carrageenan injection, the vehicle control group developed a distinct increase in paw volume, which peaked at 4 h (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Fifteen-minute pretreatment with intraperitoneal (IP) injection of either <b>1b</b> or <b>2d</b> resulted in a significant and dose-dependent inhibition of the carrageenan-induced paw edema (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). At the highest dose (30 mg/kg), <b>1b</b> significantly reduced paw edema at 1 h (71%), 2 h (59%), 4 h (60%), and 6 h (64%) following carrageenan administration. The highest dose of <b>2d</b> (30 mg/kg) resulted in a significant inhibition of the carrageenan-induced response compared to a vehicle at 1 h (90%), 2 h (52%), and 4 h (32%) post-carrageenan injection (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Pretreatment with the positive control indomethacin via IP injection (5 mg/kg) resulted in a significant inhibition of the carrageenan-induced response at 1 h (79%), 2 h (56%), 4 h (54%), and 6 h (48%) post-carrageenan injection (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). The obtained inhibitory levels of this COX-inhibitor are in line with previous findings in the rat paw edema model.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> efficacy of <b>2d</b> and <b>1b</b> in a male, Sprague-Dawley rat paw edema model. (A) Subplantar carrageenan injection induced a distinct increase in paw volume in the vehicle control group. Pretreatment with the positive control indomethacin via IP injection (5 mg/kg) resulted in a significant inhibition of the carrageenan-induced paw edema. Pretreatment with IP injection (30, 10, or 3 mg/kg) of <b>1b</b> or <b>2d</b> resulted in a significant and dose-dependent inhibition of the carrageenan-induced response. (B) The area under the curve was calculated for the different conditions from 0 to 2 h, which revealed a prominent dose–response for both <b>2d</b> and <b>1b</b>. Data are shown as mean ± SEM (* <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Various mediators appear to be involved in the acute inflammation process of the rat paw edema model, including pro-inflammatory cytokines, histamine, 5-hydroxytryptamine (5-HT), prostaglandins, and kinins.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> It has been described by Di Rosa et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> that carrageenan-induced edema is characterized by an interplay of 3 distinct phases, namely an initial phase mediated by histamine and 5-HT, a second phase regulated by release of kinins, and a third phase where prostaglandins play the main role in the inflammation-dependent edema formation. Kininogen depletion experiments in the rat paw edema model with cellulose sulfate indeed demonstrated that the inhibitory effect on the edema formation was limited to 2.5 h. Therefore, the area under the curve was calculated for the different conditions from 0 to 2 h, which revealed a prominent dose–response for both peptides (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). The two higher doses (30 mg/kg and 10 mg/kg) showed significant inhibition of edema formation for both <b>2d</b> and <b>1b</b> (<i>p</i> < 0.05).</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Effect on Retinal Vessel Permeability in Diabetic Rodent Models</h3><div class="NLM_p">Streptozotocin (STZ) is a glucosamine-nitrosourea sugar analogue selectively toxic to pancreatic beta-cells. Administration of STZ in animal models results in insulin deficiency and systemic hyperglycemia. STZ rodent models are one of the most popular type 1 diabetic models and have been routinely used in fundamental studies and therapeutic drug experiments.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Retinal vascular permeability, measured by analyzing extravasation of FITC-BSA (fluorescein isothiocyanate-labeled bovine serum albumin), was markedly increased in mice (3-fold) and rats (1.5-fold) after STZ-induction of diabetes compared to nondiabetic control animals (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In the mouse model, a single application of 6.2 μg/eye of the positive control anti-VEGFR2 antibody DC101 resulted in a pronounced reduction (57%, <i>p</i> < 0.05) of the diabetes-dependent retinal permeability 8 weeks after diabetes onset. Similarly, a repeated 4 × 100 μg IVT administration of peptide <b>1b</b> resulted in a statistically significant reduction of the DR-related retinal vascular permeability (36%, <i>p</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). In the same model, treatment with peptide <b>2d</b> did not result in a statistically significant reduction of the retinal permeability (data not shown), most probably because of its lower cross-reactivity against the mouse PKal (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, peptide <b>2d</b> did show efficacy in a diabetic rat STZ model where sufficient cross-reactivity of <b>2d</b> against rat PKal is maintained (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Intravitreal administration of <b>2d</b> (100 μg/eye) resulted in a 30% reduction in retinal vascular leakage (back to baseline levels) 4 weeks after diabetes onset, as compared to the vehicle-treated group (<i>p</i> < 0.05) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). This effect was comparable to the one obtained with a soluble VEGF-trap positive control (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Efficacy of peptide <b>1b</b> in a diabetic, male C57BL/6J mouse model of retinal permeability. Black bars represent data for diabetic animals. Both treatment with the anti-VEGFR2 positive control antibody DC101 as well as repeated intravitreal injections of <b>1b</b> decreased vessel leakage as compared to vehicle-treated diabetic mice. (B) Efficacy of peptide <b>2d</b> in a diabetic, male Brown-Norway rat model of retinal permeability. Black bars represent data for diabetic animals. Intravitreal administration of 100 μg/eye of <b>2d</b> resulted in a statistically significant reduction of vascular leakage, as compared to vehicle-treated animals. The effect was comparable to the one obtained following administration of a soluble VEGF-trap used as a positive control. Data are shown as mean ± SEM (* <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Constrained peptides, like macrocyclic or bicyclic peptides, allow the conformational locking of the bioactive, productive conformation, resulting in lower entropic cost on binding, consequently leading to dramatically increased affinity and specificity compared to the linear peptides derived from the same sequence.<a onclick="showRef(event, 'ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47">(44−47)</a> Due to their large, extended interaction surface areas, such scaffolds have proven useful to target proteins that otherwise are intractable by typical small molecules.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48−50)</a> Here we describe the generation of human PKal bicyclic peptide inhibitors. The power of phage display-based selections of constrained peptide libraries combined with rationally designed synthetic modifications has allowed the identification of molecules that combine potency, specificity, favorable pharmacokinetics, and <i>in vivo</i> stability.</div><div class="NLM_p">With low nanomolar or subnanomolar <i>K</i><sub>i</sub> values against human PKal (e.g., 0.15 and 0.36 nM for <b>2b</b> and <b>2d</b>, respectively), these bicyclic peptides exhibit affinities similar to DX-2930 (reported <i>K</i><sub>i</sub> = 0.12 nM),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> an anti-PKal antibody currently in Phase 3 for the treatment of patients with type I and type II HAE (ClinicalTrials.gov Identifier: NCT02586805), and, more generally, within the high end of the range of affinities observed for antibodies.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Importantly, we also show that these peptides can prevent the release of the bioactive peptide BK both in plasma and in vitreous humor, thereby demonstrating the ability of these molecules to block PKal activity against its natural substrate HMWK. The exquisite target selectivity of <b>1b</b> and <b>2d</b> (>10,000–100,000 fold difference in <i>K</i><sub>i</sub> between PKal and other serine proteases tested) eventually led us to focus our attention on these two peptides.</div><div class="NLM_p">Achieving good species cross-reactivity beyond cynomolgus monkey proved more challenging, and with the exception of <b>1b</b> against the rat enzyme (<i>K</i><sub>i</sub> = 3.1 nM), the latter peptide and <b>2d</b> showed either a more limited or a poor degree of cross-reactivity against PKal from other species. Nonetheless, the cross-reactivity toward rat and mouse PKal proved sufficient to demonstrate efficacy in the rat paw edema model with both <b>1b</b> and <b>2d</b> and in a mouse and rat diabetic eye vessel permeability model with <b>1b</b> and <b>2d</b>, respectively.</div><div class="NLM_p">The <b>1b</b> and <b>2d</b> peptides, even at concentrations of up to 10 μM, induced only a clinically nonrelevant prolongation of the clotting time in the aPTT assay. As PKal is part of an amplification loop in this pathway, this observation is at first sight surprising. Other PKal inhibitors have indeed been reported to more markedly impact the aPTT coagulation time. E.g., KALI-DY, an engineered molecule obtained from Kunitz domain phage libraries, prolonged the aPTT clotting time by more than 3.5-fold at 1 μM,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and PF-04886847, a small molecule competitive inhibitor of PKal, increased the aPTT clotting time 2-fold at 14 μM.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, both KALI-DY and PF-04886847 inhibit Factor XIa at <i>K</i><sub>i</sub> = 8.2 nM and 1 μM, respectively,<a onclick="showRef(event, 'ref33 ref53'); return false;" href="javascript:void(0);" class="ref ref33 ref53">(33,53)</a> which should amplify their activity in the aPTT assay. It is therefore conceivable that the more limited effect of <b>1b</b> and <b>2d</b> on the aPTT clotting time is in fact due to their highly specific selectivity profile against other serine proteases from the clotting cascade. This hypothesis is supported by the fact that <b>4b</b>, which does show some activity against Factor XIa (<i>K</i><sub>i</sub> = 0.5 μM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), is able to increase the aPPT clotting time ∼1.5-fold at 10 μM.</div><div class="NLM_p">The <i>in vivo</i> stability and pharmacokinetic properties of the peptidic bicyclic inhibitors are essential parameters to consider. Despite their constrained conformation, the peptides are not necessarily stable <i>in vitro</i> or <i>in vivo</i>, as seen for example for <b>2b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). To this end, protease recognition points were removed in <b>2b</b> by replacing arginine with homoarginine and by introduction of a nonpeptidic, protease stable CH<sub>2</sub>–NH pseudopeptide bond at His<sub>7</sub>. Associated minor losses in affinity due to homoarginine introduction were counteracted by the replacement of proline with the more constrained analogue azetidine carboxylic acid. The resulting derivative <b>2d</b> was virtually equipotent to its progenitor <b>2b</b> and by contrast highly stable in all tested biological matrices, whether vitreous humor or plasma. <b>1b</b> by contrast, although not specifically engineered for proteolytic stability, was natively stable in all matrices tested (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p"><i>In vivo</i> plasma clearance in the rat for <b>1b</b> and <b>2d</b> was consistent with renal clearance at glomerular filtration rate, confirming that unlike the nonstabilized <b>2b</b>, <b>1b</b> and <b>2d</b> are not measurably cleared <i>in vivo</i> by other mechanisms, such as proteolytic degradation (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In the context of drugs developed for ophthalmologic indications, the relatively fast clearance from the circulation is generally seen as an advantage since it limits the risk of systemic toxicity.</div><div class="NLM_p">By contrast, clearance in the rabbit eye was low, with a half-life of 39 h for <b>2d</b>, only ∼2–3 times shorter than much larger molecules such as antibodies or antibody fragments.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> With a molecular weight ∼90-fold smaller than conventional antibodies, and a similar potency, the slightly faster clearance in the eye can conceivably be compensated by achieving a much higher molar concentration of the active agent following IVT administration.</div><div class="NLM_p">Despite a somewhat limited species cross-reactivity, both <b>1b</b> and <b>2d</b> showed <i>in vivo</i> efficacy in a rat paw edema model as good as or superior to the positive control indomethacin. Corresponding to our findings, Kenniston et al. reported a paw edema reduction of 47.2% and 55.6% after pretreatment with indomethacin (5 mg/kg) and DX-2930 (30 mg/kg), respectively.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">While significant progress in therapeutic management of diabetic retinopathy has been achieved, it remains the major cause of blindness in industrialized countries. In the past decades, therapies focused on symptomatic prevention of vision loss. In the meantime, the elucidation of the molecular pathways underlying the disease has become the cornerstone of future drug development. IVT administration of anti-VEGF agents has emerged as a primary therapy and is often very effective in reducing macular edema and improving visual acuity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> However, frequent injections are needed to achieve full pharmacological benefit, and a significant fraction of the patients responds poorly or is refractory to the therapy. Furthermore, anti-VEGF agents block both the pathological as well as the potential beneficial effects of VEGF in the eye.<a onclick="showRef(event, 'ref57 ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60 ref61">(57−61)</a> Inhibition of the pathways leading to edema downstream of VEGF or inhibition of VEGF-independent pathways therefore represents attractive therapeutic opportunities.</div><div class="NLM_p">Recently, Clermont and co-workers<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> showed that PKal, although not involved in the direct effects of VEGF, is required for the full effects of VEGF and other mediators of edema (e.g., TNF-α) on retinal vascular permeability and retinal thickening, suggesting that PKal contributes to the sustained effects of VEGF and other mediators on blood-retinal barrier function. The authors hypothesized that extravasation of PKal into the retina induced by mediators of edema (including VEGF) contributes to their effects on retinal edema, e.g. by increasing intraocular bradykinin. The same authors, however, demonstrated that PKal is not required for VEGF’s angiogenic effects that are critical for vascular growth and survival. In another study, Kita and co-workers<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> reported that the levels of PKal and prekallikrein, on the one hand, and those of VEGF, on the other hand, are elevated in the vitreous of DME patients but do not correlate. Also, the RVP response induced by IVT injection of vitreous from DME patients containing high levels of PKal and low levels of VEGF in diabetic rats was not affected by anti-VEGF or anti-VEGFR2 treatment.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Taken together, these results implicate the KKS system as a VEGF-independent mediator of retinal permeability and identify PKal as a promising target for the treatment of diabetes-related eye diseases such as DME.</div><div class="NLM_p last">In conclusion, we describe the identification and design of highly stable, potent, and selective human PKal inhibitory bicyclic peptides and report their prolonged retention in the eye together with <i>in vivo</i> efficacy in diabetic models of retinal vascular permeability. Noteworthy, peptide <b>2d</b> also proved to be safe upon systemic administration in rat and cynomolgus, with no overt toxicological effect observed at the highest tested systemic dose of 125 μg (0.43–0.60 mg/kg) in rat and 1.25 mg (0.42–0.49 mg/kg) in cynomolgus (data not shown). Taken together, these data demonstrate the potential of PKal inhibitory bicyclic peptides for the treatment of diabetes-related eye diseases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Reagents, Enzymes, and Proteins</h3><div class="NLM_p">Aprotinin was purchased from Sigma-Aldrich (cat. A6279). Single-chain HMWK was obtained from Enzyme Research Laboratories (cat. HK1300) or Creative BioMart (cat. KNG1-1844H). PKal purified from human plasma was purchased from Molecular Innovations (cat. HPKA). Recombinant mouse PKal was from R&D Systems (cat. 2498-SE). Rat PKal was either prepared in-house (see below) or purchased from Athens Research & Technology (cat. 16-16-110112-RAT).</div><div class="NLM_p">PKal from other species was prepared in-house. Briefly, 250 mL of plasma was mixed with 250 mL of chloroform, and the top (aqueous) phase was collected and activated by addition of an equal volume of a 10 mg/mL suspension of kaolin in H<sub>2</sub>O. The activated plasma phase was then acidified by addition of 500 mL of 1/6 N HCl, incubated at room temperature for 15 min, and neutralized by addition of 500 mL of 1/6 N NaOH. This material was then filtered (0.45 μm) and purified in two steps. First, a 12 mL SoyBean Trypsin Inhibitor-agarose (Thermo Scientific, cat. 20235) column was used for the capture of the activated PKal. Following alkaline elution with 10 mM NaOH, the active fractions (see activity assay below) were pooled and pH-adjusted by a 1:1 dilution in 100 mM sodium acetate, pH 5.3. The material was then loaded on a 1 mL Mono S column (GE Healthcare, cat. 17-5168-01) equilibrated with 50 mM sodium acetate, pH 5.5 for polishing and eluted with a 0 to 2 M NaCl gradient on 20 column volumes. The active fractions were pooled and dialyzed against 4 mM sodium acetate, 0.15 M NaCl, pH 5.3 before storage.</div><div class="NLM_p">The source of the other serine proteases (all of human origin) was as follows: KLK1 (cat. 10407-H08H), KLK6 (cat. 12142-H08H), and KLK13 (cat. 10199-H08H) were from Sino Biological Inc., KLK2 (cat. 4104-SE), KLK5 (cat. 1108-SE), KLK12 (cat. 3095-SE), KLK14 (cat. 2626-SE), Factor Xa (cat. 1063-SE), matriptase (cat. 3946-SE), and complement component C 1s (cat. 2060-SE) were from R&D Systems, alpha thrombin (cat. HT1002A), Factor XIa (cat. HFXIa-2810), Factor XIIa (cat. HFXIIa-2764AL), and Factor VIIa (cat. HFVIIa) were from Enzyme Research Laboratories, granzyme B (cat. BML-SE238) and cathepsin G (cat. BML-SE283) were from Enzo Life Sciences, plasmin (cat. HCPM-0140) was from Haematologic Technologies Inc., and activated protein C (cat. P2200) was from Sigma.</div><div class="NLM_p last">All other reagents were of analytical grade.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Identification of Plasma Kallikrein Inhibitory Peptides</h3><div class="NLM_p last">Bicyclic peptides (Bicycles) with inhibitory activity against PKal were identified using Bicycle Therapeutics proprietary phage display platform, which is derived from methodology developed by Heinis and Winter.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, linear peptide libraries containing randomized AA between 3 cysteine residues were displayed on the surface of filamentous phage and cyclized on the phage with a thiol-reactive molecular scaffold (TBMB). The libraries formats used were 5 × 5 and 6 × 6, such that either 5 or 6 randomized AA were between the first and second and second and third cysteine, respectively. Following cyclization of the phage libraries, repeated selections were performed against human and rat PKal, according to methodology previously described.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Phage clones isolated from the selections were sequenced, and peptides were chemically synthesized for characterization.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis and Optimization and of Plasma Kallikrein Inhibitory Peptides</h3><div class="NLM_p last">The synthesis of bicyclic peptides was performed by first synthesizing the linear peptide by standard Fmoc (9-fluorenylmethyloxycarbonyl) solid phase peptide synthesis, using a Symphony automated peptide synthesizer (Protein Technologies) and Rink amide resin. Following cleavage from the resin, peptides were precipitated with diethyl ether, lyophilized, and optionally purified by HPLC (using a Phenomenex Luna C8 or Gemini C18 column) with H<sub>2</sub>O/0.1% (v/v) trifluoroacetic acid (TFA) (A) and acetonitrile/0.1% (v/v) TFA (B) as solvents. Cyclization of the linear peptides (either crude or prepurified) with TBMB was performed in 30–60% (v/v) acetonitrile in water at ∼1 mM concentration peptide with ∼1.3 equiv TBMB, using ammonium bicarbonate (100 mM) as base. Completion of cyclization was followed by matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) (Voyager DE, Applied Biosystems), and crude reactions were lyophilized and purified as described above. Eligible fractions containing cyclized peptide of sufficient purity and correct molecular weight (verified again by MALDI-TOF) were pooled, lyophilized, and reconstituted in buffer prior to use. The final purity of the peptides was confirmed at >95% based on UPLC analysis at 215/254 nm using a Waters CSH column (1.7 μm × 2.1 mm × 150 mm) employing the solvent system described above and a gradient of 5%–30% B in 0–20 min and 30%–55% B in 20–50 min. Key compounds <b>1b</b>, <b>2d</b>, and <b>4b</b> were prepared as the acetate salt (obtained by ion exchange using HPLC and 0.5% acetic acid in place of TFA in the mobile phase, followed by lyophilization), and molecular weights were further verified by LC-MS. Concentrations were estimated by absorption using the extinction coefficient at 280 nm, which was based on Trp/Tyr content. Standard Fmoc AA as well as nonproteinogenic Fmoc-AA were obtained from Sigma-Aldrich and Iris Biotech GmbH. Synthesis of the pseudopeptide bond in <b>2d</b> was adapted from protocols reported in Sasaki and Coy, using Fmoc-<span class="smallcaps smallerCapital">l</span>-alanine-aldehyde from Bachem.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Peptide sequences described here are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf" class="ext-link">Supporting Information Table 1</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Plasma Stability Profiling</h3><div class="NLM_p last">A rapid plasma stability profiling assay was developed that employed mass spectrometric detection (MALDI-TOF, Voyager DE, Applied Biosystems) of the parent mass and protease-induced metabolites. One millimolar peptide stocks (in DMSO) were diluted into mouse, rat, or human plasma (Seralabs, citrate as anticoagulant) to a concentration of 50 μM and incubated at 37 °C up to 2 days. At various time points, 10 μL of samples was withdrawn, added to 30 μL of 1:1 acetonitrile/methanol, and centrifuged at 13,000 rpm for 5 min. Five microliters of supernatant was withdrawn and mixed with 5 μL of 30 mM ammonium bicarbonate dissolved in 1:1 acetonitrile/water. For mass spectrometric analysis, 1 μL of the mixture was spotted directly onto the MALDI plate. Matrix (α-cyanocinnamic acid, Sigma, prepared as a saturated solution in 1:1 acetonitrile:water containing 0.1% (v/v) TFA) was layered over the sample (1 μL) and dried, and total ion chromatograms were obtained for analysis.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Nonlinear Regression Analyses</h3><div class="NLM_p last">Nonlinear regression analyses were performed using the GraphPad Prism software ver. 5.02 (GraphPad Software Inc., La Jolla, CA), applying, unless otherwise stated, equal weighting (i.e., performing minimization based on absolute distances squared).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Plasma Kallikrein Activity Measurements</h3><div class="NLM_p last">The hydrolytic activity of PKal was measured using the fluorogenic substrate H-Pro-Phe-Arg-AMC (Bachem, cat. I-1295.0050). Typical substrate concentrations were 10–25 μM. Substrate hydrolysis was monitored by recording the increase in fluorescence at 480 nm (with excitation at 360 nm) using a Spectramax M2e plate reader (Molecular Devices). The measurements were performed in such a way that no more than 10% of the substrate were hydrolyzed, therefore allowing the determination of initial rates of hydrolysis.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Enzyme Inhibition Assays and <i>K</i><sub>i</sub> Measurements</h3><div class="NLM_p">The intrinsic potency of the bicyclic peptides was determined through <i>K</i><sub>i</sub> measurements in enzyme inhibition assays. Experiments were performed at 25 °C in 50 mM Tris-HCl, 250 mM NaCl, 1.5 μM bovine serum albumin, pH 7.5. PKal (typical nominal concentration 1–2 nM) was preincubated in 96-well plates with different concentrations of the tested peptide (or of aprotinin, used as a control molecule) for 15 min. The maximum final concentration of a given peptide was chosen based on its potency and was followed by a 1.25- to 3-fold serial dilution, plus a control with no peptide. The reactions were initiated by the addition of H-Pro-Phe-Arg-AMC at a final concentration of 10 to 25 μM, and initial rates of substrate hydrolysis were determined by linear fit of the raw fluorescence versus time traces.</div><div class="NLM_p">The data were plotted as the initial rate of substrate hydrolysis as a function of the peptide concentration and were fitted to <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> where the parameters <i>v</i><sub>0</sub>, [PKal]<sub>0</sub>, [I]<sub>0</sub>, and <i>K</i><sub>i,app</sub> are the rate of substrate hydrolysis in the absence of peptide, the total concentration of PKal, the total concentration of peptide, and the apparent <i>K</i><sub>i</sub>, respectively. <a class="ref internalNav" href="#eq1" aria-label="Eq 1">Eq 1</a> is the full rate equation for a reaction inhibited by a tight-binding inhibitor. It is however applicable to both tight-binding inhibitors (<i>K</i><sub>i</sub> < [PKal]<sub>0</sub> or <i>K</i><sub>i</sub> ∼ [PKal]<sub>0</sub>) and poor inhibitors (<i>K</i><sub>i</sub> > [PKal]<sub>0</sub>). Here, the term [PKal]<sub>0</sub> was either treated as an adjustable parameter (potent inhibitors) or fixed to its estimated value (poor inhibitors). The terms <i>v</i><sub>0</sub> and <i>K</i><sub>i,app</sub> were always treated as adjustable parameters.</div><div class="NLM_p last">The way the term <i>K</i><sub>i,app</sub> is linked to the absolute <i>K</i><sub>i</sub> value depends on the inhibition mechanism. Here, and although not demonstrated experimentally, the blocking peptides were considered to be competitive inhibitors, and therefore <a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>, where [S] and <i>K</i><sub>m</sub> are the substrate concentration and the <i>K</i><sub>m</sub> of the enzyme for this particular substrate, respectively, applies. <a class="ref internalNav" href="#eq2" aria-label="Eq 2">Eq 2</a> shows that the apparent inhibitory potential of a competitive inhibitor decreases with increasing concentrations of substrate. In the case of H-Pro-Phe-Arg-AMC however, the <i>K</i><sub>m</sub> for PKal is large (not shown), and all experiments were performed under conditions where [S] ≪ <i>K</i><sub>m</sub>. Therefore, <i>K</i><sub>i,app</sub> values obtained from <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a> can be considered as representing actual <i>K</i><sub>i</sub> values. <i>K</i><sub>i</sub> values reported are presented as mean ± SD. The number of replicate measurements varied between 2 and 60, depending on the compound and the enzyme tested.<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_m001.gif" alt="" id="_i32" /></img><span class="labelSpan">(1)</span></span><span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_m002.gif" alt="" id="_i33" /></img><span class="labelSpan">(2)</span></span></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Specificity Profiling</h3><div class="NLM_p last">A panel of 18 serine proteases of human origin was identified from commercial sources (see above). The synthetic substrates as well as the conditions of the assay were chosen following the providers’ recommendations. The peptides were first tested at a concentration of 50 μM for their ability to inhibit the selected proteases. Whenever detectable inhibition was observed, the <i>K</i><sub>i</sub> of the peptide toward a particular protease was determined by measuring the hydrolytic activity in the presence of various peptide concentrations and analyzing the data with <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Activated Partial Thromboplastin Time</h3><div class="NLM_p last">The aPTT clotting times were measured on a BCS-XP coagulation analyzer (Siemens) using actin FS, 0.025 M CaCl<sub>2</sub>, FVIII-deficient human plasma, and Owren’s Veronal Buffer, pH 7.35 (all from Siemens) and were performed according to the manufacturer’s recommendations. Peptide concentration ranged from zero (vehicle control) to 10 μM.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Inhibition of Bradykinin Release in Plasma</h3><div class="NLM_p last">The peptides were incubated at various concentrations (including a vehicle, i.e. zero concentration, control) in human plasma (Siemens, SMN10446238) for 15 min. The plasma samples were then diluted 2-fold in a 10 mg/mL suspension of kaolin in order to convert endogenous prekallikrein into active Pkal at 37 °C. Bradykinin (BK) generated by the activity of PKal on the endogenous HMWK was then quantified by ELISA (Enzo Life Sciences, cat. ADI-900-206) 15 min after the addition of kaolin. In order to block any further accumulation of BK as well as to stabilize BK, the plasma samples were treated with a cocktail of protease inhibitors (ROCHE, cat. 04693116001) prior to performing the ELISA. The measured BK concentration was plotted as a function of the peptide concentration (in plasma, prior to the addition of kaolin), and the data were fitted to <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>, where [I]<sub>0</sub> is the total concentration of peptide, A and D are the BK concentrations in the absence and in the presence of saturating concentrations of peptide, respectively, and <i>B</i> is an empirical fitting parameter, in order to calculate the IC<sub>50</sub> of the inhibition reaction. IC<sub>50</sub> values reported here are expressed as mean ± SD of 15 (peptide <b>2d</b>) and 6 (peptide <b>1b</b>) individual experiments.<span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_m003.gif" alt="" id="_i37" /></img><span class="labelSpan">(3)</span></span></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Inhibition of Bradykinin Release in Vitreous</h3><div class="NLM_p last">Pig vitreous was homogenized and clarified as previously described<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> and dialyzed against phosphate buffered saline (PBS) in order to stabilize the pH to physiological values. Human PKal (nominal concentration 10 nM) was incubated in the presence of various concentrations of peptide (including a vehicle, i.e. zero concentration, control) at 37 °C for 15 min in vitreous, at which point purified, single-chain HMWK (final concentration 25 μg/mL) was added. After an additional 15 min incubation at 37 °C, the reaction was stopped by the addition of a cocktail of protease inhibitors, and the BK levels were quantified by ELISA as described above. The BK concentration was plotted as a function of the peptide concentration, and the data were fitted to <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a> to calculate the IC<sub>50</sub> of the inhibition reaction. IC<sub>50</sub> values reported here are expressed as mean ± SD of 3 individual experiments.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Measurement of Stability in Plasma and Vitreous Humor</h3><div class="NLM_p last">The half-life of degradation of the peptides in plasma or vitreous was used to assess the comparative stability. Peptide stock solutions in DMSO at 0.16 mM were mixed with plasma (human, rat, or mouse, obtained from Seralabs) or with human vitreous humor (from vitreous biopsies collected by Dr. Joachim Van Calster at the University Hospital Leuven, Belgium) to a final concentration of 4 μM and 1 μM, respectively. Vitreous was homogenized as described above. The samples (containing an analytical internal standard) were incubated up to 24 h at 37 °C. Forty microliters of plasma samples and 20 μL of vitreous samples were collected at various time points and frozen at −80 °C. For analysis, samples were thawed rapidly, and aliquots were treated with 3 volumes of extraction solvent (1:3:3 v/v/v mixture of water, acetonitrile, and methanol). Precipitated proteins were removed by centrifugation (40 min at 13,000 rpm and at 4 °C), and the supernatant was analyzed for the remaining parent peptide by LC-MS/MS (Waters TQD) using standard bioanalytical protocols. Summarizing briefly, two collision-induced fragment ions of each peptide were first quantitated in calibration lines (concentration range 0.25 to 4 μM) in the presence of vitreous/plasma (extracted as described above), and the linearity and specificity of the responses were verified (5 μL injection onto a Waters BEH C18 column, using a 0.1% formic acid in water/acetonitrile solvent system and 8 min elution gradient of 5 to 60% acetonitrile). Signal to background ratios were >10 at all concentrations. Subsequently, samples derived from the stability time course were quantitated against the calibration line and half-lives estimated by performing nonlinear regression fitting assuming a single exponential decay process.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Animal Studies</h3><div class="NLM_p last">Housing and all experimental procedures were conducted according to accepted best practice (EU Directive/AAALAC or similar) and approved by Institutional Animal Care and Research Advisory Committee of the KU Leuven, according to the 2010/63/EU Directive. All animal procedures were also performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Measurement of Pharmacokinetics Following Intravenous Administration</h3><div class="NLM_p">Intravenous pharmacokinetics studies were conducted at Argenta Discovery and BioFocus for the in-life and <i>in vitro</i> aspects, respectively. Groups of 2 male Sprague-Dawley rats were administered 5 mg/kg of <b>2d</b> or <b>1b</b>. In a separate experiment, <b>2b</b> was administered as an infusion into the jugular vein of 10 mg/kg peptide over 1 h. Serial blood samples were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, 180, and 240 min postdose, into EDTA tubes, and centrifuged to generate plasma samples for analysis.</div><div class="NLM_p last">Peptide concentration in plasma samples was quantified by LC-MS/MS as detailed above, using calibration lines at concentrations between 16 and 4000 ng/mL in control rat plasma, 5 μL sample injections with a 0.01% formic acid in water/acetonitrile solvent system, and a 1 min elution gradient of 5 to 95% acetonitrile. The limits of quantification for <b>1b</b> and <b>2</b>d were 16 and 32 ng/mL, respectively. For peptides <b>2d</b> and <b>1b</b>, pharmacokinetic parameters were determined by noncompartmental analysis using PK Solutions 2.0 (Summit Research Services). Area under the curve values were calculated by the trapezoidal method.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Measurement of Pharmacokinetics Following Intravitreal Administration</h3><div class="NLM_p">For IVT studies, male New-Zealand White rabbits (10 weeks old, ∼ 2 kg, Charles River) received a single injection of 50 μL of <b>2d</b> (2 mg/mL in 50 mM sodium phosphate, pH 7.2) in each eye. IVT injections were performed using a 30G insulin needle of 0.3 mL with half-unit (50 μL) marks. The animals were sacrificed 15 min, 1 h, 4 h, 8 h, 24 h, 48, and 96 h after injection (3 animals per time point), the injected eyes were enucleated, and the complete vitreous was collected. The vitreous samples were homogenized and clarified as described above and then further clarified by 0.2 μm filtration (Nanosep MF with Bio-Inert membrane, VWR). The peptide was then quantified in the vitreous samples by HPLC using an Acquity UPLC instrument (Waters). Samples were diluted with 1.5 volumes of 8.33% (v/v) acetonitrile, 0.17% (v/v) TFA, 0.067% (v/v) Tween-20, and 6 μL was injected on a BEH300 C18 1.7 μm, 2.1 × 100 mm Acquity UPLC column. Elution was performed over 10 min (0.1 mL/min) from 5 to 40% acetonitrile in the presence of 0.1% TFA, monitoring at 215 nm. The concentration of peptide in the samples was calculated by integration of the relevant peak and reference to a standard curve obtained under conditions of linear response.</div><div class="NLM_p last">The peptide concentration was plotted as a function of the time of collection, and the half-life in the eye (reported as best-fit value ± standard error) was obtained by fitting the data with <a class="ref internalNav" href="#eq4" aria-label="eq 4">eq 4</a>, where <i>C</i><sub>0</sub> and HL are the peptide concentration at time zero and the half-life in the eye, respectively, using a proportional weighting.<span class="NLM_disp-formula" id="eq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_m004.gif" alt="" id="_i43" /></img><span class="labelSpan">(4)</span></span></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Rat Model of Carrageenan-Induced Paw Edema</h3><div class="NLM_p last">The rat paw edema model study was performed by Washington Biotechnology, Inc. Male Sprague-Dawley rats with a body weight of 180–200 g (∼6–7 weeks old) (Harlan Laboratories) were randomized into 8 experimental groups (<i>n</i> = 10). The animals received one IP injection of either formulation buffer (vehicle: 20% PEG 400, 10% Kolliphor, 50 mM sodium acetate, pH 5), indomethacin positive control (Sigma, 5 mg/kg prepared in 0.1 M NaHCO<sub>3</sub> at a concentration of 1.25 mg/mL), or different doses of either <b>2d</b> or <b>1b</b> (3, 10, or 30 mg/kg prepared in 20% PEG 400, 10% Kolliphor, 50 mM sodium acetate, pH 5, at concentrations of 7.5, 2.5, and 0.75 mg/mL, respectively). The dose range for <b>2d</b> and <b>1b</b> was similar to the one used with DX-2930 in the same model.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Fifteen minutes after treatment, the rats were injected subcutaneously into the subplantar region of the right hind paw with 0.1 mL of 1% lambda carrageenan (Fluka, prepared in deionized water). Right hind paw volumes were recorded by means of plethysmography before and 1, 2, 4, and 6 h after carrageenan injection. Results or measurements are reported to be significantly different for probability values (p-values) < 0.05.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Diabetic Rodent Models of Retinal Permeability</h3><div class="NLM_p">Male C57BL/6J mice (3–5 weeks old) and male Brown-Norway rats (200–250 g, 9 weeks old) were obtained from Charles River Laboratories (L’Arbresle Cedex, France). Mice were rendered diabetic with 5 consecutive daily IP injections of STZ (Sigma-Aldrich, cat. S0130) at 50 mg/kg freshly dissolved in 100 mM sodium citrate, pH 4.5, whereas rats received a single IP injection of 55 mg/kg STZ (dissolved in the same buffer). Animals treated IP with the vehicle served as nondiabetic controls (<i>n</i> = 10 for mice, and <i>n</i> = 8 for rats). Blood glucose levels were monitored weekly after the first STZ injection (glucometer, OneTouch Vita, LifeScan Inc., Milpitas, CA, USA), and diabetic status was defined by glucose levels higher than 250 mg/dL. Only animals with consistent hyperglycemic levels were included in the experimental diabetic groups. No exogenous insulin treatment was given.</div><div class="NLM_p">Seven weeks after diabetes onset, the first two diabetic mice groups were treated with four binocular IVT injections of <b>1b</b> (100 μg/eye, using a 100 mg/mL solution of the peptide prepared in 15 mM NaOH in water, with pH adjusted to 5.4–5.5 with acetic acid; <i>n</i> = 13) or vehicle (<i>n</i> = 10), with an interval of 2 days between each injection. The dosing regimen of <b>1b</b> corresponded to the maximal possible dose to compensate for the fast clearance that is expected in rodent eyes. As a positive control, an additional group was treated with one IVT injection of the anti-mouse VEGFR2 antibody DC101 (Thrombogenics N.V. 6.2 μg/eye, prepared in PBS; <i>n</i> = 7). Mice were sacrificed 1 week after initiation of treatment to evaluate vessel leakage. In diabetic rats, peptide <b>2d</b> (20 mg/mL in 10 mM HCl; <i>n</i> = 8) or vehicle (<i>n</i> = 6) was administered IVT immediately after diabetes onset. Here too, dosing of <b>2d</b> was maximized to compensate for the fast ocular clearance. As a positive control for the model, an additional group (<i>n</i> = 10) with repeated IP injections (3 times a week) of 2 mg/kg of a soluble VEGF-trap (formulated in 10 mM sodium phosphate, 40 mM NaCl, 0.03% Tween-20, 5% sucrose, pH 6.2) was included and compared to its vehicle (<i>n</i> = 10). The soluble VEGF-trap used here was a research reagent obtained by recombinant expression of a protein which sequence was identical to the one of aflibercept.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Systemic administration was chosen in correlation with previously reported studies in this model.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> Rats were sacrificed 4 weeks after diabetes onset to quantify vascular retinal leakage. The IVT injections in all animals were performed by using an analytic science syringe (SGE Analytic Science) and glass capillaries with a diameter of 50–70 μm at the end, controlled by the UMP3I Microsyringe Injector and Micro4 Controller (all from World Precision Instruments Inc., Hertfordshire, UK).</div><div class="NLM_p last">Retinal permeability was assessed using an approach adapted from previous studies.<a onclick="showRef(event, 'ref68 ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70 ref71">(68−71)</a> Briefly, FITC-BSA (Sigma-Aldrich, cat. A9771) dissolved in PBS (10 mg/mL) was injected retrobulbarly in the right eye (OD) in mice (at 100 μg/g) and via vena femoralis (at 500 μg/g) in rats. Twenty to 30 min later, the animals were sacrificed, and eyes were enucleated and placed in 1% formaldehyde overnight followed by paraffin wax embedding. Sagittal serial sections of the left eyes (OS) through the central retina were collected and dewaxed for vessel leakage assessment. Using a fluorescence microscope equipped with a digital camera (Axiocam MrC5, Zeiss), images were taken at a magnification of 20X from retinal cross sections adjacent to either side of the optic nerve head. The retinal fluorescence intensity per image was measured and normalized to the background fluorescence intensity on the slide. Morphometric analyses were performed using a commercial software (KS300 and AxioVision, Zeiss). Results or measurements are reported to be significantly different for p-values < 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01625" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01625" class="ext-link">10.1021/acs.jmedchem.7b01625</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figure of comparative plasma stability of <b>2b</b> and <b>2d</b>, table of bicyclic peptide names and their corresponding sequences (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf">jm7b01625_si_001.pdf (151.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_002.csv">jm7b01625_si_002.csv (0.99 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01625" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean H. M. Feyen</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#610b04000f4f070418040f211509130e0c030e06040f0802124f020e0c"><span class="__cf_email__" data-cfemail="325857535c1c54574b575c72465a405d5f505d55575c5b51411c515d5f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel
P. Teufel</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gavin Bennett</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Harrison</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katerine van Rietschoten</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Pavan</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Stace</span> - <span class="hlFld-Affiliation affiliation">Bicycle Therapeutics
Limited, Building 900, Babraham Research
Campus, Cambridge CB22
3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">François Le Floch</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span>; 
    <span>Present Address:
                        Innate Pharma SA, 117 Avenue de Luminy - BP 30191, 13276 MARSEILLE Cedex 09, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tine Van Bergen</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span>; 
    <span>Present Address:
                        Laboratory of Ophthalmology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elke Vermassen</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Barbeaux</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tjing-Tjing Hu</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc Vanhove</span> - <span class="hlFld-Affiliation affiliation">Thrombogenics
N.V., Gaston Geenslaan 1, 3001 Leuven, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4144-7688" title="Orcid link">http://orcid.org/0000-0003-4144-7688</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): D.P.T., G.B., H.H., K.v.R., and S.P. are employees at Bicycle Therapeutics Inc.; T.V.B., E.V., P.B., T.-T.H., M.V., and J.H.M.F. work for ThromboGenics N.V.<br /></br></div></li></ul></div><div class="ack" id="ACK-d50e3659-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors wish to thank Prof. Marc Hoylaerts (Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Belgium) for performing the aPTT measurements and Dr. Joachim Van Calster (University Hospital Leuven, Belgium) for providing human vitreous biopsies. The authors also thank Bernard Noppen, Kelly Vanhulst, Huberte Moreau, Astrid De Vriese, Valerie Vanheukelom, Tom Janssens, Sarah Nauwelaerts, Sofie Beckers, Ann Verbeek, and Martine Leijssen for excellent technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PKal</td><td class="NLM_def"><p class="first last">plasma kallikrein</p></td></tr><tr><td class="NLM_term">CAS</td><td class="NLM_def"><p class="first last">contact activation system</p></td></tr><tr><td class="NLM_term">KKS</td><td class="NLM_def"><p class="first last">kallikrein-kinin system</p></td></tr><tr><td class="NLM_term">BK</td><td class="NLM_def"><p class="first last">bradykinin</p></td></tr><tr><td class="NLM_term">HMWK</td><td class="NLM_def"><p class="first last">high molecular weight kininogen</p></td></tr><tr><td class="NLM_term">C1-INH</td><td class="NLM_def"><p class="first last">C1 inhibitor</p></td></tr><tr><td class="NLM_term">HAE</td><td class="NLM_def"><p class="first last">hereditary angioedema</p></td></tr><tr><td class="NLM_term">DR</td><td class="NLM_def"><p class="first last">diabetic retinopathy</p></td></tr><tr><td class="NLM_term">NPDR</td><td class="NLM_def"><p class="first last">nonproliferative diabetic retinopathy</p></td></tr><tr><td class="NLM_term">PDR</td><td class="NLM_def"><p class="first last">proliferative diabetic retinopathy</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">diabetic macular edema</p></td></tr><tr><td class="NLM_term">RVP</td><td class="NLM_def"><p class="first last">retinal vascular permeability</p></td></tr><tr><td class="NLM_term">TBMB</td><td class="NLM_def"><p class="first last">1,3,5-tris(bromomethyl)benzene</p></td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">amino acid</p></td></tr><tr><td class="NLM_term">aPTT</td><td class="NLM_def"><p class="first last">activated partial thromboplastin time</p></td></tr><tr><td class="NLM_term">IVT</td><td class="NLM_def"><p class="first last">intravitreal</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine</p></td></tr><tr><td class="NLM_term">STZ</td><td class="NLM_def"><p class="first last">strepozotocine</p></td></tr><tr><td class="NLM_term">FITC-BSA</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate-labeled bovine serum albumin</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 71 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kresse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E.</span></span> <span> </span><span class="NLM_article-title">Expression of plasma prekallikrein mRNA in human nonhepatic tissues and cell lineages suggests special local functions of the enzyme</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1515/BC.1999.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1515%2FBC.1999.136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1999&pages=1097-1102&author=A.+Hermannauthor=M.+Arnholdauthor=H.+Kresseauthor=P.+Nethauthor=E.+Fink&title=Expression+of+plasma+prekallikrein+mRNA+in+human+nonhepatic+tissues+and+cell+lineages+suggests+special+local+functions+of+the+enzyme&doi=10.1515%2FBC.1999.136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1515%2FBC.1999.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.1999.136%26sid%3Dliteratum%253Aachs%26aulast%3DHermann%26aufirst%3DA.%26aulast%3DArnhold%26aufirst%3DM.%26aulast%3DKresse%26aufirst%3DH.%26aulast%3DNeth%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DE.%26atitle%3DExpression%2520of%2520plasma%2520prekallikrein%2520mRNA%2520in%2520human%2520nonhepatic%2520tissues%2520and%2520cell%2520lineages%2520suggests%2520special%2520local%2520functions%2520of%2520the%2520enzyme%26jtitle%3DBiol.%2520Chem.%26date%3D1999%26volume%3D380%26spage%3D1097%26epage%3D1102%26doi%3D10.1515%2FBC.1999.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/35060059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2F35060059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=11231576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFenuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=267-275&author=S.+Selvarajanauthor=L.+R.+Lundauthor=T.+Takeuchiauthor=C.+S.+Craikauthor=Z.+Werb&title=A+plasma+kallikrein-dependent+plasminogen+cascade+required+for+adipocyte+differentiation&doi=10.1038%2F35060059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation</span></div><div class="casAuthors">Selvarajan, Sushma; Lund, Leif R.; Takeuchi, Toshihiko; Craik, Charles S.; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we show that plasma kallikrein (PKal) mediates a plasminogen (Pig) cascade in adipocyte differentiation.  Ecotin, an inhibitor of serine proteases, inhibits cell-shape change, adipocyte-specific gene expression, and lipid accumulation during adipogenesis in culture.  Deficiency of Pig, but not of urokinase or tissue-type plasminogen activator, suppresses adipogenesis during differentiation of 3T3-L1 cells and mammary-gland involution.  PKal, which is inhibited by ecotin, is required for adipose conversion, Pig activation and 3T3-L1 differentiation.  Human plasma lacking PKal does not support differentiation of 3T3-L1 cells.  PKal is therefore a physiol. regulator that acts in the Pig cascade during adipogenesis.  We propose that the Pig cascade fosters adipocyte differentiation by degrdn. of the fibronectin-rich preadipocyte stromal matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEC38vIj-Oz7Vg90H21EOLACvtfcHk0likvVtBlGsZOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFenuro%253D&md5=9bc97a4c41ab2748f6344c1fbc8035fe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35060059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060059%26sid%3Dliteratum%253Aachs%26aulast%3DSelvarajan%26aufirst%3DS.%26aulast%3DLund%26aufirst%3DL.%2BR.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DA%2520plasma%2520kallikrein-dependent%2520plasminogen%2520cascade%2520required%2520for%2520adipocyte%2520differentiation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D267%26epage%3D275%26doi%3D10.1038%2F35060059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeb-Lundberg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Esterl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuraw, B. L.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1124/pr.57.1.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1124%2Fpr.57.1.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15734727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=27-77&author=L.+M.+Leeb-Lundbergauthor=F.+Marceauauthor=W.+M%C3%BCller-Esterlauthor=D.+J.+Pettiboneauthor=B.+L.+Zuraw&title=International+union+of+pharmacology.+XLV.+Classification+of+the+kinin+receptor+family%3A+from+molecular+mechanisms+to+pathophysiological+consequences&doi=10.1124%2Fpr.57.1.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences</span></div><div class="casAuthors">Leeb-Lundberg, L. M. Fredrik; Marceau, Francois; Mueller-Esterl, Werner; Pettibone, Douglas J.; Zuraw, Bruce L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-77</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Kinins are proinflammatory peptides that mediate numerous vascular and pain responses to tissue injury.  Two pharmacol. distinct kinin receptor subtypes have been identified and characterized for these peptides, which are named B1 and B2 and belong to the rhodopsin family of G protein-coupled receptors.  The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B1 receptor mediates the action of des-Arg9-BK and Lys-des-Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, resp.  The B2 receptor is ubiquitous and constitutively expressed, whereas the B1 receptor is expressed at a very low level in healthy tissues but induced following injury by various proinflammatory cytokines such as interleukin-1β.  Both receptors act through Gαq to stimulate phospholipase Cβ followed by phosphoinositide hydrolysis and intracellular free Ca2+ mobilization and through Gαi to inhibit adenylate cyclase and stimulate the mitogen-activated protein kinase pathways.  The use of mice lacking each receptor gene and various specific peptidic and non-peptidic antagonists have implicated both B1 and B2 receptors as potential therapeutic targets in several pathophysiol. events related to inflammation such as pain, sepsis, allergic asthma, rhinitis, and edema, as well as diabetes and cancer.  This review is a comprehensive presentation of our current understanding of these receptors in terms of mol. and cell biol., physiol., pharmacol., and involvement in human disease and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDJ2JFxaOYz7Vg90H21EOLACvtfcHk0likvVtBlGsZOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtr0%253D&md5=cfa8e13f88fa09602e7e4dcc38872981</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.1.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.1.2%26sid%3Dliteratum%253Aachs%26aulast%3DLeeb-Lundberg%26aufirst%3DL.%2BM.%26aulast%3DMarceau%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Esterl%26aufirst%3DW.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DZuraw%26aufirst%3DB.%2BL.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XLV.%2520Classification%2520of%2520the%2520kinin%2520receptor%2520family%253A%2520from%2520molecular%2520mechanisms%2520to%2520pathophysiological%2520consequences%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D27%26epage%3D77%26doi%3D10.1124%2Fpr.57.1.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmaier, A. H.</span></span> <span> </span><span class="NLM_article-title">The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1111/jth.13194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fjth.13194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26565070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=28-39&author=A.+H.+Schmaier&title=The+contact+activation+and+kallikrein%2Fkinin+systems%3A+pathophysiologic+and+physiologic+activities&doi=10.1111%2Fjth.13194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities</span></div><div class="casAuthors">Schmaier, A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : The contact activation system (CAS) and kallikrein/kinin system (KKS) are older recognized biochem. pathways that include several proteins that skirt the fringes of the blood coagulation, fibrinolytic, complement and renin-angiotensin fields.  These proteins initially were proposed as part of the hemostatic pathways because their deficiencies are assocd. with prolonged clin. assays.  However, the absence of bleeding states with deficiencies of factor XII (FXII), prekallikrein (PK) and high-mol.-wt. kininogen indicates that the CAS and KKS do not contribute to hemostasis.  Since the discovery of the Hageman factor 60 years ago much has been learned about the biochem., cell biol. and animal physiol. of these proteins.  The CAS is a pathophysiol. surface defense mechanism against foreign proteins, organisms and artificial materials.  The KKS is an inflammatory response mechanism.  Targeting their activation through FXIIa or plasma kallikrein inhibition when blood interacts with the artificial surfaces of modern interventional medicine or in acute attacks of hereditary angioedema restores vascular homeostasis.  FXII/FXIIa and products that arise with PK deficiency also offer novel ways to reduce arterial and venous thrombosis without an effect on hemostasis.  In summary, there is revived interest in the CAS and KKS due to better understanding of their activities.  The new appreciation of these systems will lead to several new therapies for a variety of medical disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkD1I_arQFy7Vg90H21EOLACvtfcHk0lgkBCGiB45Ukg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtLY%253D&md5=8bf50534f95c4cba82133a32a64c83c2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fjth.13194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13194%26sid%3Dliteratum%253Aachs%26aulast%3DSchmaier%26aufirst%3DA.%2BH.%26atitle%3DThe%2520contact%2520activation%2520and%2520kallikrein%252Fkinin%2520systems%253A%2520pathophysiologic%2520and%2520physiologic%2520activities%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2016%26volume%3D14%26spage%3D28%26epage%3D39%26doi%3D10.1111%2Fjth.13194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochrane, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revak, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuepper, K. D.</span></span> <span> </span><span class="NLM_article-title">Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1084/jem.138.6.1564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1084%2Fjem.138.6.1564" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1973&pages=1564-1583&author=C.+G.+Cochraneauthor=S.+D.+Revakauthor=K.+D.+Wuepper&title=Activation+of+Hageman+factor+in+solid+and+fluid+phases.+A+critical+role+of+kallikrein&doi=10.1084%2Fjem.138.6.1564"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.138.6.1564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.138.6.1564%26sid%3Dliteratum%253Aachs%26aulast%3DCochrane%26aufirst%3DC.%2BG.%26aulast%3DRevak%26aufirst%3DS.%2BD.%26aulast%3DWuepper%26aufirst%3DK.%2BD.%26atitle%3DActivation%2520of%2520Hageman%2520factor%2520in%2520solid%2520and%2520fluid%2520phases.%2520A%2520critical%2520role%2520of%2520kallikrein%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1973%26volume%3D138%26spage%3D1564%26epage%3D1583%26doi%3D10.1084%2Fjem.138.6.1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaier, A. H.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">17962</span>– <span class="NLM_lpage">17969</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106101200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.M106101200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=17962-17969&author=Z.+Shariat-Madarauthor=F.+Mahdiauthor=A.+H.+Schmaier&title=Identification+and+characterization+of+prolylcarboxypeptidase+as+an+endothelial+cell+prekallikrein+activator&doi=10.1074%2Fjbc.M106101200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106101200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106101200%26sid%3Dliteratum%253Aachs%26aulast%3DShariat-Madar%26aufirst%3DZ.%26aulast%3DMahdi%26aufirst%3DF.%26aulast%3DSchmaier%26aufirst%3DA.%2BH.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520prolylcarboxypeptidase%2520as%2520an%2520endothelial%2520cell%2520prekallikrein%2520activator%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D17962%26epage%3D17969%26doi%3D10.1074%2Fjbc.M106101200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bork, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staubach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardt, J.</span></span> <span> </span><span class="NLM_article-title">Hereditary angioedema: new findings concerning symptoms, affected organs, and course</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2005.09.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.amjmed.2005.09.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=16490473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD287gt1KgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=267-274&author=K.+Borkauthor=G.+Mengauthor=P.+Staubachauthor=J.+Hardt&title=Hereditary+angioedema%3A+new+findings+concerning+symptoms%2C+affected+organs%2C+and+course&doi=10.1016%2Fj.amjmed.2005.09.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hereditary angioedema: new findings concerning symptoms, affected organs, and course</span></div><div class="casAuthors">Bork Konrad; Meng Gabriele; Staubach Petra; Hardt Jochen</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction.  Our aim was to examine a temporal and spatial pattern of the edema episodes by evaluating the long-term course of hereditary angioedema in order to establish a specific swelling pattern.  SUBJECTS AND METHODS:  Data were generated from 221 patients with C1 inhibitor deficiency by asking them about symptoms they experienced during their edema episodes.  Documentation was accomplished through the use of standardized questionnaires.  RESULTS:  A total of 131110 edema episodes were observed.  Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.  During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.  Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.  The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.  The per-patient analysis and the per-episode analysis revealed markedly discrepant results.  On average, women had a more severe course of the disease than men.  Patients with early onset of clinical symptoms were affected more severely than those with late onset.  CONCLUSION:  The described swelling pattern is specific for HAE and allows a tentative diagnosis based on clinical symptoms and the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTKHdpx19dgZ0d-O_J5C0AfW6udTcc2eYkBi8V-nttDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287gt1KgsA%253D%253D&md5=4f0708b76a8f977f29e81ccb4f366aed</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2005.09.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2005.09.064%26sid%3Dliteratum%253Aachs%26aulast%3DBork%26aufirst%3DK.%26aulast%3DMeng%26aufirst%3DG.%26aulast%3DStaubach%26aufirst%3DP.%26aulast%3DHardt%26aufirst%3DJ.%26atitle%3DHereditary%2520angioedema%253A%2520new%2520findings%2520concerning%2520symptoms%252C%2520affected%2520organs%252C%2520and%2520course%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3D267%26epage%3D274%26doi%3D10.1016%2Fj.amjmed.2005.09.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1586/eci.13.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1586%2Feci.13.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=23634741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVSmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=477-488&author=A.+Zanichelliauthor=M.+Mansiauthor=G.+Peritiauthor=M.+Cicardi&title=Therapeutic+management+of+hereditary+angioedema+due+to+C1+inhibitor+deficiency&doi=10.1586%2Feci.13.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency</span></div><div class="casAuthors">Zanichelli, Andrea; Mansi, Marta; Periti, Giulia; Cicardi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-488</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency is a rare genetic disease characterized by recurrent swellings of the s.c. and submucosal tissues that can manifest as cutaneous edema, abdominal pain and laryngeal edema with airway obstruction.  These symptoms have a significant impact on patients' quality of life.  The redn. in C1-INH function leads to uncontrolled activation of the contact system and generation of bradykinin, the mediator of increased vascular permeability and edema formation.  In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.  Such therapies can improve disease outcome.  This article reviews the therapeutic management of HAE, which involves the treatment of acute attacks and prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS_4laFjZeAbVg90H21EOLACvtfcHk0lgkBCGiB45Ukg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVSmsbY%253D&md5=9a70912e49b76f70ec0dc481c6d56555</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1586%2Feci.13.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.13.22%26sid%3Dliteratum%253Aachs%26aulast%3DZanichelli%26aufirst%3DA.%26aulast%3DMansi%26aufirst%3DM.%26aulast%3DPeriti%26aufirst%3DG.%26aulast%3DCicardi%26aufirst%3DM.%26atitle%3DTherapeutic%2520management%2520of%2520hereditary%2520angioedema%2520due%2520to%2520C1%2520inhibitor%2520deficiency%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D9%26spage%3D477%26epage%3D488%26doi%3D10.1586%2Feci.13.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span> <span> </span><span class="NLM_article-title">Current treatment options for hereditary angioedema due to C1 inhibitor deficiency</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1517/14656566.2016.1104300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1517%2F14656566.2016.1104300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26512744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=27-40&author=M.+A.+Wuauthor=A.+Zanichelliauthor=M.+Mansiauthor=M.+Cicardi&title=Current+treatment+options+for+hereditary+angioedema+due+to+C1+inhibitor+deficiency&doi=10.1517%2F14656566.2016.1104300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatment options for hereditary angioedema due to C1 inhibitor deficiency</span></div><div class="casAuthors">Wu, Maddalena Alessandra; Zanichelli, Andrea; Mansi, Marta; Cicardi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-40</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Hereditary angioedema (HAE) usually results from C1 inhibitor (C1-INH) deficiency or dysfunction.  It is a rare autosomal dominant disorder characterized by localized, non-pitting edema of the skin and submucosal tissues of the upper respiratory and gastrointestinal tracts, without significant wheals or pruritus, due to a temporary increase in vascular permeability.  Other forms of HAE have been described, but therapies are approved only for HAE with C1-INH deficiency: hence, this review focuses on C1-INH-HAE.  The aim of this review article is to present current available therapies for treatment of acute attacks as well as for short- and long-term prophylaxis of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).  The Authors highlight also crit. issues on the management of C1-INH-HAE, which is continuously evolving thanks to evidence from clin. trials, post-marketing experience and ongoing studies.  In the last decade, the quality of life of C1-INH-HAE patients has significantly improved due to increased knowledge and awareness of the disease, improved patient support and major progress in pharmacotherapy.  Ongoing research will probably provide patients with other new effective therapeutic agents in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsU2tl__aPbVg90H21EOLACvtfcHk0li-flToh8kErA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWntLfI&md5=1cf9b8018878b234c5098d560a61dc19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1104300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1104300%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%2BA.%26aulast%3DZanichelli%26aufirst%3DA.%26aulast%3DMansi%26aufirst%3DM.%26aulast%3DCicardi%26aufirst%3DM.%26atitle%3DCurrent%2520treatment%2520options%2520for%2520hereditary%2520angioedema%2520due%2520to%2520C1%2520inhibitor%2520deficiency%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D27%26epage%3D40%26doi%3D10.1517%2F14656566.2016.1104300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B. E.</span></span> <span> </span><span class="NLM_article-title">The 14-year incidence of visual loss in a diabetic population</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/S0161-6420(98)96025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2FS0161-6420%2898%2996025-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1998&pages=998-1003&author=S.+E.+Mossauthor=R.+Kleinauthor=B.+E.+Klein&title=The+14-year+incidence+of+visual+loss+in+a+diabetic+population&doi=10.1016%2FS0161-6420%2898%2996025-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0161-6420%2898%2996025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-6420%252898%252996025-0%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DS.%2BE.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DB.%2BE.%26atitle%3DThe%252014-year%2520incidence%2520of%2520visual%2520loss%2520in%2520a%2520diabetic%2520population%26jtitle%3DOphthalmology%26date%3D1998%26volume%3D105%26spage%3D998%26epage%3D1003%26doi%3D10.1016%2FS0161-6420%2898%2996025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobrin
Klein, B. E.</span></span> <span> </span><span class="NLM_article-title">Overview of epidemiologic studies of diabetic retinopathy</span>. <i>Ophthalmic Epidemiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1080/09286580701396720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F09286580701396720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17896294" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=179-183&author=B.+E.+Kobrin%0AKlein&title=Overview+of+epidemiologic+studies+of+diabetic+retinopathy&doi=10.1080%2F09286580701396720"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F09286580701396720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09286580701396720%26sid%3Dliteratum%253Aachs%26aulast%3DKobrin%2BKlein%26aufirst%3DB.%2BE.%26atitle%3DOverview%2520of%2520epidemiologic%2520studies%2520of%2520diabetic%2520retinopathy%26jtitle%3DOphthalmic%2520Epidemiol.%26date%3D2007%26volume%3D14%26spage%3D179%26epage%3D183%26doi%3D10.1080%2F09286580701396720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Diabetic retinopathy</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)62124-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2FS0140-6736%2809%2962124-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20580421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsFagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=124-136&author=N.+Cheungauthor=P.+Mitchellauthor=T.+Y.+Wong&title=Diabetic+retinopathy&doi=10.1016%2FS0140-6736%2809%2962124-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetic retinopathy</span></div><div class="casAuthors">Cheung Ning; Mitchell Paul; Wong Tien Yin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9735</span>),
    <span class="NLM_cas:pages">124-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetic retinopathy is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people.  It is identified in a third of people with diabetes and associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure.  Optimum control of blood glucose, blood pressure, and possibly blood lipids remains the foundation for reduction of risk of retinopathy development and progression.  Timely laser therapy is effective for preservation of sight in proliferative retinopathy and macular oedema, but its ability to reverse visual loss is poor.  Vitrectomy surgery might occasionally be needed for advanced retinopathy.  New therapies, such as intraocular injection of steroids and antivascular endothelial growth-factor agents, are less destructive to the retina than are older therapies, and could be useful in patients who respond poorly to conventional therapy.  The outlook for future treatment modalities, such as inhibition of other angiogenic factors, regenerative therapy, and topical therapy, is promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-zCpfQ9sM6TW1zwg2yUK5fW6udTcc2eYUPnhQw1HqG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsFagsw%253D%253D&md5=457af59cd94a589ee5e870b6aa721e49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2962124-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252962124-3%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DN.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DDiabetic%2520retinopathy%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D124%26epage%3D136%26doi%3D10.1016%2FS0140-6736%2809%2962124-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokofyeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrenner, E.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of major eye diseases leading to blindness in Europe: A literature review</span>. <i>Ophthalmic Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1159/000329603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1159%2F000329603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22123077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38zotFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=171-188&author=E.+Prokofyevaauthor=E.+Zrenner&title=Epidemiology+of+major+eye+diseases+leading+to+blindness+in+Europe%3A+A+literature+review&doi=10.1159%2F000329603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of major eye diseases leading to blindness in Europe: a literature review</span></div><div class="casAuthors">Prokofyeva Elena; Zrenner Eberhart</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmic research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">171-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The objective of this work was to study the epidemiology of major eye diseases leading to blindness in Europe through a systematic literature review.  The literature search was performed using the Medline database (PubMed), with MeSH and free text search terms.  Inclusion criteria for the studies were: (a) performed on a healthy population of Caucasian origin aged between 50 and 75 years; (b) diagnosed by ophthalmological examination in accordance with the International Classification of Diseases 10; (c) contained a detailed description of the sampling and diagnostic procedures and data resources; (d) sample size>500, and (e) published between 1990 and 2008.  The results of 57 studies on the prevalence and incidence of age-related macular degeneration, diabetic retinopathy and glaucoma are reported, providing an up-to-date and comprehensive overview of these diseases in Europe from an epidemiological perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSXUve1sLb_IkFb3mqPUYDfW6udTcc2eYUPnhQw1HqG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zotFSqsw%253D%253D&md5=948e7717a173b0c3eab449c101bcb16f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000329603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000329603%26sid%3Dliteratum%253Aachs%26aulast%3DProkofyeva%26aufirst%3DE.%26aulast%3DZrenner%26aufirst%3DE.%26atitle%3DEpidemiology%2520of%2520major%2520eye%2520diseases%2520leading%2520to%2520blindness%2520in%2520Europe%253A%2520A%2520literature%2520review%26jtitle%3DOphthalmic%2520Res.%26date%3D2012%26volume%3D47%26spage%3D171%26epage%3D188%26doi%3D10.1159%2F000329603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, M. J.</span></span> <span> </span><span class="NLM_article-title">Current and investigational drugs for the treatment of diabetic retinopathy</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F13543784.2016.1201062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1011-1022&author=M.+S.+Tolentinoauthor=A.+J.+Tolentinoauthor=M.+J.+Tolentino&title=Current+and+investigational+drugs+for+the+treatment+of+diabetic+retinopathy&doi=10.1080%2F13543784.2016.1201062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DTolentino%26aufirst%3DM.%2BS.%26aulast%3DTolentino%26aufirst%3DA.%2BJ.%26aulast%3DTolentino%26aufirst%3DM.%2BJ.%26atitle%3DCurrent%2520and%2520investigational%2520drugs%2520for%2520the%2520treatment%2520of%2520diabetic%2520retinopathy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1011%26epage%3D1022%26doi%3D10.1080%2F13543784.2016.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicree, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmet, P. Z.</span></span> <span> </span><span class="NLM_article-title">Global estimates of the prevalence of diabetes for 2010 and 2030</span>. <i>Diabetes Res. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.diabres.2009.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.diabres.2009.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19896746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fot1Witg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=4-14&author=J.+E.+Shawauthor=R.+A.+Sicreeauthor=P.+Z.+Zimmet&title=Global+estimates+of+the+prevalence+of+diabetes+for+2010+and+2030&doi=10.1016%2Fj.diabres.2009.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Global estimates of the prevalence of diabetes for 2010 and 2030</span></div><div class="casAuthors">Shaw J E; Sicree R A; Zimmet P Z</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes research and clinical practice</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  We estimated the number of people worldwide with diabetes for the years 2010 and 2030.  METHODS:  Studies from 91 countries were used to calculate age- and sex-specific diabetes prevalences, which were applied to national population estimates, to determine national diabetes prevalences for all 216 countries for 2010 and 2030.  Studies were identified using Medline, and contact with all national and regional International Diabetes Federation offices.  Studies were included if diabetes prevalence was assessed using a population-based methodology, and was based on World Health Organization or American Diabetes Association diagnostic criteria for at least three separate age-groups within the 20-79 year range.  Self-report or registry data were used if blood glucose assessment was not available.  RESULTS:  The world prevalence of diabetes among adults (aged 20-79 years) will be 6.4%, affecting 285 million adults, in 2010, and will increase to 7.7%, and 439 million adults by 2030.  Between 2010 and 2030, there will be a 69% increase in numbers of adults with diabetes in developing countries and a 20% increase in developed countries.  CONCLUSION:  These predictions, based on a larger number of studies than previous estimates, indicate a growing burden of diabetes, particularly in developing countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRahe1LLx72-EEksK8CslK8fW6udTcc2eatkGqJ6etKSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fot1Witg%253D%253D&md5=111a4bed809880f5584fda783e64de89</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.diabres.2009.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diabres.2009.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26aulast%3DSicree%26aufirst%3DR.%2BA.%26aulast%3DZimmet%26aufirst%3DP.%2BZ.%26atitle%3DGlobal%2520estimates%2520of%2520the%2520prevalence%2520of%2520diabetes%2520for%25202010%2520and%25202030%26jtitle%3DDiabetes%2520Res.%2520Clin.%2520Pract.%26date%3D2010%26volume%3D87%26spage%3D4%26epage%3D14%26doi%3D10.1016%2Fj.diabres.2009.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ting, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review</span>. <i>Clin. Experiment. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1111/ceo.12696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fceo.12696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26716602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC28rlvVWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=260-277&author=D.+S.+Tingauthor=G.+C.+Cheungauthor=T.+Y.+Wong&title=Diabetic+retinopathy%3A+global+prevalence%2C+major+risk+factors%2C+screening+practices+and+public+health+challenges%3A+a+review&doi=10.1111%2Fceo.12696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review</span></div><div class="casAuthors">Ting Daniel Shu Wei; Cheung Gemmy Chui Ming; Wong Tien Yin; Ting Daniel Shu Wei; Cheung Gemmy Chui Ming; Wong Tien Yin; Cheung Gemmy Chui Ming; Wong Tien Yin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & experimental ophthalmology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes retinopathy (DR) is a leading cause of vision loss in middle-aged and elderly people globally.  Early detection and prompt treatment allow prevention of diabetes-related visual impairment.  Patients with diabetes require regular follow-up with primary care physicians to optimize their glycaemic, blood pressure and lipid control to prevent development and progression of DR and other diabetes-related complications.  Other risk factors of DR include higher body mass index, puberty and pregnancy, and cataract surgery.  There are weaker associations with some genetic and inflammatory markers.  With the rising incidence and prevalence of diabetes and DR, public health systems in both developing and developed countries will be faced with increasing costs of implementation and maintenance of a DR screening program for people with diabetes.  To reduce the impact of DR-related visual loss, it is important that all stakeholders continue to look for innovative ways of managing and preventing diabetes, and optimize cost-effective screening programs within the community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkxrtbCXO5hUwlCcfExbvbfW6udTcc2eatkGqJ6etKSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlvVWiug%253D%253D&md5=8e4b934f4abe68713b713c676258ca68</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fceo.12696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fceo.12696%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DD.%2BS.%26aulast%3DCheung%26aufirst%3DG.%2BC.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DDiabetic%2520retinopathy%253A%2520global%2520prevalence%252C%2520major%2520risk%2520factors%252C%2520screening%2520practices%2520and%2520public%2520health%2520challenges%253A%2520a%2520review%26jtitle%3DClin.%2520Experiment.%2520Ophthalmol.%26date%3D2016%26volume%3D44%26spage%3D260%26epage%3D277%26doi%3D10.1111%2Fceo.12696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunirakasiwi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjay, S.</span></span> <span> </span><span class="NLM_article-title">Updates in the management of diabetic macular edema</span>. <i>J. Diabetes Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">794036</span>, <span class="refDoi"> DOI: 10.1155/2015/794036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1155%2F2015%2F794036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25984537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MbpsVentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=794036&author=C.+Mathewauthor=A.+Yunirakasiwiauthor=S.+Sanjay&title=Updates+in+the+management+of+diabetic+macular+edema&doi=10.1155%2F2015%2F794036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Updates in the management of diabetic macular edema</span></div><div class="casAuthors">Mathew Christopher; Yunirakasiwi Anastasia; Sanjay Srinivasan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">794036</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes mellitus is a chronic disease which has multiple effects on different end-organs, including the retina.  In this paper, we discuss updates on diabetic macular edema (DME) and the management options.  The underlying pathology of DME is the leakage of exudates from retinal microaneurysms, which trigger subsequent inflammatory reactions.  Both clinical and imaging techniques are useful in diagnosing, classifying, and gauging the severity of DME.  We performed a comprehensive literature search using the keywords "diabetes," "macula edema," "epidemiology," "pathogenesis," "optical coherence tomography," "intravitreal injections," "systemic treatment," "hypertension," "hyperlipidemia," "anemia," and "renal disease" and collated a total of 47 relevant articles published in English language.  The main modalities of treatment currently in use comprise laser photocoagulation, intravitreal pharmacological and selected systemic pharmacological options.  In addition, we mention some novel therapies that show promise in treating DME.  We also review systemic factors associated with exacerbation or improvement in DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVk08ed0nQFUewzGPswiWOfW6udTcc2eatkGqJ6etKSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbpsVentg%253D%253D&md5=ee823778fe601100d2b1ed80c3d47a88</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2015%2F794036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F794036%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DC.%26aulast%3DYunirakasiwi%26aufirst%3DA.%26aulast%3DSanjay%26aufirst%3DS.%26atitle%3DUpdates%2520in%2520the%2520management%2520of%2520diabetic%2520macular%2520edema%26jtitle%3DJ.%2520Diabetes%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D794036%26doi%3D10.1155%2F2015%2F794036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein and diabetic macular edema</span>. <i>Curr. Diabetes Rep.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1007/s11892-010-0127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1007%2Fs11892-010-0127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20535647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1CjsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=270-275&author=E.+P.+Feener&title=Plasma+kallikrein+and+diabetic+macular+edema&doi=10.1007%2Fs11892-010-0127-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma kallikrein and diabetic macular edema</span></div><div class="casAuthors">Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Recent proteomic studies have identified components of the kallikrein kinin system, including plasma kallikrein, factor XII, and kininogen, in vitreous obtained from individuals with advanced diabetic retinopathy.  In rodent models, activation of plasma kallikrein in vitreous increases retinal vascular permeability; whereas inhibition of the kallikrein kinin system reduces retinal leakage induced by diabetes and hypertension.  These findings suggest that intraocular activation of the plasma kallikrein pathway may contribute to excessive retinal vascular permeability that can lead to diabetic macular edema.  The kallikrein kinin system contains two sep. and independently regulated serine proteases that generate bradykinin peptides: plasma kallikrein and tissue kallikrein.  Tissue kallikrein is expressed in the retina and ciliary body, where it has been implicated in exerting autocrine or paracrine effects via bradykinin receptors that are colocalized in these tissues.  Emerging evidence suggests that plasma kallikrein inhibitors may provide a new therapeutic opportunity to reduce retinal vascular permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEKZDO9o3ju7Vg90H21EOLACvtfcHk0lhUKqiAaIiKVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1CjsbzK&md5=6dbf844cf720bce4e6f59ffc10538e3f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11892-010-0127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-010-0127-1%26sid%3Dliteratum%253Aachs%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520and%2520diabetic%2520macular%2520edema%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2010%26volume%3D10%26spage%3D270%26epage%3D275%26doi%3D10.1007%2Fs11892-010-0127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdouh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasséssian, H. M.</span></span> <span> </span><span class="NLM_article-title">Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fbjp.2008.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=18311190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFOrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=136-143&author=M.+Abdouhauthor=S.+Talbotauthor=R.+Coutureauthor=H.+M.+Hass%C3%A9ssian&title=Retinal+plasma+extravasation+in+streptozotocin-diabetic+rats+mediated+by+kinin+B%281%29+and+B%282%29+receptors&doi=10.1038%2Fbjp.2008.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors</span></div><div class="casAuthors">Abdouh, M.; Talbot, S.; Couture, R.; Hassessian, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-143</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We investigated whether or not kinin receptors play a role in diabetic blood-retinal barrier breakdown, which is a leading cause of vision loss.  Blood-retinal barrier breakdown was quantified using Evans blue, and expression of kinin B1 receptor mRNA was measured using quant. reverse transcription-PCR.  Diabetic rats (streptozotocin (STZ), 65 mg kg-1) received a single intraocular injection of bradykinin (BK) or des-Arg9-BK, alone, or in combination with antagonists for B1 (des-Arg10-Hoe140, R-715) and/or B2 (Hoe140) receptors, given intraocularly or i.v. (i.v.).  In control rats, BK (0.1-10 nmol) dose-dependently increased plasma extravasation, which was inhibited by Hoe140 (0.2 nmol), whereas des-Arg9-BK (0.1 and 1 nmol) was without effect.  B1 receptor mRNA was markedly increased in retinas of diabetic rats, and this was prevented by N-acetyl-L-cysteine (1 g kg-1 day-1 for 7 days).  Plasma extravasation in retinas of STZ-diabetic rats was higher than in controls and enhanced by des-Arg9-BK.  Response to des-Arg9-BK was inhibited by intraocular or i.v. injection of B1 receptor antagonists.  Diabetes-induced plasma extravasation was inhibited only by a combination of des-Arg10-Hoe140 and Hoe 140 (100 nmol kg-1, i.v. 15 min earlier) or by R-715 (1 μmol kg-1, i.v.) injected daily for 7 days.  Kinin B1 receptors are upregulated in retinas of STZ-diabetic rats through a mechanism involving oxidative stress.  Both kinin B1 and B2 receptors contribute to increased plasma extravasation in diabetic retinopathy.  Chronic inhibition of both kinin receptors, possibly with antioxidant adjuvants, may be a novel therapeutic strategy for diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplkRsasjse6rVg90H21EOLACvtfcHk0lhUKqiAaIiKVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFOrurw%253D&md5=e9263e68c006050a8387dab7237f1480</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.48%26sid%3Dliteratum%253Aachs%26aulast%3DAbdouh%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DS.%26aulast%3DCouture%26aufirst%3DR.%26aulast%3DHass%25C3%25A9ssian%26aufirst%3DH.%2BM.%26atitle%3DRetinal%2520plasma%2520extravasation%2520in%2520streptozotocin-diabetic%2520rats%2520mediated%2520by%2520kinin%2520B%25281%2529%2520and%2520B%25282%2529%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D136%26epage%3D143%26doi%3D10.1038%2Fbjp.2008.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonda, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrigg, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nm1534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnm1534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17259996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=181-188&author=B.+B.+Gaoauthor=A.+Clermontauthor=S.+Rookauthor=S.+J.+Fondaauthor=V.+J.+Srinivasanauthor=M.+Wojtkowskiauthor=J.+G.+Fujimotoauthor=R.+L.+Averyauthor=P.+G.+Arriggauthor=S.+E.+Bursellauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Extracellular+carbonic+anhydrase+mediates+hemorrhagic+retinal+and+cerebral+vascular+permeability+through+prekallikrein+activation&doi=10.1038%2Fnm1534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation</span></div><div class="casAuthors">Gao, Ben-Bo; Clermont, Allen; Rook, Susan; Fonda, Stephanie J.; Srinivasan, Vivek J.; Wojtkowski, Maciej; Fujimoto, James G.; Avery, Robert L.; Arrigg, Paul G.; Bursell, Sven-Erik; Aiello, Lloyd Paul; Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-188</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Excessive retinal vascular permeability contributes to the pathogenesis of proliferative diabetic retinopathy and diabetic macular edema, leading causes of vision loss in working-age adults.  Using mass spectroscopy-based proteomics, we detected 117 proteins in human vitreous and elevated levels of extracellular carbonic anhydrase-I (CA-I) in vitreous from individuals with diabetic retinopathy, suggesting that retinal hemorrhage and erythrocyte lysis contribute to the diabetic vitreous proteome.  Intravitreous injection of CA-I in rats increased retinal vessel leakage and caused intraretinal edema.  CA-I-induced alkalinization of vitreous increased kallikrein activity and its generation of factor XIIa, revealing a new pathway for contact system activation.  CA-I-induced retinal edema was decreased by complement 1 inhibitor, neutralizing antibody to prekallikrein and bradykinin receptor antagonism.  Subdural infusion of CA-I in rats induced cerebral vascular permeability, suggesting that extracellular CA-I could have broad relevance to neurovascular edema.  Inhibition of extracellular CA-I and kallikrein-mediated innate inflammation could provide new therapeutic opportunities for the treatment of hemorrhage-induced retinal and cerebral edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ-m__J9Zk9bVg90H21EOLACvtfcHk0lhUKqiAaIiKVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyktbg%253D&md5=5b1f84e067258905cc21247986308abb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnm1534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1534%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DB.%2BB.%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DRook%26aufirst%3DS.%26aulast%3DFonda%26aufirst%3DS.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DV.%2BJ.%26aulast%3DWojtkowski%26aufirst%3DM.%26aulast%3DFujimoto%26aufirst%3DJ.%2BG.%26aulast%3DAvery%26aufirst%3DR.%2BL.%26aulast%3DArrigg%26aufirst%3DP.%2BG.%26aulast%3DBursell%26aufirst%3DS.%2BE.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DExtracellular%2520carbonic%2520anhydrase%2520mediates%2520hemorrhagic%2520retinal%2520and%2520cerebral%2520vascular%2520permeability%2520through%2520prekallikrein%2520activation%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D181%26epage%3D188%26doi%3D10.1038%2Fnm1534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timothy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2516</span>– <span class="NLM_lpage">2525</span>, <span class="refDoi"> DOI: 10.1021/pr800112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr800112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVeitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2516-2525&author=B.+B.+Gaoauthor=X.+Chenauthor=N.+Timothyauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Characterization+of+the+vitreous+proteome+in+diabetes+without+diabetic+retinopathy+and+diabetes+with+proliferative+diabetic+retinopathy&doi=10.1021%2Fpr800112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Vitreous Proteome in Diabetes without Diabetic Retinopathy and Diabetes with Proliferative Diabetic Retinopathy</span></div><div class="casAuthors">Gao, Ben-Bo; Chen, Xiaohong; Timothy, Nigel; Aiello, Lloyd Paul; Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2516-2525</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An understanding of the diabetes-induced alterations in vitreous protein compn. in the absence and in the presence of proliferative diabetic retinopathy (PDR) may provide insights into factors and mechanisms responsible for this disease.  We have performed a comprehensive proteomic anal. and comparison of vitreous samples from individuals with diabetes but without diabetic retinopathy (noDR) or with PDR and nondiabetic individuals (NDM).  Using preparative one-dimensional SDS-PAGE and nano-LC/MS/MS of 17 independent vitreous samples, we identified 252 proteins from human vitreous.  Fifty-six proteins were differentially abundant in noDR and PDR vitreous compared with NDM vitreous, including 32 proteins increased and 10 proteins decreased in PDR vitreous compared with NDM vitreous.  Comparison of noDR and PDR groups revealed increased levels of angiotensinogen and decreased levels of calsyntenin-1, interphotoreceptor retinoid-binding protein, and neuroserpin in PDR vitreous.  Biol. pathway anal. revealed that vitreous contains 30 proteins assocd. with the kallikrein-kinin, coagulation, and complement systems.  Five of them (complement C3, complement factor I, prothrombin, alpha-1-antitrypsin, and antithrombin III) were increased in PDR vitreous compared with NDM vitreous.  Factor XII was detected in PDR vitreous but not obsd. in either NDM or noDR vitreous.  PDR vitreous also had increased levels of peroxiredoxin-1 and decreased levels of extracellular superoxide dismutase, compared with noDR or NDM vitreous.  These data provide an in depth anal. of the human vitreous proteome and reveal protein alterations that are assocd. with PDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvUR5b89k5tLVg90H21EOLACvtfcHk0liY8XyGpiaDBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVeitrk%253D&md5=6b14662bae828e12147a648bb71ca341</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fpr800112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr800112g%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DB.%2BB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DTimothy%26aufirst%3DN.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520vitreous%2520proteome%2520in%2520diabetes%2520without%2520diabetic%2520retinopathy%2520and%2520diabetes%2520with%2520proliferative%2520diabetic%2520retinopathy%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2008%26volume%3D7%26spage%3D2516%26epage%3D2525%26doi%3D10.1021%2Fpr800112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3588</span>– <span class="NLM_lpage">3599</span>, <span class="refDoi"> DOI: 10.2337/db15-0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdb15-0317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=3588-3599&author=T.+Kitaauthor=A.+C.+Clermontauthor=N.+Murugesanauthor=Q.+Zhouauthor=K.+Fujisawaauthor=T.+Ishibashiauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Plasma+kallikrein-kinin+system+as+a+VEGF-independent+mediator+of+diabetic+macular+edema&doi=10.2337%2Fdb15-0317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0317%26sid%3Dliteratum%253Aachs%26aulast%3DKita%26aufirst%3DT.%26aulast%3DClermont%26aufirst%3DA.%2BC.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DFujisawa%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DT.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein-kinin%2520system%2520as%2520a%2520VEGF-independent%2520mediator%2520of%2520diabetic%2520macular%2520edema%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26spage%3D3588%26epage%3D3599%26doi%3D10.2337%2Fdb15-0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilcote, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.2337/db10-1260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdb10-1260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1590-1598&author=A.+Clermontauthor=T.+J.+Chilcoteauthor=T.+Kitaauthor=J.+Liuauthor=P.+Rivaauthor=S.+Sinhaauthor=E.+P.+Feener&title=Plasma+kallikrein+mediates+retinal+vascular+dysfunction+and+induces+retinal+thickening+in+diabetic+rats&doi=10.2337%2Fdb10-1260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2337%2Fdb10-1260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb10-1260%26sid%3Dliteratum%253Aachs%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DChilcote%26aufirst%3DT.%2BJ.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRiva%26aufirst%3DP.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520mediates%2520retinal%2520vascular%2520dysfunction%2520and%2520induces%2520retinal%2520thickening%2520in%2520diabetic%2520rats%26jtitle%3DDiabetes%26date%3D2011%26volume%3D60%26spage%3D1590%26epage%3D1598%26doi%3D10.2337%2Fdb10-1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neugebauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirois, P.</span></span> <span> </span><span class="NLM_article-title">Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2004.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.regpep.2004.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15544863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2crntlejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2005&pages=221-224&author=S.+R.+Lawsonauthor=B.+H.+Gabraauthor=B.+Gu%C3%A9rinauthor=W.+Neugebauerauthor=F.+Nantelauthor=B.+Battistiniauthor=P.+Sirois&title=Enhanced+dermal+and+retinal+vascular+permeability+in+streptozotocin-induced+type+1+diabetes+in+Wistar+rats%3A+blockade+with+a+selective+bradykinin+B1+receptor+antagonist&doi=10.1016%2Fj.regpep.2004.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist</span></div><div class="casAuthors">Lawson Sibi R; Gabra Bichoy H; Guerin Brigitte; Neugebauer Witold; Nantel Francois; Battistini Bruno; Sirois Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory peptides</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">221-4</span>
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    </div><div class="casAbstract">The vascular complications associated with type 1 diabetes are to some extent related to the dysfunction of the endothelium leading to an increased vascular permeability and plasma extravasation in the surrounding tissues.  The various micro- and macro-vascular complications of diabetes develop over time, leading to nephropathy, retinopathy and neuropathy and cardiomyopathy.  In the present study, the effect of a novel selective bradykinin B1 receptor (BKB1-R) antagonist, R-954, was investigated on the changes of vascular permeability in the skin and retina of streptozotocin (STZ)-induced type 1 diabetic rats.  Plasma extravasation increased in the skin and retina of STZ-diabetic rats after 1 week and persisted over 4 weeks following STZ injection.  Acute treatment with R-954 (2 mg/kg, bolus s.c.) highly reduced the elevated vascular permeability in both 1- and 4-week STZ-diabetic rats.  These results showed that the inducible BKB1-R subtype modulates the vascular permeability of the skin and retina of type 1 diabetic rats and suggests that BKB1-R antagonists could have a beneficial role in diabetic neuropathy and retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTF_TVSB24GPresJRIHUP1ofW6udTcc2eYIFnAfBtc2orntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crntlejsg%253D%253D&md5=65d4eeef1c4c0c73f70542f670ac27d3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2004.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2004.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DS.%2BR.%26aulast%3DGabra%26aufirst%3DB.%2BH.%26aulast%3DGu%25C3%25A9rin%26aufirst%3DB.%26aulast%3DNeugebauer%26aufirst%3DW.%26aulast%3DNantel%26aufirst%3DF.%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DSirois%26aufirst%3DP.%26atitle%3DEnhanced%2520dermal%2520and%2520retinal%2520vascular%2520permeability%2520in%2520streptozotocin-induced%2520type%25201%2520diabetes%2520in%2520Wistar%2520rats%253A%2520blockade%2520with%2520a%2520selective%2520bradykinin%2520B1%2520receptor%2520antagonist%26jtitle%3DRegul.%2520Pept.%26date%3D2005%26volume%3D124%26spage%3D221%26epage%3D224%26doi%3D10.1016%2Fj.regpep.2004.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sénécal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotigny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span> <span> </span><span class="NLM_article-title">Ocular application of the kinin B1 receptor antagonist LF22–0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e33864</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0033864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1371%2Fjournal.pone.0033864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e33864&author=M.+Pouliotauthor=S.+Talbotauthor=J.+S%C3%A9n%C3%A9calauthor=F.+Dotignyauthor=E.+Vaucherauthor=R.+Couture&title=Ocular+application+of+the+kinin+B1+receptor+antagonist+LF22%E2%80%930542+inhibits+retinal+inflammation+and+oxidative+stress+in+streptozotocin-diabetic+rats&doi=10.1371%2Fjournal.pone.0033864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0033864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0033864%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DS.%26aulast%3DS%25C3%25A9n%25C3%25A9cal%26aufirst%3DJ.%26aulast%3DDotigny%26aufirst%3DF.%26aulast%3DVaucher%26aufirst%3DE.%26aulast%3DCouture%26aufirst%3DR.%26atitle%3DOcular%2520application%2520of%2520the%2520kinin%2520B1%2520receptor%2520antagonist%2520LF22%25E2%2580%25930542%2520inhibits%2520retinal%2520inflammation%2520and%2520oxidative%2520stress%2520in%2520streptozotocin-diabetic%2520rats%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De33864%26doi%3D10.1371%2Fjournal.pone.0033864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0ljTjg2BZabbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarroz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzavarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelillo-Scherrer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01548</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01548" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1151-1158&author=S.+J.+Middendorpauthor=J.+Wilbsauthor=C.+Quarrozauthor=S.+Calzavariniauthor=A.+Angelillo-Scherrerauthor=C.+Heinis&title=Peptide+macrocycle+inhibitor+of+coagulation+factor+XII+with+subnanomolar+affinity+and+high+target+selectivity&doi=10.1021%2Facs.jmedchem.6b01548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity</span></div><div class="casAuthors">Middendorp, Simon J.; Wilbs, Jonas; Quarroz, Claudia; Calzavarini, Sara; Angelillo-Scherrer, Anne; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1151-1158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathol. thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angioedema.  While several protein based inhibitors with high affinity for activated FXII (FXIIa) were developed, the generation of small mol. inhibitors has been challenging.  The authors have generated a potent and selective FXIIa inhibitor by optimizing a peptide macrocycle that was recently evolved by phage display (Ki = 0.84±0.03 nM).  A fluorine atom introduced in the para-position of phenylalanine enhanced the binding affinity as much as 10-fold.  Furthermore, the authors improved the proteolytic stability by substituting the N-terminal arginine by norarginine.  The resulting inhibitor combines high inhibitory affinity and selectivity with a good stability in plasma (Ki = 1.63±0.18 nM, >27,000-fold selectivity, t1/2 plasma = 16±4 h).  The inhibitor efficiently blocked activation of the intrinsic coagulation pathway in human blood ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtHmZYsV_bi7Vg90H21EOLACvtfcHk0ljTjg2BZabbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yqtw%253D%253D&md5=66f9fe274cdd51f9148f7e13f27617e4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01548%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%2BJ.%26aulast%3DWilbs%26aufirst%3DJ.%26aulast%3DQuarroz%26aufirst%3DC.%26aulast%3DCalzavarini%26aufirst%3DS.%26aulast%3DAngelillo-Scherrer%26aufirst%3DA.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520macrocycle%2520inhibitor%2520of%2520coagulation%2520factor%2520XII%2520with%2520subnanomolar%2520affinity%2520and%2520high%2520target%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1151%26epage%3D1158%26doi%3D10.1021%2Facs.jmedchem.6b01548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide ligands stabilized by small molecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1602</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+ligands+stabilized+by+small+molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0lhEPQUrzlPpuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520ligands%2520stabilized%2520by%2520small%2520molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeriswyl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fcmdc.201200071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22492508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1173-1176&author=V.+Baeriswylauthor=H.+Rapleyauthor=L.+Pollaroauthor=C.+Staceauthor=D.+Teufelauthor=E.+Walkerauthor=S.+Chenauthor=G.+Winterauthor=J.+Titeauthor=C.+Heinis&title=Bicyclic+peptides+with+optimized+ring+size+inhibit+human+plasma+kallikrein+and+its+orthologues+while+sparing+paralogous+proteases&doi=10.1002%2Fcmdc.201200071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases</span></div><div class="casAuthors">Baeriswyl, Vanessa; Rapley, Helen; Pollaro, Lisa; Stace, Catherine; Teufel, Dan; Walker, Edward; Chen, Shiyu; Winter, Greg; Tite, John; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1173-1176, S1173/1-S1173/5</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this work, we aimed at generating bicyclic peptides inhibiting both human and murine plasma kallikrein (PK) but not any paralogous proteases.  We speculated that inhibitors with the desired specificity profile could be obtained by generating binders to a surface region that is identical in PK orthologues but different in paralogues.  By comparing structural models of target and related nontarget proteases to identify conserved regions in the vicinity of the active site and by modulating the loop size of our libraries of peptide macrocycles accordingly, we succeeded in identifying potent inhibitors of human, rat and monkey plasma kallikrein that do not also inhibit related human serum proteases.  Our strategy should facilitate the evaluation of this type of peptide macrocycles in animal models, and furthermore, avoid unwanted off-target activities that would be detrimental to their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTYMUG-b7ubVg90H21EOLACvtfcHk0lhEPQUrzlPpuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D&md5=5a3177403617ce635c46b0a759a110ab</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200071%26sid%3Dliteratum%253Aachs%26aulast%3DBaeriswyl%26aufirst%3DV.%26aulast%3DRapley%26aufirst%3DH.%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DStace%26aufirst%3DC.%26aulast%3DTeufel%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DTite%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DBicyclic%2520peptides%2520with%2520optimized%2520ring%2520size%2520inhibit%2520human%2520plasma%2520kallikrein%2520and%2520its%2520orthologues%2520while%2520sparing%2520paralogous%2520proteases%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1173%26epage%3D1176%26doi%3D10.1002%2Fcmdc.201200071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuweiler, H.</span></span> <span> </span><span class="NLM_article-title">Backbone-driven collapse in unfolded protein chains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2011.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.jmb.2011.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21497607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=250-262&author=D.+P.+Teufelauthor=C.+M.+Johnsonauthor=J.+K.+Lumauthor=H.+Neuweiler&title=Backbone-driven+collapse+in+unfolded+protein+chains&doi=10.1016%2Fj.jmb.2011.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Backbone-Driven Collapse in Unfolded Protein Chains</span></div><div class="casAuthors">Teufel, Daniel P.; Johnson, Christopher M.; Lum, Jenifer K.; Neuweiler, Hannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Collapse of unfolded protein chains is an early event in folding.  It affects structural properties of intrinsically disordered proteins (IDPs), which take up a considerable fraction of the human proteome.  Collapse is generally believed to be driven by hydrophobic forces imposed by the presence of nonpolar amino acid side chains.  Contributions from backbone hydrogen bonds to protein folding and stability, however, are controversial.  To date, the exptl. dissection of side-chain and backbone contributions has not yet been achieved because both types of interactions are integral parts of protein structure.  Here, we realized this goal by applying mutagenesis and chem. modification on a set of disordered peptides and proteins.  We measured the protein dimensions and kinetics of intra-chain diffusion of modified polypeptides at the level of individual mols. using fluorescence correlation spectroscopy (FCS), thereby avoiding artifacts commonly caused by aggregation of unfolded protein material in bulk.  We found no contributions from side chains to collapse, but instead, identified backbone interactions as a source sufficient to form globules of native-like dimensions.  The presence of backbone hydrogen bonds decreased polypeptide water soly. dramatically and accelerated the nanosecond kinetics of loop closure, in agreement with recent predictions from computer simulation.  The presence of side chains, instead, slowed loop closure and modulated the dimensions of intrinsically disordered domains.  It appeared that the transient formation of backbone interactions facilitates the diffusive search for productive conformations at the early stage of folding and within intrinsically disordered proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCa-Q7pukl7bVg90H21EOLACvtfcHk0lhEPQUrzlPpuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D&md5=c8bcdbf4dbc91f7afe960d2aa7cf6024</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2011.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2011.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DLum%26aufirst%3DJ.%2BK.%26aulast%3DNeuweiler%26aufirst%3DH.%26atitle%3DBackbone-driven%2520collapse%2520in%2520unfolded%2520protein%2520chains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D409%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.jmb.2011.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tugyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iván, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecz, F.</span></span> <span> </span><span class="NLM_article-title">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.0407677102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1073%2Fpnas.0407677102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15630090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=413-418&author=R.+Tugyiauthor=K.+Urayauthor=D.+Iv%C3%A1nauthor=E.+Fellingerauthor=A.+Perkinsauthor=F.+Hudecz&title=Partial+D-amino+acid+substitution%3A+Improved+enzymatic+stability+and+preserved+Ab+recognition+of+a+MUC2+epitope+peptide&doi=10.1073%2Fpnas.0407677102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span></div><div class="casAuthors">Tugyi, Regina; Uray, Katalin; Ivan, Dora; Fellinger, Erzsebet; Perkins, Alan; Hudecz, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The stability of an immunogen against enzymic degrdn. is considered an important factor for the design of synthetic vaccines.  For our studies, we have selected an epitope from the tandem-repeat unit of the high-mol.-wt. MUC2 mucin glycoprotein, which can be underglycosylated in case of colon cancer.  In this study, we prepd. a MUC2 peptide contg. the PTGTQ epitope of a MUC2 protein backbone-specific mAb 996 and its derivs.  In these peptides, the N- and C-terminal flanking regions were systematically substituted by up to three D-amino acids.  Peptides prepd. by solid-phase synthesis were tested for their mAb 996 binding in competitive ELISA expts., and their stability was studied in serum and lysosomal prepn.  Our data show that the epitope function of peptide 15TPTPTGTQTPT25 is retained even in the presence of two D-amino acid residues at its N-terminal flanking region and up to three at its C-terminal flanking region (tpTPTGTQtpt).  Also, this partly D peptide shows high resistance against proteolytic degrdn. in dild. human serum and in lysosomal prepn.  These findings suggest that, by appropriate combination of structural modifications (namely, D-amino acid substitution) in the flanks of an Ab epitope, it is feasible to construct a synthetic antigen with preserved recognition properties and high stability against enzymic degrdn.  Peptides tPTPTGTQTpt and tpTPTGTQTpt derived from this study can be used for immunization expts. and as potential components of synthetic vaccines for tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MtlZFnf6a7Vg90H21EOLACvtfcHk0ljvxbYDHPHhtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D&md5=aa80020d0dcf9d18d18775fcf77b050a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0407677102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0407677102%26sid%3Dliteratum%253Aachs%26aulast%3DTugyi%26aufirst%3DR.%26aulast%3DUray%26aufirst%3DK.%26aulast%3DIv%25C3%25A1n%26aufirst%3DD.%26aulast%3DFellinger%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DHudecz%26aufirst%3DF.%26atitle%3DPartial%2520D-amino%2520acid%2520substitution%253A%2520Improved%2520enzymatic%2520stability%2520and%2520preserved%2520Ab%2520recognition%2520of%2520a%2520MUC2%2520epitope%2520peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.0407677102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, N. R.</span></span> <span> </span><span class="NLM_article-title">Perioperative systemic haemostatic agents</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1093/bja/aeh227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1093%2Fbja%2Faeh227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15277296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSrurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=842-858&author=A.+M.+Mahdyauthor=N.+R.+Webster&title=Perioperative+systemic+haemostatic+agents&doi=10.1093%2Fbja%2Faeh227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Perioperative systemic haemostatic agents</span></div><div class="casAuthors">Mahdy, A. M.; Webster, N. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">842-858</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Skilful surgery combined with blood-saving methods and careful management of blood coagulation will all help reduce unnecessary blood loss and transfusion requirements.  Excessive surgical bleeding causes hypovolemia, hemodynamic instability, anemia and reduced oxygen delivery to tissues, with a subsequent increase in postoperative morbidity and mortality.  The role of anesthetists in managing surgical blood loss has increased greatly in the last decade.  Position of the patient during surgery and the provision of a hypotensive anesthetic regimen were once considered the most important contributions of the anesthetist to decreasing blood loss.  Now, several pharmacol. hemostatic agents are being used by anesthetists as blood-saving agents.  After a brief discussion of the physiol. of hemostasis, this article will review the evidence for the role of such agents in reducing perioperative blood loss and transfusion requirements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZUXHdKQ09sbVg90H21EOLACvtfcHk0ljvxbYDHPHhtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSrurvE&md5=5c31ac116c4b392bcc42f902ace5922a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fbja%2Faeh227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252Faeh227%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BM.%26aulast%3DWebster%26aufirst%3DN.%2BR.%26atitle%3DPerioperative%2520systemic%2520haemostatic%2520agents%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2004%26volume%3D93%26spage%3D842%26epage%3D858%26doi%3D10.1093%2Fbja%2Faeh227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, R. A.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">25411</span>– <span class="NLM_lpage">25417</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.43.25411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.270.43.25411" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=25411-25417&author=M.+S.+Dennisauthor=A.+Herzkaauthor=R.+A.+Lazarus&title=Potent+and+selective+Kunitz+domain+inhibitors+of+plasma+kallikrein+designed+by+phage+display&doi=10.1074%2Fjbc.270.43.25411"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.43.25411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.43.25411%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DHerzka%26aufirst%3DA.%26aulast%3DLazarus%26aufirst%3DR.%2BA.%26atitle%3DPotent%2520and%2520selective%2520Kunitz%2520domain%2520inhibitors%2520of%2520plasma%2520kallikrein%2520designed%2520by%2520phage%2520display%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D25411%26epage%3D25417%26doi%3D10.1074%2Fjbc.270.43.25411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Contact pathway of coagulation and inflammation</span>. <i>Thromb. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1186/s12959-015-0048-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1186%2Fs12959-015-0048-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25949215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MfhsF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=17&author=Y.+Wu&title=Contact+pathway+of+coagulation+and+inflammation&doi=10.1186%2Fs12959-015-0048-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Contact pathway of coagulation and inflammation</span></div><div class="casAuthors">Wu Yi</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17</span>
        ISSN:<span class="NLM_cas:issn">1477-9560</span>.
    </div><div class="casAbstract">The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor high molecular weight kininogen (HK).  This system has been investigated actively for more than 50 years.  The components of this system and their interactions have been elucidated from in vitro experiments, which indicates that this system is prothrombotic by activating intrinsic pathway, and proinflammatory by producing bioactive peptide bradykinin.  Although the activation of the contact system have been implicated in various types of human disease, in only a few instances is its role clearly defined.  In the last 10 years, our understanding of the contact system, particularly its biology and (patho)physiology has greatly increased through investigations using gene-modified animal models.  In this review we will describe a revitalized view of the contact system as a critical (patho)physiologic mediator of coagulation and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu8gBlm77WhAWRJ3OJdH_qfW6udTcc2eZERikKO1nDQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfhsF2jtw%253D%253D&md5=a44dd0a6efab3b58507e4252d509cbb4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs12959-015-0048-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12959-015-0048-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26atitle%3DContact%2520pathway%2520of%2520coagulation%2520and%2520inflammation%26jtitle%3DThromb.%2520J.%26date%3D2015%26volume%3D13%26spage%3D17%26doi%3D10.1186%2Fs12959-015-0048-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raber, M. N.</span></span> <span> </span><span class="NLM_article-title">Coagulation Tests</span>. In  <i>Clinical Methods: The History, Physical, and Laboratory Examinations</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, H. K.</span>, <span class="NLM_string-name">Hall, W. D.</span>, <span class="NLM_string-name">Hurst, J. W.</span></span>, Eds.; <span class="NLM_publisher-name">Butterworths</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+N.+Raberauthor=H.+K.+Walker&author=W.+D.+Hall&author=J.+W.+Hurst&title=Clinical+Methods%3A+The+History%2C+Physical%2C+and+Laboratory+Examinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRaber%26aufirst%3DM.%2BN.%26atitle%3DCoagulation%2520Tests%26btitle%3DClinical%2520Methods%253A%2520The%2520History%252C%2520Physical%252C%2520and%2520Laboratory%2520Examinations%26aulast%3DWalker%26aufirst%3DH.%2BK.%26pub%3DButterworths%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruttmann, T.</span></span> <span> </span><span class="NLM_article-title">Coagulation for the clinician</span>. <i>S. Afr. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">26</span>, 28–30, 32–37</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=24-26&issue=22&author=T.+Ruttmann&title=Coagulation+for+the+clinician"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuttmann%26aufirst%3DT.%26atitle%3DCoagulation%2520for%2520the%2520clinician%26jtitle%3DS.%2520Afr.%2520J.%2520Surg.%26date%3D2006%26volume%3D44%26issue%3D22%26spage%3D24%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, J.</span></span> <span> </span><span class="NLM_article-title">The vitreous</span>. In  <i>Adler’s Physiology of the Eye</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, W.</span></span>, Eds.; <span class="NLM_publisher-name">Mosby</span>: <span class="NLM_publisher-loc">St. Louis</span>, <span class="NLM_year">1992</span>; pp  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">347</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&pages=268-347&author=J.+Sebagauthor=W.+Hart&title=Adler%E2%80%99s+Physiology+of+the+Eye"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSebag%26aufirst%3DJ.%26atitle%3DThe%2520vitreous%26btitle%3DAdler%25E2%2580%2599s%2520Physiology%2520of%2520the%2520Eye%26aulast%3DHart%26aufirst%3DW.%26pub%3DMosby%26date%3D1992%26spage%3D268%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jobin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonjour, J. P.</span></span> <span> </span><span class="NLM_article-title">Measurement of glomerular filtration rate in conscious unrestrained rats with inulin infused by implanted osmotic pumps</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">F734</span>– <span class="NLM_lpage">F738</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1985.248.5.F734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1152%2Fajprenal.1985.248.5.F734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1985&pages=F734-F738&author=J.+Jobinauthor=J.+P.+Bonjour&title=Measurement+of+glomerular+filtration+rate+in+conscious+unrestrained+rats+with+inulin+infused+by+implanted+osmotic+pumps&doi=10.1152%2Fajprenal.1985.248.5.F734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1985.248.5.F734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1985.248.5.F734%26sid%3Dliteratum%253Aachs%26aulast%3DJobin%26aufirst%3DJ.%26aulast%3DBonjour%26aufirst%3DJ.%2BP.%26atitle%3DMeasurement%2520of%2520glomerular%2520filtration%2520rate%2520in%2520conscious%2520unrestrained%2520rats%2520with%2520inulin%2520infused%2520by%2520implanted%2520osmotic%2520pumps%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1985%26volume%3D248%26spage%3DF734%26epage%3DF738%26doi%3D10.1152%2Fajprenal.1985.248.5.F734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del
Amo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtti, A.</span></span> <span> </span><span class="NLM_article-title">Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of published data</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2015.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.exer.2015.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25975234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=111-124&author=E.+M.+del%0AAmoauthor=A.+Urtti&title=Rabbit+as+an+animal+model+for+intravitreal+pharmacokinetics%3A+clinical+predictability+and+quality+of+published+data&doi=10.1016%2Fj.exer.2015.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data</span></div><div class="casAuthors">del Amo, Eva M.; Urtti, Arto</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-124</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Intravitreal administration is the method of choice in drug delivery to the retina and/or choroid.  Rabbit is the most commonly used animal species in intravitreal pharmacokinetics, but it has been criticized as being a poor model of human eye.  The critique is based on some anatomical differences, properties of the vitreous humor, and obsd. differences in drug concns. in the anterior chamber after intravitreal injections.  We have systematically analyzed all published information on intravitreal pharmacokinetics in the rabbit and human eye.  The anal. revealed major problems in the design of the pharmacokinetic studies.  In this review we provide advice for study design.  Overall, the pharmacokinetic parameters (clearance, vol. of distribution, half-life) in the human and rabbit eye have good correlation and comparable abs. values.  Therefore, reliable rabbit-to-man translation of intravitreal pharmacokinetics should be feasible.  The relevant anatomical and physiol. parameters in rabbit and man show only small differences.  Furthermore, the claimed discrepancy between drug concns. in the human and rabbit aq. humor is not supported by the data anal.  Based on the available and properly conducted pharmacokinetic studies, the differences in the vitreous structure in rabbits and human patients do not lead to significant pharmacokinetic differences.  This review is the first step towards inter-species translation of intravitreal pharmacokinetics.  More information is still needed to dissect the roles of drug delivery systems, disease states, age and ocular manipulation on the intravitreal pharmacokinetics in rabbit and man.  Anyway, the published data and the derived pharmacokinetic parameters indicate that the rabbit is a useful animal model in intravitreal pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwLXcII4mXhLVg90H21EOLACvtfcHk0lgUm-pp1b7JYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGnu7Y%253D&md5=c6a3e013b0e4e03f260120bfb8df055f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2015.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2015.05.003%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BAmo%26aufirst%3DE.%2BM.%26aulast%3DUrtti%26aufirst%3DA.%26atitle%3DRabbit%2520as%2520an%2520animal%2520model%2520for%2520intravitreal%2520pharmacokinetics%253A%2520clinical%2520predictability%2520and%2520quality%2520of%2520published%2520data%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2015%26volume%3D137%26spage%3D111%26epage%3D124%26doi%3D10.1016%2Fj.exer.2015.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenniston, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopacz, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrapeli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenHoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of plasma kallikrein by a highly specific active site blocking antibody</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">23596</span>– <span class="NLM_lpage">235608</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.569061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.M114.569061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24970892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSms7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=23596-235608&author=J.+A.+Kennistonauthor=R.+R.+Faucetteauthor=D.+Martikauthor=S.+R.+Comeauauthor=A.+P.+Lindbergauthor=K.+J.+Kopaczauthor=G.+P.+Conleyauthor=J.+Chenauthor=M.+Viswanathanauthor=N.+Kastrapeliauthor=J.+Cosicauthor=S.+Masonauthor=M.+DiLeoauthor=J.+Abendrothauthor=P.+Kuzmicauthor=R.+C.+Ladnerauthor=T.+E.+Edwardsauthor=C.+TenHoorauthor=B.+A.+Adelmanauthor=A.+E.+Nixonauthor=D.+J.+Sexton&title=Inhibition+of+plasma+kallikrein+by+a+highly+specific+active+site+blocking+antibody&doi=10.1074%2Fjbc.M114.569061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody</span></div><div class="casAuthors">Kenniston, Jon A.; Faucette, Ryan R.; Martik, Diana; Comeau, Stephen R.; Lindberg, Allison P.; Kopacz, Kris J.; Conley, Gregory P.; Chen, Jie; Viswanathan, Malini; Kastrapeli, Niksa; Cosic, Janja; Mason, Shauna; Di Leo, Mike; Abendroth, Jan; Kuzmic, Petr; Ladner, Robert C.; Edwards, Thomas E.; Ten Hoor, Christopher; Adelman, Burt A.; Nixon, Andrew E.; Sexton, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">23596-23608</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasma kallikrein (pKal) proteolytically cleaves high mol. wt. kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin.  PKal activity is tightly regulated in healthy individuals by the serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibitor and consequently exhibit excessive bradykinin generation that in turn causes debilitating and potentially fatal swelling attacks.  To develop a potential therapeutic agent for HAE and other pKal-mediated disorders, the authors used phage display to discover a fully human IgG1 monoclonal antibody (DX-2930) against pKal.  In vitro expts. demonstrated that DX-2930 potently inhibits active pKal (Ki = 0.120 nm) but does not target either the zymogen (prekallikrein) or any other serine protease tested.  These findings are supported by a 2.1-Å resoln. crystal structure of pKal complexed to a DX-2930 Fab construct, which establishes that the pKal active site is fully occluded by the antibody.  DX-2930 injected s.c. into cynomolgus monkeys exhibited a long half-life (t1/2 ∼12.5 days) and blocked high mol. wt. kininogen proteolysis in activated plasma in a dose- and time-dependent manner.  Furthermore, s.c. DX-2930 reduced carrageenan-induced paw edema in rats.  A potent and long acting inhibitor of pKal activity could be an effective treatment option for pKal-mediated diseases, such as HAE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-4XVHdXBJ7Vg90H21EOLACvtfcHk0lgUm-pp1b7JYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSms7%252FL&md5=4bdd050b8cd5aa7e50daa04e8e260437</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.569061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.569061%26sid%3Dliteratum%253Aachs%26aulast%3DKenniston%26aufirst%3DJ.%2BA.%26aulast%3DFaucette%26aufirst%3DR.%2BR.%26aulast%3DMartik%26aufirst%3DD.%26aulast%3DComeau%26aufirst%3DS.%2BR.%26aulast%3DLindberg%26aufirst%3DA.%2BP.%26aulast%3DKopacz%26aufirst%3DK.%2BJ.%26aulast%3DConley%26aufirst%3DG.%2BP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DM.%26aulast%3DKastrapeli%26aufirst%3DN.%26aulast%3DCosic%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DDiLeo%26aufirst%3DM.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DLadner%26aufirst%3DR.%2BC.%26aulast%3DEdwards%26aufirst%3DT.%2BE.%26aulast%3DTenHoor%26aufirst%3DC.%26aulast%3DAdelman%26aufirst%3DB.%2BA.%26aulast%3DNixon%26aufirst%3DA.%2BE.%26aulast%3DSexton%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520plasma%2520kallikrein%2520by%2520a%2520highly%2520specific%2520active%2520site%2520blocking%2520antibody%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D23596%26epage%3D235608%26doi%3D10.1074%2Fjbc.M114.569061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C. J.</span></span> <span> </span><span class="NLM_article-title">Carrageenan-induced paw edema in the rat and mouse</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1385/1-59259-374-7:115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1385%2F1-59259-374-7%3A115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=12769480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3s3ks1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2003&pages=115-121&author=C.+J.+Morris&title=Carrageenan-induced+paw+edema+in+the+rat+and+mouse&doi=10.1385%2F1-59259-374-7%3A115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Carrageenan-induced paw edema in the rat and mouse</span></div><div class="casAuthors">Morris Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-21</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIeD9uSGbBLEGy1nwu7K2mfW6udTcc2eb9x-QxEfuiQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s3ks1ensw%253D%253D&md5=b012018ed50b034ed911c9e0d863a3b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1385%2F1-59259-374-7%3A115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-374-7%253A115%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%2BJ.%26atitle%3DCarrageenan-induced%2520paw%2520edema%2520in%2520the%2520rat%2520and%2520mouse%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2003%26volume%3D225%26spage%3D115%26epage%3D121%26doi%3D10.1385%2F1-59259-374-7%3A115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroud, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, D. A.</span></span> <span> </span><span class="NLM_article-title">Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/path.1711040103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fpath.1711040103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=4398139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADyaE38XktFyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1971&pages=15-29&author=M.+Di%0ARosaauthor=J.+P.+Giroudauthor=D.+A.+Willoughby&title=Studies+on+the+mediators+of+the+acute+inflammatory+response+induced+in+rats+in+different+sites+by+carrageenan+and+turpentine&doi=10.1002%2Fpath.1711040103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine</span></div><div class="casAuthors">Di Rosa, M.; Giroud, J. P.; Willoughby, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-29</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    </div><div class="casAbstract">Pharmacol. expts. on carrageenan-induced edema in rats indicated that there are 3 time phases in the inflammatory response which are sequentially mediated by histamine (I) [51-45-6] and 5-hydroxytryptamine (II) [50-67-9] release, kinins, and prostaglandins.  The actions of all the mediators were dependent upon the presence of complement.  The same sequential release of the mediators I and II, kinins, and prostaglandins occurred in other types of inflammatory response in rats:  carrageenan-induced pleurisy, turpentine-induced foot edema, and turpentine-induced pleurisy.  Complement seemed to be important in all these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDBiHhmh-9yLVg90H21EOLACvtfcHk0lhlmV9ahh2yXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XktFyqug%253D%253D&md5=80b5e506e0d9ca5c86aae4426dd73a96</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fpath.1711040103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1711040103%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRosa%26aufirst%3DM.%26aulast%3DGiroud%26aufirst%3DJ.%2BP.%26aulast%3DWilloughby%26aufirst%3DD.%2BA.%26atitle%3DStudies%2520on%2520the%2520mediators%2520of%2520the%2520acute%2520inflammatory%2520response%2520induced%2520in%2520rats%2520in%2520different%2520sites%2520by%2520carrageenan%2520and%2520turpentine%26jtitle%3DJ.%2520Pathol.%26date%3D1971%26volume%3D104%26spage%3D15%26epage%3D29%26doi%3D10.1002%2Fpath.1711040103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span> <span> </span><span class="NLM_article-title">Animal models of diabetic retinopathy: summary and comparison</span>. <i>J. Diabetes Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">106594</span>, <span class="refDoi"> DOI: 10.1155/2013/106594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1155%2F2013%2F106594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24286086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2c3it1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=106594&author=A.+K.+Laiauthor=A.+C.+Lo&title=Animal+models+of+diabetic+retinopathy%3A+summary+and+comparison&doi=10.1155%2F2013%2F106594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of diabetic retinopathy: summary and comparison</span></div><div class="casAuthors">Lai Angela Ka Wai; Lo Amy C Y</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106594</span>
        ISSN:<span class="NLM_cas:issn">2314-6745</span>.
    </div><div class="casAbstract">Diabetic retinopathy (DR) is a microvascular complication associated with chronic exposure to hyperglycemia and is a major cause of blindness worldwide.  Although clinical assessment and retinal autopsy of diabetic patients provide information on the features and progression of DR, its underlying pathophysiological mechanism cannot be deduced.  In order to have a better understanding of the development of DR at the molecular and cellular levels, a variety of animal models have been developed.  They include pharmacological induction of hyperglycemia and spontaneous diabetic rodents as well as models of angiogenesis without diabetes (to compensate for the absence of proliferative DR symptoms).  In this review, we summarize the existing protocols to induce diabetes using STZ.  We also describe and compare the pathological presentations, in both morphological and functional aspects, of the currently available DR animal models.  The advantages and disadvantages of using different animals, ranging from zebrafish, rodents to other higher-order mammals, are also discussed.  Until now, there is no single model that displays all the clinical features of DR as seen in human.  Yet, with the understanding of the pathological findings in these animal models, researchers can select the most suitable models for mechanistic studies or drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm7MKbRi3Cu4JKJbLTgsvCfW6udTcc2eb9x-QxEfuiQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3it1CktQ%253D%253D&md5=6580a125aa1466471a7694fd3f0ce404</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1155%2F2013%2F106594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F106594%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BK.%26aulast%3DLo%26aufirst%3DA.%2BC.%26atitle%3DAnimal%2520models%2520of%2520diabetic%2520retinopathy%253A%2520summary%2520and%2520comparison%26jtitle%3DJ.%2520Diabetes%2520Res.%26date%3D2013%26volume%3D2013%26spage%3D106594%26doi%3D10.1155%2F2013%2F106594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mas-Moruno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechenmacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span> <span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21269250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate+design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span></div><div class="casAuthors">Mas-Moruno, Carlos; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilengitide, a cyclic RGD pentapeptide, is currently in clin. phase III for treatment of glioblastomas and in phase II for several other tumors.  This drug is the first anti-angiogenic small mol. targeting the integrins αvβ3, αvβ5 and α5β1.  It was developed by us in the early 90s by a novel procedure, the spatial screening.  This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear ref. peptides), which in addn. exhibited high selectivity against the platelet receptor αIIbβ3.  This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V).  This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany).  This article describes the chem. development of Cilengitide, the biochem. background of its activity and a short review about the present clin. trials.  The pos. anti-angiogenic effects in cancer treatment can be further increased by combination with "classical" anti-cancer therapies.  Several clin. trials in this direction are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlP-_WXS6GbVg90H21EOLACvtfcHk0lh4Zj-IH9NULQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D&md5=694b4a2876be15ec767dcc82278a316c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate%2520design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavenonis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kritzer, J. A.</span></span> <span> </span><span class="NLM_article-title">Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1021/cb300515u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300515u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWksbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=488-499&author=J.+E.+Bockauthor=J.+Gavenonisauthor=J.+A.+Kritzer&title=Getting+in+shape%3A+controlling+peptide+bioactivity+and+bioavailability+using+conformational+constraints&doi=10.1021%2Fcb300515u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Getting in Shape: Controlling Peptide Bioactivity and Bioavailability Using Conformational Constraints</span></div><div class="casAuthors">Bock, Jonathan E.; Gavenonis, Jason; Kritzer, Joshua A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-499</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chem. biologists commonly seek out correlations between the physicochem. properties of mols. and their behavior in biol. systems.  However, a new paradigm is emerging for peptides in which conformation is recognized as the primary determinant of bioactivity and bioavailability.  This review highlights an emerging body of work that directly addresses how a peptide's conformation controls its biol. effects, cell penetration, and intestinal absorption.  Based on this work, the dream of mimicking the potency and bioavailability of natural product peptides is getting closer to reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTflF3sA9dgrVg90H21EOLACvtfcHk0lh4Zj-IH9NULQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWksbjM&md5=cb95fdecb85b9588ef3c95673e59431a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcb300515u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300515u%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DGavenonis%26aufirst%3DJ.%26aulast%3DKritzer%26aufirst%3DJ.%2BA.%26atitle%3DGetting%2520in%2520shape%253A%2520controlling%2520peptide%2520bioactivity%2520and%2520bioavailability%2520using%2520conformational%2520constraints%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D488%26epage%3D499%26doi%3D10.1021%2Fcb300515u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diness, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Constraining cyclic peptides to mimic protein structure motifs</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">13020</span>– <span class="NLM_lpage">13041</span>, <span class="refDoi"> DOI: 10.1002/anie.201401058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201401058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGit77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=13020-13041&author=T.+A.+Hillauthor=N.+E.+Shepherdauthor=F.+Dinessauthor=D.+P.+Fairlie&title=Constraining+cyclic+peptides+to+mimic+protein+structure+motifs&doi=10.1002%2Fanie.201401058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Constraining Cyclic Peptides To Mimic Protein Structure Motifs</span></div><div class="casAuthors">Hill, Timothy A.; Shepherd, Nicholas E.; Diness, Frederik; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">13020-13041</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Many proteins exert their biol. activities through small exposed surface regions called epitopes that are folded peptides of well-defined three-dimensional structures.  Short synthetic peptide sequences corresponding to these bioactive protein surfaces do not form thermodynamically stable protein-like structures in water.  However, short peptides can be induced to fold into protein-like bioactive conformations (strands, helixes, turns) by cyclization, in conjunction with the use of other mol. constraints, that helps to fine-tune three-dimensional structure.  Such constrained cyclic peptides can have protein-like biol. activities and potencies, enabling their uses as biol. probes and leads to therapeutics, diagnostics and vaccines.  This Review highlights examples of cyclic peptides that mimic three-dimensional structures of strand, turn or helical segments of peptides and proteins, and identifies some addnl. restraints incorporated into natural product cyclic peptides and synthetic macrocyclic peptidomimetics that refine peptide structure and confer biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhn7uR358YLVg90H21EOLACvtfcHk0lh4Zj-IH9NULQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGit77K&md5=77180acba388f5c2a0af461ce965b82a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201401058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201401058%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DT.%2BA.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DDiness%26aufirst%3DF.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DConstraining%2520cyclic%2520peptides%2520to%2520mimic%2520protein%2520structure%2520motifs%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D13020%26epage%3D13041%26doi%3D10.1002%2Fanie.201401058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelay-Gimeno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, T. N.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8896</span>– <span class="NLM_lpage">8927</span>, <span class="refDoi"> DOI: 10.1002/anie.201412070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201412070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26119925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8896-8927&author=M.+Pelay-Gimenoauthor=A.+Glasauthor=O.+Kochauthor=T.+N.+Grossmann&title=Structure-based+design+of+inhibitors+of+protein-protein+interactions%3A+mimicking+peptide+binding+epitopes&doi=10.1002%2Fanie.201412070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes</span></div><div class="casAuthors">Pelay-Gimeno, Marta; Glas, Adrian; Koch, Oliver; Grossmann, Tom N.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8896-8927</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions (PPIs) are involved at all levels of cellular organization, thus making the development of PPI inhibitors extremely valuable.  The identification of selective inhibitors is challenging because of the shallow and extended nature of PPI interfaces.  Inhibitors can be obtained by mimicking peptide binding epitopes in their bioactive conformation.  For this purpose, several strategies have been evolved to enable a projection of side chain functionalities in analogy to peptide secondary structures, thereby yielding mols. that are generally referred to as peptidomimetics.  Herein, we introduce a new classification of peptidomimetics (classes A-D) that enables a clear assignment of available approaches.  Based on this classification, the Review summarizes strategies that have been applied for the structure-based design of PPI inhibitors through stabilizing or mimicking turns, β-sheets, and helixes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPTEmZpatXbrVg90H21EOLACvtfcHk0lh4Zj-IH9NULQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOmu7rM&md5=447c84aab6275b1057fda9a610918f2b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201412070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201412070%26sid%3Dliteratum%253Aachs%26aulast%3DPelay-Gimeno%26aufirst%3DM.%26aulast%3DGlas%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGrossmann%26aufirst%3DT.%2BN.%26atitle%3DStructure-based%2520design%2520of%2520inhibitors%2520of%2520protein-protein%2520interactions%253A%2520mimicking%2520peptide%2520binding%2520epitopes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8896%26epage%3D8927%26doi%3D10.1002%2Fanie.201412070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bianco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the NOTCH transcription factor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature08543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnature08543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19907488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSjsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=182-188&author=R.+E.+Moelleringauthor=M.+Cornejoauthor=T.+N.+Davisauthor=C.+Del+Biancoauthor=J.+C.+Asterauthor=S.+C.+Blacklowauthor=A.+L.+Kungauthor=D.+G.+Gillilandauthor=G.+L.+Verdineauthor=J.+E.+Bradner&title=Direct+inhibition+of+the+NOTCH+transcription+factor+complex&doi=10.1038%2Fnature08543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the NOTCH transcription factor complex</span></div><div class="casAuthors">Moellering, Raymond E.; Cornejo, Melanie; Davis, Tina N.; Del Bianco, Cristina; Aster, Jon C.; Blacklow, Stephen C.; Kung, Andrew L.; Gilliland, D. Gary; Verdine, Gregory L.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">182-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Direct inhibition of transcription factor complexes remains a central challenge in the discipline of ligand discovery.  In general, these proteins lack surface involutions suitable for high-affinity binding by small mols.  Here the authors report the design of synthetic, cell-permeable, stabilized α-helical peptides that target a crit. protein-protein interface in the NOTCH transactivation complex.  The authors demonstrate that direct, high-affinity binding of the hydrocarbon-stapled peptide SAHM1 prevents assembly of the active transcriptional complex.  Inappropriate NOTCH activation is directly implicated in the pathogenesis of several disease states, including T-cell acute lymphoblastic leukemia (T-ALL).  The treatment of leukemic cells with SAHM1 results in genome-wide suppression of NOTCH-activated genes.  Direct antagonism of the NOTCH transcriptional program causes potent, NOTCH-specific anti-proliferative effects in cultured cells and in a mouse model of NOTCH1-driven T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hyuFJHX0T7Vg90H21EOLACvtfcHk0ljIz0J7CT9zjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSjsr3F&md5=a12f19dd03303fd054e3052d7bbffd47</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature08543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08543%26sid%3Dliteratum%253Aachs%26aulast%3DMoellering%26aufirst%3DR.%2BE.%26aulast%3DCornejo%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DT.%2BN.%26aulast%3DDel%2BBianco%26aufirst%3DC.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520NOTCH%2520transcription%2520factor%2520complex%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D182%26epage%3D188%26doi%3D10.1038%2Fnature08543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1021/jm400887j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400887j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGnurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=278-295&author=F.+Giordanettoauthor=J.+Kihlberg&title=Macrocyclic+drugs+and+clinical+candidates%3A+what+can+medicinal+chemists+learn+from+their+properties%3F&doi=10.1021%2Fjm400887j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?</span></div><div class="casAuthors">Giordanetto, Fabrizio; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles are ideal in efforts to tackle difficult targets, but our understanding of what makes them cell permeable and orally bioavailable is limited.  Anal. of approx. 100 macrocyclic drugs and clin. candidates revealed that macrocycles are predominantly used for infectious disease and in oncol. and that most belong to the macrolide or cyclic peptide class.  A significant no. (N = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at mol. wts. up to and above 1 kDa and polar surface areas ranging toward 250 Å2.  Moreover, insight from a group of de novo designed oral macrocycles in clin. studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery.  However, the no. of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaeM2DXwvmiLVg90H21EOLACvtfcHk0ljIz0J7CT9zjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGnurjI&md5=a3e1743bd5ba34f73d8e78f8cb1bee5f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm400887j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400887j%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DMacrocyclic%2520drugs%2520and%2520clinical%2520candidates%253A%2520what%2520can%2520medicinal%2520chemists%2520learn%2520from%2520their%2520properties%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D278%26epage%3D295%26doi%3D10.1021%2Fjm400887j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyaya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clippinger, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7602</span>– <span class="NLM_lpage">7606</span>, <span class="refDoi"> DOI: 10.1002/anie.201502763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201502763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=7602-7606&author=P.+Upadhyayaauthor=Z.+Qianauthor=N.+G.+Selnerauthor=S.+R.+Clippingerauthor=Z.+Wuauthor=R.+Briesewitzauthor=D.+Pei&title=Inhibition+of+Ras+signaling+by+blocking+Ras-effector+interactions+with+cyclic+peptides&doi=10.1002%2Fanie.201502763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras Signaling by Blocking Ras-Effector Interactions with Cyclic Peptides</span></div><div class="casAuthors">Upadhyaya, Punit; Qian, Ziqing; Selner, Nicholas G.; Clippinger, Sarah R.; Wu, Zhengrong; Briesewitz, Roger; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7602-7606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ras genes are frequently activated in human cancers, but the mutant Ras proteins remain largely "undruggable" through the conventional small-mol. approach owing to the absence of any obvious binding pockets on their surfaces.  By screening a combinatorial peptide library, followed by structure-activity relationship (SAR) anal., we discovered a family of cyclic peptides possessing both Ras-binding and cell-penetrating properties.  These cell-permeable cyclic peptides inhibit Ras signaling by binding to Ras-GTP and blocking its interaction with downstream proteins and they induce apoptosis of cancer cells.  Our results demonstrate the feasibility of developing cyclic peptides for the inhibition of intracellular protein-protein interactions and of direct Ras inhibitors as a novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs7bDEvBhzUbVg90H21EOLACvtfcHk0ljIz0J7CT9zjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSrtrw%253D&md5=ad761df9481ab6b206b85ea63c1d1f29</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fanie.201502763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201502763%26sid%3Dliteratum%253Aachs%26aulast%3DUpadhyaya%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSelner%26aufirst%3DN.%2BG.%26aulast%3DClippinger%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBriesewitz%26aufirst%3DR.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Ras%2520signaling%2520by%2520blocking%2520Ras-effector%2520interactions%2520with%2520cyclic%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D7602%26epage%3D7606%26doi%3D10.1002%2Fanie.201502763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, A.</span>; <span class="NLM_string-name">Roskos, L.</span>; <span class="NLM_string-name">Klakamp, S.</span>; <span class="NLM_string-name">Liang, M.</span>; <span class="NLM_string-name">Arends, R.</span>; <span class="NLM_string-name">Green, L.</span></span> <span> </span><span class="NLM_article-title">Antibody Affinity</span>. In  <i>Handbook of Therapeutic Antibodies</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dübel, S.</span>, <span class="NLM_string-name">Reichert, J. M.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2014</span>; DOI: <span class="refDoi"> DOI: 10.1002/9783527682423.ch6</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2F9783527682423.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Frenzel&author=L.+Roskos&author=S.+Klakamp&author=M.+Liang&author=R.+Arends&author=L.+Greenauthor=S.+D%C3%BCbel&author=J.+M.+Reichert&title=Handbook+of+Therapeutic+Antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2F9783527682423.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527682423.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DA.%26atitle%3DAntibody%2520Affinity%26btitle%3DHandbook%2520of%2520Therapeutic%2520Antibodies%26aulast%3DD%25C3%25BCbel%26aufirst%3DS.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2014%26doi%3D10.1002%2F9783527682423.ch6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span> <span> </span><span class="NLM_article-title">PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis</span>. <i>Cardiovasc. Hematol. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.2174/187152512800388939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2174%2F187152512800388939" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=154-166&author=D.+Kolteauthor=J.+W.+Bryantauthor=G.+W.+Gibsonauthor=J.+Wangauthor=Z.+Shariat-Madar&title=PF-04886847+%28an+inhibitor+of+plasma+kallikrein%29+attenuates+inflammatory+mediators+and+activation+of+blood+coagulation+in+rat+model+of+lipopolysaccharide+%28LPS%29-induced+sepsis&doi=10.2174%2F187152512800388939"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F187152512800388939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152512800388939%26sid%3Dliteratum%253Aachs%26aulast%3DKolte%26aufirst%3DD.%26aulast%3DBryant%26aufirst%3DJ.%2BW.%26aulast%3DGibson%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShariat-Madar%26aufirst%3DZ.%26atitle%3DPF-04886847%2520%2528an%2520inhibitor%2520of%2520plasma%2520kallikrein%2529%2520attenuates%2520inflammatory%2520mediators%2520and%2520activation%2520of%2520blood%2520coagulation%2520in%2520rat%2520model%2520of%2520lipopolysaccharide%2520%2528LPS%2529-induced%2520sepsis%26jtitle%3DCardiovasc.%2520Hematol.%2520Agents%2520Med.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D154%26epage%3D166%26doi%3D10.2174%2F187152512800388939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holsworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01170.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fj.1476-5381.2010.01170.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21175583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1639-1649&author=D.+Kolteauthor=J.+Bryantauthor=D.+Holsworthauthor=J.+Wangauthor=P.+Akbariauthor=G.+Gibsonauthor=Z.+Shariat-Madar&title=Biochemical+characterization+of+a+novel+high-affinity+and+specific+plasma+kallikrein+inhibitor&doi=10.1111%2Fj.1476-5381.2010.01170.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor</span></div><div class="casAuthors">Kolte, D.; Bryant, J. W.; Holsworth, D.; Wang, J.; Akbari, P.; Gibson, G. W.; Shariat-Madar, Z.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1639-1649</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Kallikrein acts on high mol. wt. kininogen (HK) to generate HKa (cleaved HK) and bradykinin (BK).  BK exerts its effects by binding to B2 receptors.  The activation of B2 receptors leads to the formation of tissue plasminogen activator, nitric oxide (NO) and prostacyclin (PGI2).  An elevated kallikrein-dependent pathway has been linked to cardiovascular disease risk.  This study investigated whether our the plasma kallikrein inhibitor PF-04886847 abolishes kallikrein-mediated generation of BK from HK and subsequent BK-induced NO and PGI2 formation, thereby influencing endothelial pathophysiol. during chronic inflammatory diseases.  Kinetic anal. was initially used to det. the potency of PF-04886847.  Biochem. ligand binding assays, immunol. methods and calcium flux studies were used to det. the selectivity of the kallikrein inhibitor.  In addn., the effect of PF-04886847 on BK-induced relaxation of the rat aortic ring was detd. in a model of lipopolysaccharide-induced tissue inflammation.  Evidence was obtained in vitro and in situ, indicating that PF-04886847 is a potent and specific inhibitor of plasma kallikrein.  PF-04886847 efficiently blocked calcium influx as well as NO and PGI2 formation mediated through the BK-stimulated B2 receptor signaling pathway.  PF-04886847 blocked kallikrein-induced endothelial-dependent relaxation of isolated rat aortic rings pre-contracted with phenylephrine.  PF-04886847 was shown to be the most potent small mol. inhibitor of plasma kallikrein yet described; it inhibited kallikrein in isolated aortic rings and cultured endothelial cells.  Overall, our results indicate that PF-04886847 would be useful for the treatment of kallikrein-mediated inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeQrmlqfpu9bVg90H21EOLACvtfcHk0lg579TvoAe5tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lurg%253D&md5=4140a9f24f3bd60663bfac5e552f3da6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01170.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01170.x%26sid%3Dliteratum%253Aachs%26aulast%3DKolte%26aufirst%3DD.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DHolsworth%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAkbari%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DG.%26aulast%3DShariat-Madar%26aufirst%3DZ.%26atitle%3DBiochemical%2520characterization%2520of%2520a%2520novel%2520high-affinity%2520and%2520specific%2520plasma%2520kallikrein%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1639%26epage%3D1649%26doi%3D10.1111%2Fj.1476-5381.2010.01170.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakri, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravitreal bevacizumab (Avastin)</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.ophtha.2007.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ophtha.2007.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17467524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2s3lvVyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=855-859&author=S.+J.+Bakriauthor=M.+R.+Snyderauthor=J.+M.+Reidauthor=J.+S.+Pulidoauthor=R.+J.+Singh&title=Pharmacokinetics+of+intravitreal+bevacizumab+%28Avastin%29&doi=10.1016%2Fj.ophtha.2007.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravitreal bevacizumab (Avastin)</span></div><div class="casAuthors">Bakri Sophie J; Snyder Melissa R; Reid Joel M; Pulido Jose S; Singh Ravinder J</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">855-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin).  DESIGN:  Experimental animal study.  PARTICIPANTS:  Twenty Dutch-belted rabbits.  METHODS:  One eye of each of 20 rabbits was injected with 1.25 mg of intravitreal bevacizumab.  Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15, and 29.  Bevacizumab concentrations were measured in aqueous fluid, whole vitreous, and serum.  MAIN OUTCOME MEASURES:  Bevacizumab concentrations in the aqueous, vitreous, and serum.  RESULTS:  Whereas vitreous concentrations of bevacizumab declined in a monoexponential fashion with a half-life of 4.32 days, concentrations of >10 microg/ml bevacizumab were maintained in the vitreous humor for 30 days.  Bevacizumab concentrations in the aqueous humor of the injected eye reached a peak concentration of 37.7 microg/ml 3 days after drug administration.  A maximum serum concentration of 3.3 mug/ml was achieved 8 days after intravitreal injection and the concentration fell below 1 microg/ml 29 days after injection.  Elimination of bevacizumab from the aqueous humor and serum paralleled that found in the vitreous humor, with half-life values of 4.88 days and 6.86 days, respectively.  Very low concentrations of bevacizumab were detected in the fellow uninjected eye.  Concentrations of bevacizumab in the vitreous of the fellow eye varied incrementally, from 0.35 ng/ml at 1 day to 11.17 ng/ml at 4 weeks.  Concentrations of bevacizumab in the aqueous humor of the fellow eye reached their peak at 1 week, at 29.4 ng/ml, and declined to 4.56 ng/ml at 4 weeks.  CONCLUSION:  The vitreous half-life of 1.25 mg intravitreal bevacizumab is 4.32 days in a rabbit eye.  Very small amounts of bevacizumab were detected in the serum and in the fellow uninjected eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXZWkaQXyEAcjl5L8hwNX0fW6udTcc2eae8xvR3SJ8Yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3lvVyhug%253D%253D&md5=682a220ca192f7a738ce5d3c8c78f651</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2007.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2007.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DBakri%26aufirst%3DS.%2BJ.%26aulast%3DSnyder%26aufirst%3DM.%2BR.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DPulido%26aufirst%3DJ.%2BS.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetics%2520of%2520intravitreal%2520bevacizumab%2520%2528Avastin%2529%26jtitle%3DOphthalmology%26date%3D2007%26volume%3D114%26spage%3D855%26epage%3D859%26doi%3D10.1016%2Fj.ophtha.2007.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakri, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzat, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravitreal ranibizumab (Lucentis)</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2179</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.ophtha.2007.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ophtha.2007.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=18054637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2sjisV2rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=2179-2182&author=S.+J.+Bakriauthor=M.+R.+Snyderauthor=J.+M.+Reidauthor=J.+S.+Pulidoauthor=M.+K.+Ezzatauthor=R.+J.+Singh&title=Pharmacokinetics+of+intravitreal+ranibizumab+%28Lucentis%29&doi=10.1016%2Fj.ophtha.2007.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravitreal ranibizumab (Lucentis)</span></div><div class="casAuthors">Bakri Sophie J; Snyder Melissa R; Reid Joel M; Pulido Jose S; Ezzat Mohamed K; Singh Ravinder J</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2179-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To describe the pharmacokinetics of 0.5 mg of intravitreal ranibizumab (Lucentis) and to compare it with that of 1.25 mg of intravitreal bevacizumab (Avastin), using the same rabbit model.  DESIGN:  Experimental animal study.  PARTICIPANTS:  Twenty-eight Dutch-belted rabbits.  METHODS:  One eye of each of 20 rabbits was injected with 0.5 mg of intravitreal ranibizumab.  Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15, and 29.  Ranibizumab concentrations were measured in aqueous fluid, whole vitreous, and serum.  A further 8 rabbits were used to measure serum and fellow ranibizumab at additional time points of 3 and 8 hours.  MAIN OUTCOME MEASURES:  Ranibizumab concentrations in the aqueous, vitreous, and serum.  RESULTS:  Although vitreous concentrations of ranibizumab declined in a monoexponential fashion with a half-life of 2.88 days, concentrations of >0.1 microg/ml ranibizumab were maintained in the vitreous humor for 29 days.  Ranibizumab concentrations in the aqueous humor of the injected eye reached a peak concentration of 17.9 microg/ml, 3 days after drug administration.  Elimination of ranibizumab from the aqueous humor paralleled that found in the vitreous humor, with a half-life value of 2.84 days.  No ranibizumab was detected in the serum or the fellow eye.  CONCLUSION:  In the rabbit, the vitreous half-life of 0.5-mg intravitreal ranibizumab is 2.88 days, shorter than the half-life of 1.25-mg intravitreal bevacizumab of 4.32 days.  No ranibizumab was detected in the serum or the fellow uninjected eye; whereas small amounts of intravitreal bevacizumab have been detected in the serum and fellow uninjected eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRjr64usV5p4YPsCkJIw00fW6udTcc2ebY64aKzwg7wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjisV2rtA%253D%253D&md5=aaedf8b24518dafc2e4a34cd5864f009</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2007.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2007.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DBakri%26aufirst%3DS.%2BJ.%26aulast%3DSnyder%26aufirst%3DM.%2BR.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DPulido%26aufirst%3DJ.%2BS.%26aulast%3DEzzat%26aufirst%3DM.%2BK.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetics%2520of%2520intravitreal%2520ranibizumab%2520%2528Lucentis%2529%26jtitle%3DOphthalmology%26date%3D2007%26volume%3D114%26spage%3D2179%26epage%3D2182%26doi%3D10.1016%2Fj.ophtha.2007.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampol, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoszyk, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold-Bush, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieramici, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R. W.</span></span> <span> </span><span class="NLM_article-title">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1414264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1056%2FNEJMoa1414264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25692915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFaiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1193-1203&author=J.+A.+Wellsauthor=A.+R.+Glassmanauthor=A.+R.+Ayalaauthor=L.+M.+Jampolauthor=L.+P.+Aielloauthor=A.+N.+Antoszykauthor=B.+Arnold-Bushauthor=C.+W.+Bakerauthor=N.+M.+Bresslerauthor=D.+J.+Browningauthor=M.+J.+Elmanauthor=F.+L.+Ferrisauthor=S.+M.+Friedmanauthor=M.+Meliaauthor=D.+J.+Pieramiciauthor=J.+K.+Sunauthor=R.+W.+Beck&title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema&doi=10.1056%2FNEJMoa1414264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema</span></div><div class="casAuthors">Wells, John A.; Glassman, Adam R.; Ayala, Allison R.; Jampol, Lee M.; Aiello, Lloyd Paul; Antoszyk, Andrew N.; Arnold-Bush, Bambi; Baker, Carl W.; Bressler, Neil M.; Browning, David J.; Elman, Michael J.; Ferris, Frederick L.; Friedman, Scott M.; Melia, Michele; Pieramici, Dante J.; Sun, Jennifer K.; Beck, Roy W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1193-1203</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.  At 89 clin. sites, we randomly assigned 660 adults (mean age, 61 ± 10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants).  The study drugs were administered as often as every 4 wk, according to a protocol-specified algorithm.  The primary outcome was the mean change in visual acuity at 1 yr.  From baseline to 1 yr, the mean visual-acuity letter score (range, 0 to 100, with higher scores indicating better visual acuity; a score of 85 is approx. 20/20) improved by 13.3 with aflibercept, by 9.7 with bevacizumab, and by 11.2 with ranibizumab.  Although the improvement was greater with aflibercept than with the other two drugs (P<0.001 for aflibercept vs. bevacizumab and P = 0.03 for aflibercept vs. ranibizumab), it was not clin. meaningful, because the difference was driven by the eyes with worse visual acuity at baseline (P<0.001 for interaction).  When the initial visual-acuity letter score was 78 to 69 (equiv. to approx. 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with aflibercept, 7.5 with bevacizumab, and 8.3 with ranibizumab (P>0.50 for each pairwise comparison).  When the initial letter score was less than 69 (approx. 20/50 or worse), the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab (P<0.001 for aflibercept vs. bevacizumab, P = 0.003 for aflibercept vs. ranibizumab, and P = 0.21 for ranibizumab vs. bevacizumab).  There were no significant differences among the study groups in the rates of serious adverse events (P = 0.40), hospitalization (P = 0.51), death (P = 0.72), or major cardiovascular events (P = 0.56).  Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity.  When the initial visual-acuity loss was mild, there were no apparent differences, on av., among study groups.  At worse levels of initial visual acuity, aflibercept was more effective at improving vision.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2NCewqa7M7Vg90H21EOLACvtfcHk0li9gLcHV7Vj9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFaiu74%253D&md5=1f9154feae8fd36161a05f07fb7881bc</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1414264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1414264%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DGlassman%26aufirst%3DA.%2BR.%26aulast%3DAyala%26aufirst%3DA.%2BR.%26aulast%3DJampol%26aufirst%3DL.%2BM.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DAntoszyk%26aufirst%3DA.%2BN.%26aulast%3DArnold-Bush%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DC.%2BW.%26aulast%3DBressler%26aufirst%3DN.%2BM.%26aulast%3DBrowning%26aufirst%3DD.%2BJ.%26aulast%3DElman%26aufirst%3DM.%2BJ.%26aulast%3DFerris%26aufirst%3DF.%2BL.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DMelia%26aufirst%3DM.%26aulast%3DPieramici%26aufirst%3DD.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%2BK.%26aulast%3DBeck%26aufirst%3DR.%2BW.%26atitle%3DAflibercept%252C%2520bevacizumab%252C%2520or%2520ranibizumab%2520for%2520diabetic%2520macular%2520edema%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1193%26epage%3D1203%26doi%3D10.1056%2FNEJMoa1414264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Geniez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walshe, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darland, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span> <span> </span><span class="NLM_article-title">Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e3554</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0003554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1371%2Fjournal.pone.0003554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e3554&author=M.+Saint-Geniezauthor=A.+S.+Maharajauthor=T.+E.+Walsheauthor=B.+A.+Tuckerauthor=E.+Sekiyamaauthor=T.+Kuriharaauthor=D.+C.+Darlandauthor=M.+J.+Youngauthor=P.+A.+D%E2%80%99Amore&title=Endogenous+VEGF+is+required+for+visual+function%3A+evidence+for+a+survival+role+on+muller+cells+and+photoreceptors&doi=10.1371%2Fjournal.pone.0003554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0003554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0003554%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DMaharaj%26aufirst%3DA.%2BS.%26aulast%3DWalshe%26aufirst%3DT.%2BE.%26aulast%3DTucker%26aufirst%3DB.%2BA.%26aulast%3DSekiyama%26aufirst%3DE.%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DDarland%26aufirst%3DD.%2BC.%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DEndogenous%2520VEGF%2520is%2520required%2520for%2520visual%2520function%253A%2520evidence%2520for%2520a%2520survival%2520role%2520on%2520muller%2520cells%2520and%2520photoreceptors%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De3554%26doi%3D10.1371%2Fjournal.pone.0003554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Geniez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span> <span> </span><span class="NLM_article-title">An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18751</span>– <span class="NLM_lpage">18756</span>, <span class="refDoi"> DOI: 10.1073/pnas.0905010106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1073%2Fpnas.0905010106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18751-18756&author=M.+Saint-Geniezauthor=T.+Kuriharaauthor=E.+Sekiyamaauthor=A.+E.+Maldonadoauthor=P.+A.+D%E2%80%99Amore&title=An+essential+role+for+RPE-derived+soluble+VEGF+in+the+maintenance+of+the+choriocapillaris&doi=10.1073%2Fpnas.0905010106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0905010106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0905010106%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DSekiyama%26aufirst%3DE.%26aulast%3DMaldonado%26aufirst%3DA.%2BE.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DAn%2520essential%2520role%2520for%2520RPE-derived%2520soluble%2520VEGF%2520in%2520the%2520maintenance%2520of%2520the%2520choriocapillaris%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D18751%26epage%3D18756%26doi%3D10.1073%2Fpnas.0905010106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westenskow, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span> <span> </span><span class="NLM_article-title">Targeted deletion of Vegfa in adult mice induces vision loss</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">4213</span>– <span class="NLM_lpage">4217</span>, <span class="refDoi"> DOI: 10.1172/JCI65157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1172%2FJCI65157" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4213-4217&author=T.+Kuriharaauthor=P.+D.+Westenskowauthor=S.+Bravoauthor=E.+Aguilarauthor=M.+Friedlander&title=Targeted+deletion+of+Vegfa+in+adult+mice+induces+vision+loss&doi=10.1172%2FJCI65157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1172%2FJCI65157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65157%26sid%3Dliteratum%253Aachs%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DWestenskow%26aufirst%3DP.%2BD.%26aulast%3DBravo%26aufirst%3DS.%26aulast%3DAguilar%26aufirst%3DE.%26aulast%3DFriedlander%26aufirst%3DM.%26atitle%3DTargeted%2520deletion%2520of%2520Vegfa%2520in%2520adult%2520mice%2520induces%2520vision%2520loss%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4213%26epage%3D4217%26doi%3D10.1172%2FJCI65157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. K.</span></span> <span> </span><span class="NLM_article-title">Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1762</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2014.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ajpath.2014.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24709590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFalurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2014&pages=1752-1762&author=H.+Y.+Parkauthor=J.+H.+Kimauthor=C.+K.+Park&title=Neuronal+cell+death+in+the+inner+retina+and+the+influence+of+vascular+endothelial+growth+factor+inhibition+in+a+diabetic+rat+model&doi=10.1016%2Fj.ajpath.2014.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Cell Death in the Inner Retina and the Influence of Vascular Endothelial Growth Factor Inhibition in a Diabetic Rat Model</span></div><div class="casAuthors">Park, Hae-Young Lopilly; Kim, Jie Hyun; Park, Chan Kee</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1752-1762</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To inhibit vascular changes in diabetic retinopathy, inhibiting vascular endothelial growth factor (VEGF) has become a mainstay of the treatment of diabetic retinopathy.  However, its effects on neuronal cells remain to be elucidated.  We aimed to evaluate the effect of VEGF inhibition on neuronal cells in a streptozotocin-induced diabetic rat retina.  VEGF inhibition was performed by intravitreal VEGF-A antibody injection.  After anti-VEGF treatment, apoptosis in retinal ganglion cells (RGCs) increased, and novel apoptosis in amacrine and bipolar cells of the inner nuclear layer was obsd. by TUNEL staining.  Phosphorylated Akt expression was significantly higher in RGCs but was decreased in neuronal cells of the inner nuclear layer after anti-VEGF treatment by Western blot anal. and immunohistochem. staining.  These results demonstrate that VEGF inhibition significantly increased RGC apoptosis and neuronal cell apoptosis in the inner nuclear layer of a diabetic retina, which seems to consist primarily of amacrine and bipolar cells.  The phosphorylated Akt pathway, which plays a neuroprotective role via VEGF, was significantly affected by VEGF inhibition in the inner nuclear layer, suggesting that neurotrophic factor deprivation is the main mechanism for neuronal cell death after inhibiting VEGF.  The results of this study show that inhibiting VEGF may have detrimental effects on the apoptosis of neuronal cells in the inner layers of the diabetic retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1GWuYmut7WrVg90H21EOLACvtfcHk0lhm8v2zS3gHyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFalurk%253D&md5=6b215a525a52626b617a38e275eeb440</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2014.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2014.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BK.%26atitle%3DNeuronal%2520cell%2520death%2520in%2520the%2520inner%2520retina%2520and%2520the%2520influence%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520inhibition%2520in%2520a%2520diabetic%2520rat%2520model%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2014%26volume%3D184%26spage%3D1752%26epage%3D1762%26doi%3D10.1016%2Fj.ajpath.2014.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domigan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antanesian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Happel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziyad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Collado, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Bliek, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potente, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iruela-Arispe, M. L.</span></span> <span> </span><span class="NLM_article-title">Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2236</span>– <span class="NLM_lpage">2248</span>, <span class="refDoi"> DOI: 10.1242/jcs.163774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1242%2Fjcs.163774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25956888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eiu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=2236-2248&author=C.+K.+Domiganauthor=C.+M.+Warrenauthor=V.+Antanesianauthor=K.+Happelauthor=S.+Ziyadauthor=S.+Leeauthor=A.+Krallauthor=L.+Duanauthor=A.+X.+Torres-Colladoauthor=L.+W.+Castellaniauthor=D.+Elashoffauthor=H.+R.+Christofkauthor=A.+M.+van+der+Bliekauthor=M.+Potenteauthor=M.+L.+Iruela-Arispe&title=Autocrine+VEGF+maintains+endothelial+survival+through+regulation+of+metabolism+and+autophagy&doi=10.1242%2Fjcs.163774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy</span></div><div class="casAuthors">Domigan, Courtney K.; Warren, Carmen M.; Antanesian, Vaspour; Happel, Katharina; Ziyad, Safiyyah; Lee, Sunyoung; Krall, Abigail; Duan, Lewei; Torres-Collado, Antoni X.; Castellani, Lawrence W.; Elashoff, David; Christofk, Heather R.; van der Bliek, Alexander M.; Potente, Michael; Iruela-Arispe, M. Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2236-2248</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Autocrine VEGF is necessary for endothelial survival, although the cellular mechanisms supporting this function are unknown.  Here, we show that - even after full differentiation and maturation - continuous expression of VEGF by endothelial cells is needed to sustain vascular integrity and cellular viability.  Depletion of VEGF from the endothelium results in mitochondria fragmentation and suppression of glucose metab., leading to increased autophagy that contributes to cell death.  Gene-expression profiling showed that endothelial VEGF contributes to the regulation of cell cycle and mitochondrial gene clusters, as well as several - but not all - targets of the transcription factor FOXO1.  Indeed, VEGF-deficient endothelium in vitro and in vivo showed increased levels of FOXO1 protein in the nucleus and cytoplasm.  Silencing of FOXO1 in VEGF-depleted cells reversed expression profiles of several of the gene clusters that were de-regulated in VEGF knockdown, and rescued both cell death and autophagy phenotypes.  Our data suggest that endothelial VEGF maintains vascular homeostasis through regulation of FOXO1 levels, thereby ensuring physiol. metab. and endothelial cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1WJch7FrCdLVg90H21EOLACvtfcHk0lhm8v2zS3gHyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eiu7jL&md5=e2f9b892f744ac1c1ea4d25ad6a2c8a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1242%2Fjcs.163774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.163774%26sid%3Dliteratum%253Aachs%26aulast%3DDomigan%26aufirst%3DC.%2BK.%26aulast%3DWarren%26aufirst%3DC.%2BM.%26aulast%3DAntanesian%26aufirst%3DV.%26aulast%3DHappel%26aufirst%3DK.%26aulast%3DZiyad%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKrall%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DTorres-Collado%26aufirst%3DA.%2BX.%26aulast%3DCastellani%26aufirst%3DL.%2BW.%26aulast%3DElashoff%26aufirst%3DD.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3Dvan%2Bder%2BBliek%26aufirst%3DA.%2BM.%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DIruela-Arispe%26aufirst%3DM.%2BL.%26atitle%3DAutocrine%2520VEGF%2520maintains%2520endothelial%2520survival%2520through%2520regulation%2520of%2520metabolism%2520and%2520autophagy%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26spage%3D2236%26epage%3D2248%26doi%3D10.1242%2Fjcs.163774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushbrooke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein mediates vascular endothelial growth factor-induced retinal dysfunction and thickening</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2399</span>, <span class="refDoi"> DOI: 10.1167/iovs.15-18272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1167%2Fiovs.15-18272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2390-2399&author=A.+Clermontauthor=N.+Murugesanauthor=Q.+Zhouauthor=T.+Kitaauthor=P.+A.+Robsonauthor=L.+J.+Rushbrookeauthor=D.+M.+Evansauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Plasma+kallikrein+mediates+vascular+endothelial+growth+factor-induced+retinal+dysfunction+and+thickening&doi=10.1167%2Fiovs.15-18272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1167%2Fiovs.15-18272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.15-18272%26sid%3Dliteratum%253Aachs%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRushbrooke%26aufirst%3DL.%2BJ.%26aulast%3DEvans%26aufirst%3DD.%2BM.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520mediates%2520vascular%2520endothelial%2520growth%2520factor-induced%2520retinal%2520dysfunction%2520and%2520thickening%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2016%26volume%3D57%26spage%3D2390%26epage%3D2399%26doi%3D10.1167%2Fiovs.15-18272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Solid phase synthesis of peptides containing the CH2NH peptide bond isostere</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/0196-9781(87)90174-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2F0196-9781%2887%2990174-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1987&pages=119-121&author=Y.+Sasakiauthor=D.+H.+Coy&title=Solid+phase+synthesis+of+peptides+containing+the+CH2NH+peptide+bond+isostere&doi=10.1016%2F0196-9781%2887%2990174-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0196-9781%2887%2990174-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0196-9781%252887%252990174-4%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DSolid%2520phase%2520synthesis%2520of%2520peptides%2520containing%2520the%2520CH2NH%2520peptide%2520bond%2520isostere%26jtitle%3DPeptides%26date%3D1987%26volume%3D8%26spage%3D119%26epage%3D121%26doi%3D10.1016%2F0196-9781%2887%2990174-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noppen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonteyn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waelkens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Smet, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhove, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inactivation of ocriplasmin in porcine vitreous</span>. <i>Biophys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165–166</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.bpc.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.bpc.2012.03.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165%E2%80%93166&publication_year=2012&pages=30-38&author=F.+Aertsauthor=B.+Noppenauthor=L.+Fonteynauthor=R.+Deruaauthor=E.+Waelkensauthor=M.+D.+de+Smetauthor=M.+Vanhove&title=Mechanism+of+inactivation+of+ocriplasmin+in+porcine+vitreous&doi=10.1016%2Fj.bpc.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bpc.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpc.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DAerts%26aufirst%3DF.%26aulast%3DNoppen%26aufirst%3DB.%26aulast%3DFonteyn%26aufirst%3DL.%26aulast%3DDerua%26aufirst%3DR.%26aulast%3DWaelkens%26aufirst%3DE.%26aulast%3Dde%2BSmet%26aufirst%3DM.%2BD.%26aulast%3DVanhove%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520inactivation%2520of%2520ocriplasmin%2520in%2520porcine%2520vitreous%26jtitle%3DBiophys.%2520Chem.%26date%3D2012%26volume%3D165%25E2%2580%2593166%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.bpc.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M. W.</span></span> <span> </span><span class="NLM_article-title">Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1136/bjophthalmol-2011-300654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1136%2Fbjophthalmol-2011-300654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22446028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38vptlartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2012&pages=1157-1158&author=M.+W.+Stewart&title=Aflibercept+%28VEGF+Trap-eye%29%3A+the+newest+anti-VEGF+drug&doi=10.1136%2Fbjophthalmol-2011-300654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug</span></div><div class="casAuthors">Stewart Michael W</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROCnGRd9t_6LGbPKh4T9eAfW6udTcc2eaeTwOZAxX6Crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vptlartg%253D%253D&md5=2f6d06f34014117529ebffea0f35ec8e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1136%2Fbjophthalmol-2011-300654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjophthalmol-2011-300654%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DM.%2BW.%26atitle%3DAflibercept%2520%2528VEGF%2520Trap-eye%2529%253A%2520the%2520newest%2520anti-VEGF%2520drug%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2012%26volume%3D96%26spage%3D1157%26epage%3D1158%26doi%3D10.1136%2Fbjophthalmol-2011-300654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qaum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joussen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassessian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamis, A. P.</span></span> <span> </span><span class="NLM_article-title">VEGF-initiated blood-retinal barrier breakdown in early diabetes</span>. <i>Invest. Ophthalmol. Vis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=2408-2413&author=T.+Qaumauthor=Q.+Xuauthor=A.+M.+Joussenauthor=M.+W.+Clemensauthor=W.+Qinauthor=K.+Miyamotoauthor=H.+Hassessianauthor=S.+J.+Wiegandauthor=J.+Rudgeauthor=G.+D.+Yancopoulosauthor=A.+P.+Adamis&title=VEGF-initiated+blood-retinal+barrier+breakdown+in+early+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQaum%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJoussen%26aufirst%3DA.%2BM.%26aulast%3DClemens%26aufirst%3DM.%2BW.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DMiyamoto%26aufirst%3DK.%26aulast%3DHassessian%26aufirst%3DH.%26aulast%3DWiegand%26aufirst%3DS.%2BJ.%26aulast%3DRudge%26aufirst%3DJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DAdamis%26aufirst%3DA.%2BP.%26atitle%3DVEGF-initiated%2520blood-retinal%2520barrier%2520breakdown%2520in%2520early%2520diabetes%26jtitle%3DInvest.%2520Ophthalmol.%2520Vis.%2520Sci.%26date%3D2001%26volume%3D42%26spage%3D2408%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, S. J.</span></span> <span> </span><span class="NLM_article-title">Systemic administration of VEGF trap suppresses vascular leak and leukostasis in the retinas of diabetic rats</span>. <i>Invest. Ophthalmol. Vis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=446&author=J.+Caoauthor=H.+Songauthor=R.+A.+Renardauthor=Y.+Liuauthor=G.+D.+Yancopoulosauthor=S.+J.+Wiegand&title=Systemic+administration+of+VEGF+trap+suppresses+vascular+leak+and+leukostasis+in+the+retinas+of+diabetic+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DRenard%26aufirst%3DR.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DWiegand%26aufirst%3DS.%2BJ.%26atitle%3DSystemic%2520administration%2520of%2520VEGF%2520trap%2520suppresses%2520vascular%2520leak%2520and%2520leukostasis%2520in%2520the%2520retinas%2520of%2520diabetic%2520rats%26jtitle%3DInvest.%2520Ophthalmol.%2520Vis.%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. W.</span></span> <span> </span><span class="NLM_article-title">Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1953</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.2337/diabetes.47.12.1953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdiabetes.47.12.1953" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1998&pages=1953-1959&author=D.+A.+Antonettiauthor=A.+J.+Barberauthor=S.+Khinauthor=E.+Liethauthor=J.+M.+Tarbellauthor=T.+W.+Gardner&title=Vascular+permeability+in+experimental+diabetes+is+associated+with+reduced+endothelial+occludin+content%3A+vascular+endothelial+growth+factor+decreases+occludin+in+retinal+endothelial+cells.+Penn+State+Retina+Research+Group&doi=10.2337%2Fdiabetes.47.12.1953"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.47.12.1953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.47.12.1953%26sid%3Dliteratum%253Aachs%26aulast%3DAntonetti%26aufirst%3DD.%2BA.%26aulast%3DBarber%26aufirst%3DA.%2BJ.%26aulast%3DKhin%26aufirst%3DS.%26aulast%3DLieth%26aufirst%3DE.%26aulast%3DTarbell%26aufirst%3DJ.%2BM.%26aulast%3DGardner%26aufirst%3DT.%2BW.%26atitle%3DVascular%2520permeability%2520in%2520experimental%2520diabetes%2520is%2520associated%2520with%2520reduced%2520endothelial%2520occludin%2520content%253A%2520vascular%2520endothelial%2520growth%2520factor%2520decreases%2520occludin%2520in%2520retinal%2520endothelial%2520cells.%2520Penn%2520State%2520Retina%2520Research%2520Group%26jtitle%3DDiabetes%26date%3D1998%26volume%3D47%26spage%3D1953%26epage%3D1959%26doi%3D10.2337%2Fdiabetes.47.12.1953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2010.090398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2353%2Fajpath.2010.090398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20110406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2010&pages=1517-1524&author=J.+H.+Kimauthor=J.+H.+Kimauthor=H.+O.+Junauthor=Y.+S.+Yuauthor=K.+W.+Kim&title=Inhibition+of+protein+kinase+C+delta+attenuates+blood-retinal+barrier+breakdown+in+diabetic+retinopathy&doi=10.2353%2Fajpath.2010.090398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein kinase C δ attenuates blood-retinal barrier breakdown in diabetic retinopathy</span></div><div class="casAuthors">Kim, Jeong-Hun; Kim, Jin Hyoung; Jun, Hyoung-Oh; Yu, Young Suk; Kim, Kyu-Won</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1517-1524</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Vision loss in diabetic retinopathy is due to macular edema characterized by increased vascular permeability, which involves phosphorylation assocd. with activation of protein kinase C (PKC) isoforms.  Herein, we demonstrated PKC δ inhibition could prevent blood-retinal barrier breakdown in diabetic retinopathy.  Increased vascular permeability of diabetic retina was accompanied by a decrease of zonula occludens (ZO)-1 and ZO-2 expression.  In diabetic retina and advanced glycation end product-treated human retinal microvascular endothelial cells, vascular leakage and loss of ZO-1 and ZO-2 on retinal vessels were effectively restored or prevented with treatment of rottlerin, transfection of PKC-δ-DN, or siRNA for PKC δ.  Interestingly, PKC δ translocated from cytosol to membrane in advanced glycation end product-treated human retinal microvascular endothelial cells, which was blocked by PKC δ inhibition.  Taken together, PKC δ activation, related to its subcellular translocation, is involved in vascular permeability in response to diabetes, and inhibition of PKC δ effectively restores loss of tight junction proteins in retinal vessels.  Therefore, we suggest that inhibition of PKC δ could be an alternative treatment to blood-retinal barrier breakdown in diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZg-BNmQhE_7Vg90H21EOLACvtfcHk0ljibgPsm_5QTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOitr8%253D&md5=0446f56ed5a21e8cc4d5dca1940a1ac1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.090398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.090398%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DJun%26aufirst%3DH.%2BO.%26aulast%3DYu%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BW.%26atitle%3DInhibition%2520of%2520protein%2520kinase%2520C%2520delta%2520attenuates%2520blood-retinal%2520barrier%2520breakdown%2520in%2520diabetic%2520retinopathy%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D176%26spage%3D1517%26epage%3D1524%26doi%3D10.2353%2Fajpath.2010.090398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, G. J.</span></span> <span> </span><span class="NLM_article-title">Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">e31</span>– <span class="NLM_lpage">e37</span>, <span class="refDoi"> DOI: 10.1111/j.1755-3768.2011.02243.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fj.1755-3768.2011.02243.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=e31-e37&author=Y.+H.+Kimauthor=Y.+S.+Kimauthor=G.+S.+Rohauthor=W.+S.+Choiauthor=G.+J.+Cho&title=Resveratrol+blocks+diabetes-induced+early+vascular+lesions+and+vascular+endothelial+growth+factor+induction+in+mouse+retinas&doi=10.1111%2Fj.1755-3768.2011.02243.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2011.02243.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2011.02243.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DRoh%26aufirst%3DG.%2BS.%26aulast%3DChoi%26aufirst%3DW.%2BS.%26aulast%3DCho%26aufirst%3DG.%2BJ.%26atitle%3DResveratrol%2520blocks%2520diabetes-induced%2520early%2520vascular%2520lesions%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520induction%2520in%2520mouse%2520retinas%26jtitle%3DActa%2520Ophthalmol.%26date%3D2012%26volume%3D90%26spage%3De31%26epage%3De37%26doi%3D10.1111%2Fj.1755-3768.2011.02243.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollanders, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hove, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergen, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandewalle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Pelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moons, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalmans, I.</span></span> <span> </span><span class="NLM_article-title">AMA0428, a potent rock inhibitor, attenuates early and late experimental diabetic retinopathy</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1080/02713683.2016.1183030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F02713683.2016.1183030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=27399806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2nt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=260-272&author=K.+Hollandersauthor=I.+Van+Hoveauthor=J.+Sergeysauthor=T.+V.+Bergenauthor=E.+Lefevereauthor=N.+Kindtauthor=K.+Castermansauthor=E.+Vandewalleauthor=J.+van+Peltauthor=L.+Moonsauthor=I.+Stalmans&title=AMA0428%2C+a+potent+rock+inhibitor%2C+attenuates+early+and+late+experimental+diabetic+retinopathy&doi=10.1080%2F02713683.2016.1183030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy</span></div><div class="casAuthors">Hollanders, Karolien; Van Hove, Inge; Sergeys, Jurgen; Van Bergen, Tine; Lefevere, Evy; Kindt, Nele; Castermans, Karolien; Vandewalle, Evelien; van Pelt, Jos; Moons, Lieve; Stalmans, Ingeborg</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-272</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Purpose: Diabetic retinopathy (DR) is characterized by an early stage of inflammation and vessel leakage, and an advanced vasoproliferative stage.  Also, neurodegeneration might play an important role in disease pathogenesis.  The aim of this study was to investigate the effect of the Rho kinase (ROCK) inhibitor, AMA0428, on these processes.  Methods: The response to ROCK inhibition by AMA0428 (1 μg) was studied in vivo using the murine model for streptozotocin (STZ)-induced diabetes, focusing on early non-proliferative DR features and the oxygen-induced retinopathy (OIR) model to investigate proliferative DR.  Intravitreal (IVT) administration of AMA0428 was compared with murine anti-VEGF-R2 antibody (DC101, 6.2 μg) and placebo (H2O/PEG; 1C8).  Outcome was assessed by analyzing leukostasis using fluorescein isothiocyanate coupled Con A (FITC-ConA) and vessel leakage (bovine serum albumin conjugated with fluorescein isothiocyanate; FITC-BSA)/neovascularization and neurodegeneration by immunohistol. approaches (hematoxylin and eosin (H&E), terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL), Brn3a).  ELISA and Western blotting were employed to unravel the consequences of ROCK inhibition (1 μM AMA0428) on myosin phosphatase target protein (MYPT)-1 phosphorylation, endothelial nitric oxide synthase (eNOS) phosphorylation, and vascular endothelial growth factor (VEGF) levels in retinas of diabetic mice, on NF-κβ activity and ICAM-1 expression in endothelial cells (ECs).  Results: In vivo, AMA0428 significantly reduced vessel leakage and neovascularization, resp., in the STZ and OIR model, comparable to DC101 therapy.  Addnl., the ROCK inhibitor decreased neurodegeneration in both models and inhibited leukostasis by 30% (p < 0.05) in the STZ model (p < 0.05), while DC101 had no pos. effect on the outcome of these latter processes.  ROCK activity was upregulated in the diabetic retina and AMA0428 administration resulted in decreased phospho-MYPT-1, enhanced phospho-eNOS, and reduced VEGF levels.  In vitro, AMA0428 interfered with NF-κβ activity, thereby inhibiting ICAM-1 expression in ECs.  Conclusions: Targeting ROCK with AMA0428 effectively attenuated outcome in an early DR model (STZ) and a late vasoproliferative retinopathy model (OIR).  These findings make AMA0428 a promising candidate with an addnl. anti-inflammatory and neuroprotective benefit for DR patients, as compared with anti-VEGF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtA6vdZwMgVLVg90H21EOLACvtfcHk0lgyMDZJ8SHD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2nt7rK&md5=db46391819b768b0e93c52306f80f09d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F02713683.2016.1183030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02713683.2016.1183030%26sid%3Dliteratum%253Aachs%26aulast%3DHollanders%26aufirst%3DK.%26aulast%3DVan%2BHove%26aufirst%3DI.%26aulast%3DSergeys%26aufirst%3DJ.%26aulast%3DBergen%26aufirst%3DT.%2BV.%26aulast%3DLefevere%26aufirst%3DE.%26aulast%3DKindt%26aufirst%3DN.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DVandewalle%26aufirst%3DE.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DStalmans%26aufirst%3DI.%26atitle%3DAMA0428%252C%2520a%2520potent%2520rock%2520inhibitor%252C%2520attenuates%2520early%2520and%2520late%2520experimental%2520diabetic%2520retinopathy%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2017%26volume%3D42%26spage%3D260%26epage%3D272%26doi%3D10.1080%2F02713683.2016.1183030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 17 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Daniel J. Ford, Nisharnthi M. Duggan, Sarah E. Fry, Jorge Ripoll-Rozada, Stijn M. Agten, Wenyu Liu, Leo Corcilius, Tilman M. Hackeng, Rene van Oerle, Henri M. H. Spronk, Anneliese S. Ashhurst, Vishnu Mini Sasi, Joe A. Kaczmarski, Colin J. Jackson, Pedro José Barbosa Pereira, Toby Passioura, Hiroaki Suga, <span class="NLM_string-name hlFld-ContribAuthor">Richard J. Payne</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Cyclic Peptide Inhibitors of FXIIa Discovered by mRNA Display with Genetic Code Reprogramming. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7853-7876. <a href="https://doi.org/10.1021/acs.jmedchem.1c00651" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00651</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00651%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252BCyclic%252BPeptide%252BInhibitors%252Bof%252BFXIIa%252BDiscovered%252Bby%252BmRNA%252BDisplay%252Bwith%252BGenetic%252BCode%252BReprogramming%26aulast%3DFord%26aufirst%3DDaniel%2BJ.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09042021%26date%3D28052021%26volume%3D64%26issue%3D11%26spage%3D7853%26epage%3D7876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sabrina E. Iskandar, Victoria A. Haberman, <span class="NLM_string-name hlFld-ContribAuthor">Albert A. Bowers</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Chemical Diversity of Genetically Encoded Libraries. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (12)
                                     , 712-733. <a href="https://doi.org/10.1021/acscombsci.0c00179" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00179%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DExpanding%252Bthe%252BChemical%252BDiversity%252Bof%252BGenetically%252BEncoded%252BLibraries%26aulast%3DIskandar%26aufirst%3DSabrina%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08092020%26date%3D20102020%26date%3D09112020%26volume%3D22%26issue%3D12%26spage%3D712%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kuei-Ju Cheng, Chien-Ming Hsieh, Kunal Nepali, <span class="NLM_string-name hlFld-ContribAuthor">Jing-Ping Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10533-10593. <a href="https://doi.org/10.1021/acs.jmedchem.9b01033" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01033%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOcular%252BDisease%252BTherapeutics%25253A%252BDesign%252Band%252BDelivery%252Bof%252BDrugs%252Bfor%252BDiseases%252Bof%252Bthe%252BEye%26aulast%3DCheng%26aufirst%3DKuei-Ju%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28062019%26date%3D02062020%26volume%3D63%26issue%3D19%26spage%3D10533%26epage%3D10593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Lei</span>, <span class="hlFld-ContribAuthor ">Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiwen  Dai</span>, <span class="hlFld-ContribAuthor ">Yulin  Duan</span>, <span class="hlFld-ContribAuthor ">Qing  Mao</span>, <span class="hlFld-ContribAuthor ">Jun  Gao</span>, <span class="hlFld-ContribAuthor ">Yuwei  Yang</span>, <span class="hlFld-ContribAuthor ">Ziyang  Bao</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Fu</span>, <span class="hlFld-ContribAuthor ">Kunqi  Ping</span>, <span class="hlFld-ContribAuthor ">Chengda  Yan</span>, <span class="hlFld-ContribAuthor ">Yanhua  Mou</span>, <span class="hlFld-ContribAuthor ">Shaojie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113437. <a href="https://doi.org/10.1016/j.ejmech.2021.113437" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113437%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BFXIa%252Binhibitors%252Bwith%252B2-phenyl-1H-imidazole-5-carboxamide%252Bmoiety%252Bas%252BP1%252Bfragment%26aulast%3DLei%26aufirst%3DYu%26date%3D2021%26volume%3D220%26spage%3D113437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Vanhove</span>, <span class="hlFld-ContribAuthor ">Bernard  Noppen</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Wagner</span>, <span class="hlFld-ContribAuthor ">Tine  Van Bergen</span>, <span class="hlFld-ContribAuthor ">Philippe  Barbeaux</span>, <span class="hlFld-ContribAuthor ">Alan W.  Stitt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacokinetics and Pharmacodynamics</span><span> <strong>2021,</strong> <em>126 </em><a href="https://doi.org/10.1007/s10928-021-09773-w" title="DOI URL">https://doi.org/10.1007/s10928-021-09773-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10928-021-09773-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10928-021-09773-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacokinetics%2520and%2520Pharmacodynamics%26atitle%3DSystemic%252Bexposure%252Bfollowing%252Bintravitreal%252Badministration%252Bof%252Btherapeutic%252Bagents%25253A%252Ban%252Bintegrated%252Bpharmacokinetic%252Bapproach.%252B1.%252BTHR-149%26aulast%3DVanhove%26aufirst%3DMarc%26date%3D2021%26date%3D2021%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey Y.-K.  Wong</span>, <span class="hlFld-ContribAuthor ">Raja  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Jiayuan  Miao</span>, <span class="hlFld-ContribAuthor ">Olena  Bilyk</span>, <span class="hlFld-ContribAuthor ">Vivian  Triana</span>, <span class="hlFld-ContribAuthor ">Mark  Miskolzie</span>, <span class="hlFld-ContribAuthor ">Antoine  Henninot</span>, <span class="hlFld-ContribAuthor ">John J.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Serhii  Kharchenko</span>, <span class="hlFld-ContribAuthor ">Anna  Iampolska</span>, <span class="hlFld-ContribAuthor ">Dmitriy M.  Volochnyuk</span>, <span class="hlFld-ContribAuthor ">Yu-Shan  Lin</span>, <span class="hlFld-ContribAuthor ">Lynne-Marie  Postovit</span>, <span class="hlFld-ContribAuthor ">Ratmir  Derda</span>. </span><span class="cited-content_cbyCitation_article-title">Genetically-encoded discovery of proteolytically stable bicyclic inhibitors for morphogen NODAL. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (28)
                                     , 9694-9703. <a href="https://doi.org/10.1039/D1SC01916C" title="DOI URL">https://doi.org/10.1039/D1SC01916C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC01916C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC01916C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DGenetically-encoded%252Bdiscovery%252Bof%252Bproteolytically%252Bstable%252Bbicyclic%252Binhibitors%252Bfor%252Bmorphogen%252BNODAL%26aulast%3DWong%26aufirst%3DJeffrey%2BY.-K.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D28%26spage%3D9694%26epage%3D9703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard  Noppen</span>, <span class="hlFld-ContribAuthor ">Anouk  Vanbelle</span>, <span class="hlFld-ContribAuthor ">Alan W.  Stitt</span>, <span class="hlFld-ContribAuthor ">Marc  Vanhove</span>. </span><span class="cited-content_cbyCitation_article-title">A novel assay based on pre-equilibrium titration curves for the determination of enzyme inhibitor binding kinetics. </span><span class="cited-content_cbyCitation_journal-name">European Biophysics Journal</span><span> <strong>2021,</strong> <em>271 </em><a href="https://doi.org/10.1007/s00249-021-01554-0" title="DOI URL">https://doi.org/10.1007/s00249-021-01554-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00249-021-01554-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00249-021-01554-0%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Biophysics%2520Journal%26atitle%3DA%252Bnovel%252Bassay%252Bbased%252Bon%252Bpre-equilibrium%252Btitration%252Bcurves%252Bfor%252Bthe%252Bdetermination%252Bof%252Benzyme%252Binhibitor%252Bbinding%252Bkinetics%26aulast%3DNoppen%26aufirst%3DBernard%26date%3D2021%26date%3D2021%26volume%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Vanhove</span>. </span><span class="cited-content_cbyCitation_article-title">A method to assess the robustness of complex mathematical models used for quantitative interpretation of experimental data by nonlinear regression analysis: application to high-affinity binding models. </span><span class="cited-content_cbyCitation_journal-name">European Biophysics Journal</span><span> <strong>2021,</strong> <em>221 </em><a href="https://doi.org/10.1007/s00249-021-01556-y" title="DOI URL">https://doi.org/10.1007/s00249-021-01556-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00249-021-01556-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00249-021-01556-y%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Biophysics%2520Journal%26atitle%3DA%252Bmethod%252Bto%252Bassess%252Bthe%252Brobustness%252Bof%252Bcomplex%252Bmathematical%252Bmodels%252Bused%252Bfor%252Bquantitative%252Binterpretation%252Bof%252Bexperimental%252Bdata%252Bby%252Bnonlinear%252Bregression%252Banalysis%25253A%252Bapplication%252Bto%252Bhigh-affinity%252Bbinding%252Bmodels%26aulast%3DVanhove%26aufirst%3DMarc%26date%3D2021%26date%3D2021%26volume%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Punit  Upadhyaya</span>, <span class="hlFld-ContribAuthor ">Johanna  Lahdenranta</span>, <span class="hlFld-ContribAuthor ">Kristen  Hurov</span>, <span class="hlFld-ContribAuthor ">Sailaja  Battula</span>, <span class="hlFld-ContribAuthor ">Rachel  Dods</span>, <span class="hlFld-ContribAuthor ">Eric  Haines</span>, <span class="hlFld-ContribAuthor ">Marianna  Kleyman</span>, <span class="hlFld-ContribAuthor ">Julia  Kristensson</span>, <span class="hlFld-ContribAuthor ">Jessica  Kublin</span>, <span class="hlFld-ContribAuthor ">Rachid  Lani</span>, <span class="hlFld-ContribAuthor ">Jun  Ma</span>, <span class="hlFld-ContribAuthor ">Gemma  Mudd</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Repash</span>, <span class="hlFld-ContribAuthor ">Katerine  Van Rietschoten</span>, <span class="hlFld-ContribAuthor ">Tom  Stephen</span>, <span class="hlFld-ContribAuthor ">Fanglei  You</span>, <span class="hlFld-ContribAuthor ">Helen  Harrison</span>, <span class="hlFld-ContribAuthor ">Liuhong  Chen</span>, <span class="hlFld-ContribAuthor ">Kevin  McDonnell</span>, <span class="hlFld-ContribAuthor ">Philip  Brandish</span>, <span class="hlFld-ContribAuthor ">Nicholas  Keen</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. </span><span class="cited-content_cbyCitation_journal-name">Journal for ImmunoTherapy of Cancer</span><span> <strong>2021,</strong> <em>9 </em>
                                    (1)
                                     , e001762. <a href="https://doi.org/10.1136/jitc-2020-001762" title="DOI URL">https://doi.org/10.1136/jitc-2020-001762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/jitc-2020-001762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fjitc-2020-001762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520for%2520ImmunoTherapy%2520of%2520Cancer%26atitle%3DAnticancer%252Bimmunity%252Binduced%252Bby%252Ba%252Bsynthetic%252Btumor-targeted%252BCD137%252Bagonist%26aulast%3DUpadhyaya%26aufirst%3DPunit%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D1%26spage%3De001762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emanuela  Iaccarino</span>, <span class="hlFld-ContribAuthor ">Luisa  Calvanese</span>, <span class="hlFld-ContribAuthor ">Gustavo  Untiveros</span>, <span class="hlFld-ContribAuthor ">Lucia  Falcigno</span>, <span class="hlFld-ContribAuthor ">Gabriella  D'Auria</span>, <span class="hlFld-ContribAuthor ">Debora  Latino</span>, <span class="hlFld-ContribAuthor ">Jwala Priyadarsini  Sivaccumar</span>, <span class="hlFld-ContribAuthor ">Luigi  Strizzi</span>, <span class="hlFld-ContribAuthor ">Menotti  Ruvo</span>, <span class="hlFld-ContribAuthor ">Annamaria  Sandomenico</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2020,</strong> <em>477 </em>
                                    (8)
                                     , 1391-1407. <a href="https://doi.org/10.1042/BCJ20190953" title="DOI URL">https://doi.org/10.1042/BCJ20190953</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20190953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20190953%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DStructure-based%252Bdesign%252Bof%252Bsmall%252Bbicyclic%252Bpeptide%252Binhibitors%252Bof%252BCripto-1%252Bactivity%26aulast%3DIaccarino%26aufirst%3DEmanuela%26date%3D2020%26date%3D2020%26volume%3D477%26issue%3D8%26spage%3D1391%26epage%3D1407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashay D.  Bhatwadekar</span>, <span class="hlFld-ContribAuthor ">Viral S.  Kansara</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Ciulla</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (3)
                                     , 237-244. <a href="https://doi.org/10.1080/13543784.2020.1723078" title="DOI URL">https://doi.org/10.1080/13543784.2020.1723078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1723078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1723078%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Bplasma%252Bkallikrein%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bdiabetic%252Bmacular%252Bedema%25253A%252Ban%252Bexpert%252Bassessment%26aulast%3DBhatwadekar%26aufirst%3DAshay%2BD.%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D3%26spage%3D237%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhouling  Xie</span>, <span class="hlFld-ContribAuthor ">Zhen  Li</span>, <span class="hlFld-ContribAuthor ">Yanruisheng  Shao</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and development of plasma kallikrein inhibitors for multiple diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112137. <a href="https://doi.org/10.1016/j.ejmech.2020.112137" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112137%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bdevelopment%252Bof%252Bplasma%252Bkallikrein%252Binhibitors%252Bfor%252Bmultiple%252Bdiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2020%26volume%3D190%26spage%3D112137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">MD Imam  Uddin</span>, <span class="hlFld-ContribAuthor ">Ashwath  Jayagopal</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Therapeutic Modalities for Diabetic Retinopathy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 161-187. <a href="https://doi.org/10.1007/7355_2020_101" title="DOI URL">https://doi.org/10.1007/7355_2020_101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_101%26sid%3Dliteratum%253Aachs%26atitle%3DEmerging%252BTherapeutic%252BModalities%252Bfor%252BDiabetic%252BRetinopathy%26aulast%3DUddin%26aufirst%3DMD%2BImam%26date%3D2020%26date%3D2020%26spage%3D161%26epage%3D187%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDrug%252BDelivery%252BChallenges%252Band%252BNovel%252BTherapeutic%252BApproaches%252Bfor%252BRetinal%252BDiseases%26aulast%3DCioffi%26aufirst%3DChristopher%2BL.%26date%3D2020%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiaochen  Yu</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Chang</span>, <span class="hlFld-ContribAuthor ">Mei  Xue</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Li</span>, <span class="hlFld-ContribAuthor ">Yunhong  Lu</span>, <span class="hlFld-ContribAuthor ">Ting  Li</span>, <span class="hlFld-ContribAuthor ">Ziyu  Meng</span>, <span class="hlFld-ContribAuthor ">Long  Su</span>, <span class="hlFld-ContribAuthor ">Bei  Sun</span>, <span class="hlFld-ContribAuthor ">Liming  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes. </span><span class="cited-content_cbyCitation_journal-name">Diabetologia</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 1074-1086. <a href="https://doi.org/10.1007/s00125-019-4838-9" title="DOI URL">https://doi.org/10.1007/s00125-019-4838-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00125-019-4838-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00125-019-4838-9%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetologia%26atitle%3DPancreatic%252Bkallikrein%252Bprotects%252Bagainst%252Bdiabetic%252Bretinopathy%252Bin%252BKK%252BCg-Ay%25252FJ%252Band%252Bhigh-fat%252Bdiet%25252Fstreptozotocin-induced%252Bmouse%252Bmodels%252Bof%252Btype%252B2%252Bdiabetes%26aulast%3DCheng%26aufirst%3DYing%26date%3D2019%26date%3D2019%26volume%3D62%26issue%3D6%26spage%3D1074%26epage%3D1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shahrzad  Ahangarzadeh</span>, <span class="hlFld-ContribAuthor ">Mohammad M.  Kanafi</span>, <span class="hlFld-ContribAuthor ">Simzar  Hosseinzadeh</span>, <span class="hlFld-ContribAuthor ">Ahad  Mokhtarzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmood  Barati</span>, <span class="hlFld-ContribAuthor ">Javad  Ranjbari</span>, <span class="hlFld-ContribAuthor ">Lobat  Tayebi</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic peptides: types, synthesis and applications. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (6)
                                     , 1311-1319. <a href="https://doi.org/10.1016/j.drudis.2019.05.008" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.05.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.05.008%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DBicyclic%252Bpeptides%25253A%252Btypes%25252C%252Bsynthesis%252Band%252Bapplications%26aulast%3DAhangarzadeh%26aufirst%3DShahrzad%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1311%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chan  Li</span>, <span class="hlFld-ContribAuthor ">Kayleigh M.  Voos</span>, <span class="hlFld-ContribAuthor ">Monika  Pathak</span>, <span class="hlFld-ContribAuthor ">Gareth  Hall</span>, <span class="hlFld-ContribAuthor ">Keith R.  McCrae</span>, <span class="hlFld-ContribAuthor ">Ingrid  Dreveny</span>, <span class="hlFld-ContribAuthor ">Renhao  Li</span>, <span class="hlFld-ContribAuthor ">Jonas  Emsley</span>. </span><span class="cited-content_cbyCitation_article-title">Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor
              XI. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thrombosis and Haemostasis</span><span> <strong>2019,</strong> <em>17 </em>
                                    (5)
                                     , 759-770. <a href="https://doi.org/10.1111/jth.14418" title="DOI URL">https://doi.org/10.1111/jth.14418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jth.14418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjth.14418%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thrombosis%2520and%2520Haemostasis%26atitle%3DPlasma%252Bkallikrein%252Bstructure%252Breveals%252Bapple%252Bdomain%252Bdisc%252Brotated%252Bconformation%252Bcompared%252Bto%252Bfactor%252BXI%26aulast%3DLi%26aufirst%3DChan%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D5%26spage%3D759%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iteng  Ng-Choi</span>, <span class="hlFld-ContribAuthor ">Àngel  Oliveras</span>, <span class="hlFld-ContribAuthor ">Lidia  Feliu</span>, <span class="hlFld-ContribAuthor ">Marta  Planas</span>. </span><span class="cited-content_cbyCitation_article-title">Solid-phase synthesis of biaryl bicyclic peptides containing a 3-aryltyrosine or a 4-arylphenylalanine moiety. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>15 </em>, 761-768. <a href="https://doi.org/10.3762/bjoc.15.72" title="DOI URL">https://doi.org/10.3762/bjoc.15.72</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.15.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.15.72%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSolid-phase%252Bsynthesis%252Bof%252Bbiaryl%252Bbicyclic%252Bpeptides%252Bcontaining%252Ba%252B3-aryltyrosine%252Bor%252Ba%252B4-arylphenylalanine%252Bmoiety%26aulast%3DNg-Choi%26aufirst%3DIteng%26date%3D2019%26date%3D2019%26volume%3D15%26spage%3D761%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of bicyclic peptides. (A) Canonical structure of bicyclic peptides containing 5 AA in each loop (5 × 5). Any loop format is possible, referred to in text as 6 × 6 and 5 × 6 bicyclic peptides. Cysteine residues and the 1,3,5-trismethylbenzene scaffold are indicated in red. Loop 1 is located between Cys<sub>i</sub> and Cys<sub>ii</sub>, Loop 2 is located between Cys<sub>ii</sub> and Cys<sub>iii</sub>. Residue numbering begins following the N-terminal first Cys<sub>i</sub>. (B) Rat and human plasma protease activity on <b>2b</b>. Rat and human cleavage sites and successive excision of peptide segments are indicated in blue and green, respectively. (C) Chemical structure of <b>2d</b>. The central scaffold is shown in red, with non-natural modifications (Aze, HArg, pseudopeptide bond) indicated in blue. All amino acids are in their <span class="smallcaps smallerCapital">l</span>-configuration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Degradation of bicyclic peptide <b>2b</b> in plasma. (A) MALDI-TOF derived ion chromatograms of <b>2b</b> exposed to rat plasma. Removal of Arg<sub>5</sub> in Loop 1 is observed, with larger fragments being excised subsequently. Note the low signal for intact parent peptide following 18 h of incubation. (B) MALDI-TOF derived ion chromatograms of <b>2b</b> exposed to human plasma. Removal of 3 fragments in Loop 2 is observed, centering on His<sub>7</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of human PKal activity by the bicyclic peptide <b>2d</b>. Each data point represents the mean ± SD of duplicate measurements. The solid line represents the best fit obtained using <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>1b</b>, <b>2d</b>, and <b>4b</b> on the coagulation time in the aPTT assay. Each data point represents the mean ± SD of triplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of bradykinin release in plasma and vitreous by <b>2d</b>. Each data point represents a single measurement. The solid lines represent the best fits obtained using <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>. The left and right <i>Y</i>-axes represent the bradykinin concentration in the vitreous and in plasma, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Vitreous concentrations of the <b>2d</b> peptide following intravitreal administration in rabbit. Calculated half-life is 39 ± 2 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> efficacy of <b>2d</b> and <b>1b</b> in a male, Sprague-Dawley rat paw edema model. (A) Subplantar carrageenan injection induced a distinct increase in paw volume in the vehicle control group. Pretreatment with the positive control indomethacin via IP injection (5 mg/kg) resulted in a significant inhibition of the carrageenan-induced paw edema. Pretreatment with IP injection (30, 10, or 3 mg/kg) of <b>1b</b> or <b>2d</b> resulted in a significant and dose-dependent inhibition of the carrageenan-induced response. (B) The area under the curve was calculated for the different conditions from 0 to 2 h, which revealed a prominent dose–response for both <b>2d</b> and <b>1b</b>. Data are shown as mean ± SEM (* <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/medium/jm-2017-01625a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Efficacy of peptide <b>1b</b> in a diabetic, male C57BL/6J mouse model of retinal permeability. Black bars represent data for diabetic animals. Both treatment with the anti-VEGFR2 positive control antibody DC101 as well as repeated intravitreal injections of <b>1b</b> decreased vessel leakage as compared to vehicle-treated diabetic mice. (B) Efficacy of peptide <b>2d</b> in a diabetic, male Brown-Norway rat model of retinal permeability. Black bars represent data for diabetic animals. Intravitreal administration of 100 μg/eye of <b>2d</b> resulted in a statistically significant reduction of vascular leakage, as compared to vehicle-treated animals. The effect was comparable to the one obtained following administration of a soluble VEGF-trap used as a positive control. Data are shown as mean ± SEM (* <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01625/20180406/images/large/jm-2017-01625a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01625&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 71 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kresse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E.</span></span> <span> </span><span class="NLM_article-title">Expression of plasma prekallikrein mRNA in human nonhepatic tissues and cell lineages suggests special local functions of the enzyme</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1515/BC.1999.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1515%2FBC.1999.136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1999&pages=1097-1102&author=A.+Hermannauthor=M.+Arnholdauthor=H.+Kresseauthor=P.+Nethauthor=E.+Fink&title=Expression+of+plasma+prekallikrein+mRNA+in+human+nonhepatic+tissues+and+cell+lineages+suggests+special+local+functions+of+the+enzyme&doi=10.1515%2FBC.1999.136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1515%2FBC.1999.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.1999.136%26sid%3Dliteratum%253Aachs%26aulast%3DHermann%26aufirst%3DA.%26aulast%3DArnhold%26aufirst%3DM.%26aulast%3DKresse%26aufirst%3DH.%26aulast%3DNeth%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DE.%26atitle%3DExpression%2520of%2520plasma%2520prekallikrein%2520mRNA%2520in%2520human%2520nonhepatic%2520tissues%2520and%2520cell%2520lineages%2520suggests%2520special%2520local%2520functions%2520of%2520the%2520enzyme%26jtitle%3DBiol.%2520Chem.%26date%3D1999%26volume%3D380%26spage%3D1097%26epage%3D1102%26doi%3D10.1515%2FBC.1999.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/35060059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2F35060059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=11231576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFenuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=267-275&author=S.+Selvarajanauthor=L.+R.+Lundauthor=T.+Takeuchiauthor=C.+S.+Craikauthor=Z.+Werb&title=A+plasma+kallikrein-dependent+plasminogen+cascade+required+for+adipocyte+differentiation&doi=10.1038%2F35060059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation</span></div><div class="casAuthors">Selvarajan, Sushma; Lund, Leif R.; Takeuchi, Toshihiko; Craik, Charles S.; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we show that plasma kallikrein (PKal) mediates a plasminogen (Pig) cascade in adipocyte differentiation.  Ecotin, an inhibitor of serine proteases, inhibits cell-shape change, adipocyte-specific gene expression, and lipid accumulation during adipogenesis in culture.  Deficiency of Pig, but not of urokinase or tissue-type plasminogen activator, suppresses adipogenesis during differentiation of 3T3-L1 cells and mammary-gland involution.  PKal, which is inhibited by ecotin, is required for adipose conversion, Pig activation and 3T3-L1 differentiation.  Human plasma lacking PKal does not support differentiation of 3T3-L1 cells.  PKal is therefore a physiol. regulator that acts in the Pig cascade during adipogenesis.  We propose that the Pig cascade fosters adipocyte differentiation by degrdn. of the fibronectin-rich preadipocyte stromal matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEC38vIj-Oz7Vg90H21EOLACvtfcHk0ljs996e0cMwcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFenuro%253D&md5=9bc97a4c41ab2748f6344c1fbc8035fe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35060059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060059%26sid%3Dliteratum%253Aachs%26aulast%3DSelvarajan%26aufirst%3DS.%26aulast%3DLund%26aufirst%3DL.%2BR.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DA%2520plasma%2520kallikrein-dependent%2520plasminogen%2520cascade%2520required%2520for%2520adipocyte%2520differentiation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D267%26epage%3D275%26doi%3D10.1038%2F35060059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeb-Lundberg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Esterl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuraw, B. L.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1124/pr.57.1.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1124%2Fpr.57.1.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15734727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=27-77&author=L.+M.+Leeb-Lundbergauthor=F.+Marceauauthor=W.+M%C3%BCller-Esterlauthor=D.+J.+Pettiboneauthor=B.+L.+Zuraw&title=International+union+of+pharmacology.+XLV.+Classification+of+the+kinin+receptor+family%3A+from+molecular+mechanisms+to+pathophysiological+consequences&doi=10.1124%2Fpr.57.1.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences</span></div><div class="casAuthors">Leeb-Lundberg, L. M. Fredrik; Marceau, Francois; Mueller-Esterl, Werner; Pettibone, Douglas J.; Zuraw, Bruce L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-77</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Kinins are proinflammatory peptides that mediate numerous vascular and pain responses to tissue injury.  Two pharmacol. distinct kinin receptor subtypes have been identified and characterized for these peptides, which are named B1 and B2 and belong to the rhodopsin family of G protein-coupled receptors.  The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B1 receptor mediates the action of des-Arg9-BK and Lys-des-Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, resp.  The B2 receptor is ubiquitous and constitutively expressed, whereas the B1 receptor is expressed at a very low level in healthy tissues but induced following injury by various proinflammatory cytokines such as interleukin-1β.  Both receptors act through Gαq to stimulate phospholipase Cβ followed by phosphoinositide hydrolysis and intracellular free Ca2+ mobilization and through Gαi to inhibit adenylate cyclase and stimulate the mitogen-activated protein kinase pathways.  The use of mice lacking each receptor gene and various specific peptidic and non-peptidic antagonists have implicated both B1 and B2 receptors as potential therapeutic targets in several pathophysiol. events related to inflammation such as pain, sepsis, allergic asthma, rhinitis, and edema, as well as diabetes and cancer.  This review is a comprehensive presentation of our current understanding of these receptors in terms of mol. and cell biol., physiol., pharmacol., and involvement in human disease and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDJ2JFxaOYz7Vg90H21EOLACvtfcHk0ljs996e0cMwcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtr0%253D&md5=cfa8e13f88fa09602e7e4dcc38872981</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.1.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.1.2%26sid%3Dliteratum%253Aachs%26aulast%3DLeeb-Lundberg%26aufirst%3DL.%2BM.%26aulast%3DMarceau%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Esterl%26aufirst%3DW.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DZuraw%26aufirst%3DB.%2BL.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XLV.%2520Classification%2520of%2520the%2520kinin%2520receptor%2520family%253A%2520from%2520molecular%2520mechanisms%2520to%2520pathophysiological%2520consequences%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D27%26epage%3D77%26doi%3D10.1124%2Fpr.57.1.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmaier, A. H.</span></span> <span> </span><span class="NLM_article-title">The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1111/jth.13194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fjth.13194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26565070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=28-39&author=A.+H.+Schmaier&title=The+contact+activation+and+kallikrein%2Fkinin+systems%3A+pathophysiologic+and+physiologic+activities&doi=10.1111%2Fjth.13194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities</span></div><div class="casAuthors">Schmaier, A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : The contact activation system (CAS) and kallikrein/kinin system (KKS) are older recognized biochem. pathways that include several proteins that skirt the fringes of the blood coagulation, fibrinolytic, complement and renin-angiotensin fields.  These proteins initially were proposed as part of the hemostatic pathways because their deficiencies are assocd. with prolonged clin. assays.  However, the absence of bleeding states with deficiencies of factor XII (FXII), prekallikrein (PK) and high-mol.-wt. kininogen indicates that the CAS and KKS do not contribute to hemostasis.  Since the discovery of the Hageman factor 60 years ago much has been learned about the biochem., cell biol. and animal physiol. of these proteins.  The CAS is a pathophysiol. surface defense mechanism against foreign proteins, organisms and artificial materials.  The KKS is an inflammatory response mechanism.  Targeting their activation through FXIIa or plasma kallikrein inhibition when blood interacts with the artificial surfaces of modern interventional medicine or in acute attacks of hereditary angioedema restores vascular homeostasis.  FXII/FXIIa and products that arise with PK deficiency also offer novel ways to reduce arterial and venous thrombosis without an effect on hemostasis.  In summary, there is revived interest in the CAS and KKS due to better understanding of their activities.  The new appreciation of these systems will lead to several new therapies for a variety of medical disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkD1I_arQFy7Vg90H21EOLACvtfcHk0ljs996e0cMwcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtLY%253D&md5=8bf50534f95c4cba82133a32a64c83c2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fjth.13194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13194%26sid%3Dliteratum%253Aachs%26aulast%3DSchmaier%26aufirst%3DA.%2BH.%26atitle%3DThe%2520contact%2520activation%2520and%2520kallikrein%252Fkinin%2520systems%253A%2520pathophysiologic%2520and%2520physiologic%2520activities%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2016%26volume%3D14%26spage%3D28%26epage%3D39%26doi%3D10.1111%2Fjth.13194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochrane, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revak, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuepper, K. D.</span></span> <span> </span><span class="NLM_article-title">Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1583</span>, <span class="refDoi"> DOI: 10.1084/jem.138.6.1564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1084%2Fjem.138.6.1564" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1973&pages=1564-1583&author=C.+G.+Cochraneauthor=S.+D.+Revakauthor=K.+D.+Wuepper&title=Activation+of+Hageman+factor+in+solid+and+fluid+phases.+A+critical+role+of+kallikrein&doi=10.1084%2Fjem.138.6.1564"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.138.6.1564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.138.6.1564%26sid%3Dliteratum%253Aachs%26aulast%3DCochrane%26aufirst%3DC.%2BG.%26aulast%3DRevak%26aufirst%3DS.%2BD.%26aulast%3DWuepper%26aufirst%3DK.%2BD.%26atitle%3DActivation%2520of%2520Hageman%2520factor%2520in%2520solid%2520and%2520fluid%2520phases.%2520A%2520critical%2520role%2520of%2520kallikrein%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1973%26volume%3D138%26spage%3D1564%26epage%3D1583%26doi%3D10.1084%2Fjem.138.6.1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaier, A. H.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">17962</span>– <span class="NLM_lpage">17969</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106101200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.M106101200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=17962-17969&author=Z.+Shariat-Madarauthor=F.+Mahdiauthor=A.+H.+Schmaier&title=Identification+and+characterization+of+prolylcarboxypeptidase+as+an+endothelial+cell+prekallikrein+activator&doi=10.1074%2Fjbc.M106101200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106101200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106101200%26sid%3Dliteratum%253Aachs%26aulast%3DShariat-Madar%26aufirst%3DZ.%26aulast%3DMahdi%26aufirst%3DF.%26aulast%3DSchmaier%26aufirst%3DA.%2BH.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520prolylcarboxypeptidase%2520as%2520an%2520endothelial%2520cell%2520prekallikrein%2520activator%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D17962%26epage%3D17969%26doi%3D10.1074%2Fjbc.M106101200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bork, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staubach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardt, J.</span></span> <span> </span><span class="NLM_article-title">Hereditary angioedema: new findings concerning symptoms, affected organs, and course</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2005.09.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.amjmed.2005.09.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=16490473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD287gt1KgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=267-274&author=K.+Borkauthor=G.+Mengauthor=P.+Staubachauthor=J.+Hardt&title=Hereditary+angioedema%3A+new+findings+concerning+symptoms%2C+affected+organs%2C+and+course&doi=10.1016%2Fj.amjmed.2005.09.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hereditary angioedema: new findings concerning symptoms, affected organs, and course</span></div><div class="casAuthors">Bork Konrad; Meng Gabriele; Staubach Petra; Hardt Jochen</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction.  Our aim was to examine a temporal and spatial pattern of the edema episodes by evaluating the long-term course of hereditary angioedema in order to establish a specific swelling pattern.  SUBJECTS AND METHODS:  Data were generated from 221 patients with C1 inhibitor deficiency by asking them about symptoms they experienced during their edema episodes.  Documentation was accomplished through the use of standardized questionnaires.  RESULTS:  A total of 131110 edema episodes were observed.  Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.  During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.  Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.  The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.  The per-patient analysis and the per-episode analysis revealed markedly discrepant results.  On average, women had a more severe course of the disease than men.  Patients with early onset of clinical symptoms were affected more severely than those with late onset.  CONCLUSION:  The described swelling pattern is specific for HAE and allows a tentative diagnosis based on clinical symptoms and the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTKHdpx19dgZ0d-O_J5C0AfW6udTcc2eali5aS5ir0-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287gt1KgsA%253D%253D&md5=4f0708b76a8f977f29e81ccb4f366aed</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2005.09.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2005.09.064%26sid%3Dliteratum%253Aachs%26aulast%3DBork%26aufirst%3DK.%26aulast%3DMeng%26aufirst%3DG.%26aulast%3DStaubach%26aufirst%3DP.%26aulast%3DHardt%26aufirst%3DJ.%26atitle%3DHereditary%2520angioedema%253A%2520new%2520findings%2520concerning%2520symptoms%252C%2520affected%2520organs%252C%2520and%2520course%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3D267%26epage%3D274%26doi%3D10.1016%2Fj.amjmed.2005.09.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1586/eci.13.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1586%2Feci.13.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=23634741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVSmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=477-488&author=A.+Zanichelliauthor=M.+Mansiauthor=G.+Peritiauthor=M.+Cicardi&title=Therapeutic+management+of+hereditary+angioedema+due+to+C1+inhibitor+deficiency&doi=10.1586%2Feci.13.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency</span></div><div class="casAuthors">Zanichelli, Andrea; Mansi, Marta; Periti, Giulia; Cicardi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-488</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency is a rare genetic disease characterized by recurrent swellings of the s.c. and submucosal tissues that can manifest as cutaneous edema, abdominal pain and laryngeal edema with airway obstruction.  These symptoms have a significant impact on patients' quality of life.  The redn. in C1-INH function leads to uncontrolled activation of the contact system and generation of bradykinin, the mediator of increased vascular permeability and edema formation.  In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.  Such therapies can improve disease outcome.  This article reviews the therapeutic management of HAE, which involves the treatment of acute attacks and prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS_4laFjZeAbVg90H21EOLACvtfcHk0ljJoLuJ27kokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVSmsbY%253D&md5=9a70912e49b76f70ec0dc481c6d56555</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1586%2Feci.13.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.13.22%26sid%3Dliteratum%253Aachs%26aulast%3DZanichelli%26aufirst%3DA.%26aulast%3DMansi%26aufirst%3DM.%26aulast%3DPeriti%26aufirst%3DG.%26aulast%3DCicardi%26aufirst%3DM.%26atitle%3DTherapeutic%2520management%2520of%2520hereditary%2520angioedema%2520due%2520to%2520C1%2520inhibitor%2520deficiency%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D9%26spage%3D477%26epage%3D488%26doi%3D10.1586%2Feci.13.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicardi, M.</span></span> <span> </span><span class="NLM_article-title">Current treatment options for hereditary angioedema due to C1 inhibitor deficiency</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1517/14656566.2016.1104300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1517%2F14656566.2016.1104300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26512744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=27-40&author=M.+A.+Wuauthor=A.+Zanichelliauthor=M.+Mansiauthor=M.+Cicardi&title=Current+treatment+options+for+hereditary+angioedema+due+to+C1+inhibitor+deficiency&doi=10.1517%2F14656566.2016.1104300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatment options for hereditary angioedema due to C1 inhibitor deficiency</span></div><div class="casAuthors">Wu, Maddalena Alessandra; Zanichelli, Andrea; Mansi, Marta; Cicardi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-40</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Hereditary angioedema (HAE) usually results from C1 inhibitor (C1-INH) deficiency or dysfunction.  It is a rare autosomal dominant disorder characterized by localized, non-pitting edema of the skin and submucosal tissues of the upper respiratory and gastrointestinal tracts, without significant wheals or pruritus, due to a temporary increase in vascular permeability.  Other forms of HAE have been described, but therapies are approved only for HAE with C1-INH deficiency: hence, this review focuses on C1-INH-HAE.  The aim of this review article is to present current available therapies for treatment of acute attacks as well as for short- and long-term prophylaxis of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).  The Authors highlight also crit. issues on the management of C1-INH-HAE, which is continuously evolving thanks to evidence from clin. trials, post-marketing experience and ongoing studies.  In the last decade, the quality of life of C1-INH-HAE patients has significantly improved due to increased knowledge and awareness of the disease, improved patient support and major progress in pharmacotherapy.  Ongoing research will probably provide patients with other new effective therapeutic agents in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsU2tl__aPbVg90H21EOLACvtfcHk0ljJoLuJ27kokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWntLfI&md5=1cf9b8018878b234c5098d560a61dc19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1104300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1104300%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%2BA.%26aulast%3DZanichelli%26aufirst%3DA.%26aulast%3DMansi%26aufirst%3DM.%26aulast%3DCicardi%26aufirst%3DM.%26atitle%3DCurrent%2520treatment%2520options%2520for%2520hereditary%2520angioedema%2520due%2520to%2520C1%2520inhibitor%2520deficiency%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D27%26epage%3D40%26doi%3D10.1517%2F14656566.2016.1104300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B. E.</span></span> <span> </span><span class="NLM_article-title">The 14-year incidence of visual loss in a diabetic population</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/S0161-6420(98)96025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2FS0161-6420%2898%2996025-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1998&pages=998-1003&author=S.+E.+Mossauthor=R.+Kleinauthor=B.+E.+Klein&title=The+14-year+incidence+of+visual+loss+in+a+diabetic+population&doi=10.1016%2FS0161-6420%2898%2996025-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0161-6420%2898%2996025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-6420%252898%252996025-0%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DS.%2BE.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DB.%2BE.%26atitle%3DThe%252014-year%2520incidence%2520of%2520visual%2520loss%2520in%2520a%2520diabetic%2520population%26jtitle%3DOphthalmology%26date%3D1998%26volume%3D105%26spage%3D998%26epage%3D1003%26doi%3D10.1016%2FS0161-6420%2898%2996025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobrin
Klein, B. E.</span></span> <span> </span><span class="NLM_article-title">Overview of epidemiologic studies of diabetic retinopathy</span>. <i>Ophthalmic Epidemiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1080/09286580701396720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F09286580701396720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17896294" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=179-183&author=B.+E.+Kobrin%0AKlein&title=Overview+of+epidemiologic+studies+of+diabetic+retinopathy&doi=10.1080%2F09286580701396720"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F09286580701396720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09286580701396720%26sid%3Dliteratum%253Aachs%26aulast%3DKobrin%2BKlein%26aufirst%3DB.%2BE.%26atitle%3DOverview%2520of%2520epidemiologic%2520studies%2520of%2520diabetic%2520retinopathy%26jtitle%3DOphthalmic%2520Epidemiol.%26date%3D2007%26volume%3D14%26spage%3D179%26epage%3D183%26doi%3D10.1080%2F09286580701396720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Diabetic retinopathy</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)62124-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2FS0140-6736%2809%2962124-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20580421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsFagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=124-136&author=N.+Cheungauthor=P.+Mitchellauthor=T.+Y.+Wong&title=Diabetic+retinopathy&doi=10.1016%2FS0140-6736%2809%2962124-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetic retinopathy</span></div><div class="casAuthors">Cheung Ning; Mitchell Paul; Wong Tien Yin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9735</span>),
    <span class="NLM_cas:pages">124-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetic retinopathy is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people.  It is identified in a third of people with diabetes and associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure.  Optimum control of blood glucose, blood pressure, and possibly blood lipids remains the foundation for reduction of risk of retinopathy development and progression.  Timely laser therapy is effective for preservation of sight in proliferative retinopathy and macular oedema, but its ability to reverse visual loss is poor.  Vitrectomy surgery might occasionally be needed for advanced retinopathy.  New therapies, such as intraocular injection of steroids and antivascular endothelial growth-factor agents, are less destructive to the retina than are older therapies, and could be useful in patients who respond poorly to conventional therapy.  The outlook for future treatment modalities, such as inhibition of other angiogenic factors, regenerative therapy, and topical therapy, is promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-zCpfQ9sM6TW1zwg2yUK5fW6udTcc2ea0arlsklq4sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsFagsw%253D%253D&md5=457af59cd94a589ee5e870b6aa721e49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2962124-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252962124-3%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DN.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DDiabetic%2520retinopathy%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D124%26epage%3D136%26doi%3D10.1016%2FS0140-6736%2809%2962124-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokofyeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrenner, E.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of major eye diseases leading to blindness in Europe: A literature review</span>. <i>Ophthalmic Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1159/000329603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1159%2F000329603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22123077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38zotFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=171-188&author=E.+Prokofyevaauthor=E.+Zrenner&title=Epidemiology+of+major+eye+diseases+leading+to+blindness+in+Europe%3A+A+literature+review&doi=10.1159%2F000329603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of major eye diseases leading to blindness in Europe: a literature review</span></div><div class="casAuthors">Prokofyeva Elena; Zrenner Eberhart</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmic research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">171-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The objective of this work was to study the epidemiology of major eye diseases leading to blindness in Europe through a systematic literature review.  The literature search was performed using the Medline database (PubMed), with MeSH and free text search terms.  Inclusion criteria for the studies were: (a) performed on a healthy population of Caucasian origin aged between 50 and 75 years; (b) diagnosed by ophthalmological examination in accordance with the International Classification of Diseases 10; (c) contained a detailed description of the sampling and diagnostic procedures and data resources; (d) sample size>500, and (e) published between 1990 and 2008.  The results of 57 studies on the prevalence and incidence of age-related macular degeneration, diabetic retinopathy and glaucoma are reported, providing an up-to-date and comprehensive overview of these diseases in Europe from an epidemiological perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSXUve1sLb_IkFb3mqPUYDfW6udTcc2ea0arlsklq4sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zotFSqsw%253D%253D&md5=948e7717a173b0c3eab449c101bcb16f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000329603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000329603%26sid%3Dliteratum%253Aachs%26aulast%3DProkofyeva%26aufirst%3DE.%26aulast%3DZrenner%26aufirst%3DE.%26atitle%3DEpidemiology%2520of%2520major%2520eye%2520diseases%2520leading%2520to%2520blindness%2520in%2520Europe%253A%2520A%2520literature%2520review%26jtitle%3DOphthalmic%2520Res.%26date%3D2012%26volume%3D47%26spage%3D171%26epage%3D188%26doi%3D10.1159%2F000329603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolentino, M. J.</span></span> <span> </span><span class="NLM_article-title">Current and investigational drugs for the treatment of diabetic retinopathy</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F13543784.2016.1201062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1011-1022&author=M.+S.+Tolentinoauthor=A.+J.+Tolentinoauthor=M.+J.+Tolentino&title=Current+and+investigational+drugs+for+the+treatment+of+diabetic+retinopathy&doi=10.1080%2F13543784.2016.1201062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DTolentino%26aufirst%3DM.%2BS.%26aulast%3DTolentino%26aufirst%3DA.%2BJ.%26aulast%3DTolentino%26aufirst%3DM.%2BJ.%26atitle%3DCurrent%2520and%2520investigational%2520drugs%2520for%2520the%2520treatment%2520of%2520diabetic%2520retinopathy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1011%26epage%3D1022%26doi%3D10.1080%2F13543784.2016.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicree, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmet, P. Z.</span></span> <span> </span><span class="NLM_article-title">Global estimates of the prevalence of diabetes for 2010 and 2030</span>. <i>Diabetes Res. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.diabres.2009.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.diabres.2009.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19896746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fot1Witg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=4-14&author=J.+E.+Shawauthor=R.+A.+Sicreeauthor=P.+Z.+Zimmet&title=Global+estimates+of+the+prevalence+of+diabetes+for+2010+and+2030&doi=10.1016%2Fj.diabres.2009.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Global estimates of the prevalence of diabetes for 2010 and 2030</span></div><div class="casAuthors">Shaw J E; Sicree R A; Zimmet P Z</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes research and clinical practice</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  We estimated the number of people worldwide with diabetes for the years 2010 and 2030.  METHODS:  Studies from 91 countries were used to calculate age- and sex-specific diabetes prevalences, which were applied to national population estimates, to determine national diabetes prevalences for all 216 countries for 2010 and 2030.  Studies were identified using Medline, and contact with all national and regional International Diabetes Federation offices.  Studies were included if diabetes prevalence was assessed using a population-based methodology, and was based on World Health Organization or American Diabetes Association diagnostic criteria for at least three separate age-groups within the 20-79 year range.  Self-report or registry data were used if blood glucose assessment was not available.  RESULTS:  The world prevalence of diabetes among adults (aged 20-79 years) will be 6.4%, affecting 285 million adults, in 2010, and will increase to 7.7%, and 439 million adults by 2030.  Between 2010 and 2030, there will be a 69% increase in numbers of adults with diabetes in developing countries and a 20% increase in developed countries.  CONCLUSION:  These predictions, based on a larger number of studies than previous estimates, indicate a growing burden of diabetes, particularly in developing countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRahe1LLx72-EEksK8CslK8fW6udTcc2ea0arlsklq4sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fot1Witg%253D%253D&md5=111a4bed809880f5584fda783e64de89</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.diabres.2009.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diabres.2009.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26aulast%3DSicree%26aufirst%3DR.%2BA.%26aulast%3DZimmet%26aufirst%3DP.%2BZ.%26atitle%3DGlobal%2520estimates%2520of%2520the%2520prevalence%2520of%2520diabetes%2520for%25202010%2520and%25202030%26jtitle%3DDiabetes%2520Res.%2520Clin.%2520Pract.%26date%3D2010%26volume%3D87%26spage%3D4%26epage%3D14%26doi%3D10.1016%2Fj.diabres.2009.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ting, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review</span>. <i>Clin. Experiment. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1111/ceo.12696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fceo.12696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26716602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC28rlvVWiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=260-277&author=D.+S.+Tingauthor=G.+C.+Cheungauthor=T.+Y.+Wong&title=Diabetic+retinopathy%3A+global+prevalence%2C+major+risk+factors%2C+screening+practices+and+public+health+challenges%3A+a+review&doi=10.1111%2Fceo.12696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review</span></div><div class="casAuthors">Ting Daniel Shu Wei; Cheung Gemmy Chui Ming; Wong Tien Yin; Ting Daniel Shu Wei; Cheung Gemmy Chui Ming; Wong Tien Yin; Cheung Gemmy Chui Ming; Wong Tien Yin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & experimental ophthalmology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes retinopathy (DR) is a leading cause of vision loss in middle-aged and elderly people globally.  Early detection and prompt treatment allow prevention of diabetes-related visual impairment.  Patients with diabetes require regular follow-up with primary care physicians to optimize their glycaemic, blood pressure and lipid control to prevent development and progression of DR and other diabetes-related complications.  Other risk factors of DR include higher body mass index, puberty and pregnancy, and cataract surgery.  There are weaker associations with some genetic and inflammatory markers.  With the rising incidence and prevalence of diabetes and DR, public health systems in both developing and developed countries will be faced with increasing costs of implementation and maintenance of a DR screening program for people with diabetes.  To reduce the impact of DR-related visual loss, it is important that all stakeholders continue to look for innovative ways of managing and preventing diabetes, and optimize cost-effective screening programs within the community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkxrtbCXO5hUwlCcfExbvbfW6udTcc2ebMy43hyBoU17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlvVWiug%253D%253D&md5=8e4b934f4abe68713b713c676258ca68</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fceo.12696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fceo.12696%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DD.%2BS.%26aulast%3DCheung%26aufirst%3DG.%2BC.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DDiabetic%2520retinopathy%253A%2520global%2520prevalence%252C%2520major%2520risk%2520factors%252C%2520screening%2520practices%2520and%2520public%2520health%2520challenges%253A%2520a%2520review%26jtitle%3DClin.%2520Experiment.%2520Ophthalmol.%26date%3D2016%26volume%3D44%26spage%3D260%26epage%3D277%26doi%3D10.1111%2Fceo.12696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunirakasiwi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjay, S.</span></span> <span> </span><span class="NLM_article-title">Updates in the management of diabetic macular edema</span>. <i>J. Diabetes Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">794036</span>, <span class="refDoi"> DOI: 10.1155/2015/794036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1155%2F2015%2F794036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25984537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MbpsVentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=794036&author=C.+Mathewauthor=A.+Yunirakasiwiauthor=S.+Sanjay&title=Updates+in+the+management+of+diabetic+macular+edema&doi=10.1155%2F2015%2F794036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Updates in the management of diabetic macular edema</span></div><div class="casAuthors">Mathew Christopher; Yunirakasiwi Anastasia; Sanjay Srinivasan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">794036</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes mellitus is a chronic disease which has multiple effects on different end-organs, including the retina.  In this paper, we discuss updates on diabetic macular edema (DME) and the management options.  The underlying pathology of DME is the leakage of exudates from retinal microaneurysms, which trigger subsequent inflammatory reactions.  Both clinical and imaging techniques are useful in diagnosing, classifying, and gauging the severity of DME.  We performed a comprehensive literature search using the keywords "diabetes," "macula edema," "epidemiology," "pathogenesis," "optical coherence tomography," "intravitreal injections," "systemic treatment," "hypertension," "hyperlipidemia," "anemia," and "renal disease" and collated a total of 47 relevant articles published in English language.  The main modalities of treatment currently in use comprise laser photocoagulation, intravitreal pharmacological and selected systemic pharmacological options.  In addition, we mention some novel therapies that show promise in treating DME.  We also review systemic factors associated with exacerbation or improvement in DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVk08ed0nQFUewzGPswiWOfW6udTcc2ebMy43hyBoU17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbpsVentg%253D%253D&md5=ee823778fe601100d2b1ed80c3d47a88</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2015%2F794036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F794036%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DC.%26aulast%3DYunirakasiwi%26aufirst%3DA.%26aulast%3DSanjay%26aufirst%3DS.%26atitle%3DUpdates%2520in%2520the%2520management%2520of%2520diabetic%2520macular%2520edema%26jtitle%3DJ.%2520Diabetes%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D794036%26doi%3D10.1155%2F2015%2F794036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein and diabetic macular edema</span>. <i>Curr. Diabetes Rep.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1007/s11892-010-0127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1007%2Fs11892-010-0127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20535647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1CjsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=270-275&author=E.+P.+Feener&title=Plasma+kallikrein+and+diabetic+macular+edema&doi=10.1007%2Fs11892-010-0127-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma kallikrein and diabetic macular edema</span></div><div class="casAuthors">Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Recent proteomic studies have identified components of the kallikrein kinin system, including plasma kallikrein, factor XII, and kininogen, in vitreous obtained from individuals with advanced diabetic retinopathy.  In rodent models, activation of plasma kallikrein in vitreous increases retinal vascular permeability; whereas inhibition of the kallikrein kinin system reduces retinal leakage induced by diabetes and hypertension.  These findings suggest that intraocular activation of the plasma kallikrein pathway may contribute to excessive retinal vascular permeability that can lead to diabetic macular edema.  The kallikrein kinin system contains two sep. and independently regulated serine proteases that generate bradykinin peptides: plasma kallikrein and tissue kallikrein.  Tissue kallikrein is expressed in the retina and ciliary body, where it has been implicated in exerting autocrine or paracrine effects via bradykinin receptors that are colocalized in these tissues.  Emerging evidence suggests that plasma kallikrein inhibitors may provide a new therapeutic opportunity to reduce retinal vascular permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEKZDO9o3ju7Vg90H21EOLACvtfcHk0ljDgbm5aodCIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1CjsbzK&md5=6dbf844cf720bce4e6f59ffc10538e3f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11892-010-0127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-010-0127-1%26sid%3Dliteratum%253Aachs%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520and%2520diabetic%2520macular%2520edema%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2010%26volume%3D10%26spage%3D270%26epage%3D275%26doi%3D10.1007%2Fs11892-010-0127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdouh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasséssian, H. M.</span></span> <span> </span><span class="NLM_article-title">Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fbjp.2008.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=18311190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFOrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=136-143&author=M.+Abdouhauthor=S.+Talbotauthor=R.+Coutureauthor=H.+M.+Hass%C3%A9ssian&title=Retinal+plasma+extravasation+in+streptozotocin-diabetic+rats+mediated+by+kinin+B%281%29+and+B%282%29+receptors&doi=10.1038%2Fbjp.2008.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B1 and B2 receptors</span></div><div class="casAuthors">Abdouh, M.; Talbot, S.; Couture, R.; Hassessian, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-143</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We investigated whether or not kinin receptors play a role in diabetic blood-retinal barrier breakdown, which is a leading cause of vision loss.  Blood-retinal barrier breakdown was quantified using Evans blue, and expression of kinin B1 receptor mRNA was measured using quant. reverse transcription-PCR.  Diabetic rats (streptozotocin (STZ), 65 mg kg-1) received a single intraocular injection of bradykinin (BK) or des-Arg9-BK, alone, or in combination with antagonists for B1 (des-Arg10-Hoe140, R-715) and/or B2 (Hoe140) receptors, given intraocularly or i.v. (i.v.).  In control rats, BK (0.1-10 nmol) dose-dependently increased plasma extravasation, which was inhibited by Hoe140 (0.2 nmol), whereas des-Arg9-BK (0.1 and 1 nmol) was without effect.  B1 receptor mRNA was markedly increased in retinas of diabetic rats, and this was prevented by N-acetyl-L-cysteine (1 g kg-1 day-1 for 7 days).  Plasma extravasation in retinas of STZ-diabetic rats was higher than in controls and enhanced by des-Arg9-BK.  Response to des-Arg9-BK was inhibited by intraocular or i.v. injection of B1 receptor antagonists.  Diabetes-induced plasma extravasation was inhibited only by a combination of des-Arg10-Hoe140 and Hoe 140 (100 nmol kg-1, i.v. 15 min earlier) or by R-715 (1 μmol kg-1, i.v.) injected daily for 7 days.  Kinin B1 receptors are upregulated in retinas of STZ-diabetic rats through a mechanism involving oxidative stress.  Both kinin B1 and B2 receptors contribute to increased plasma extravasation in diabetic retinopathy.  Chronic inhibition of both kinin receptors, possibly with antioxidant adjuvants, may be a novel therapeutic strategy for diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplkRsasjse6rVg90H21EOLACvtfcHk0ljDgbm5aodCIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFOrurw%253D&md5=e9263e68c006050a8387dab7237f1480</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.48%26sid%3Dliteratum%253Aachs%26aulast%3DAbdouh%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DS.%26aulast%3DCouture%26aufirst%3DR.%26aulast%3DHass%25C3%25A9ssian%26aufirst%3DH.%2BM.%26atitle%3DRetinal%2520plasma%2520extravasation%2520in%2520streptozotocin-diabetic%2520rats%2520mediated%2520by%2520kinin%2520B%25281%2529%2520and%2520B%25282%2529%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D136%26epage%3D143%26doi%3D10.1038%2Fbjp.2008.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonda, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrigg, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nm1534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnm1534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17259996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=181-188&author=B.+B.+Gaoauthor=A.+Clermontauthor=S.+Rookauthor=S.+J.+Fondaauthor=V.+J.+Srinivasanauthor=M.+Wojtkowskiauthor=J.+G.+Fujimotoauthor=R.+L.+Averyauthor=P.+G.+Arriggauthor=S.+E.+Bursellauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Extracellular+carbonic+anhydrase+mediates+hemorrhagic+retinal+and+cerebral+vascular+permeability+through+prekallikrein+activation&doi=10.1038%2Fnm1534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation</span></div><div class="casAuthors">Gao, Ben-Bo; Clermont, Allen; Rook, Susan; Fonda, Stephanie J.; Srinivasan, Vivek J.; Wojtkowski, Maciej; Fujimoto, James G.; Avery, Robert L.; Arrigg, Paul G.; Bursell, Sven-Erik; Aiello, Lloyd Paul; Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-188</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Excessive retinal vascular permeability contributes to the pathogenesis of proliferative diabetic retinopathy and diabetic macular edema, leading causes of vision loss in working-age adults.  Using mass spectroscopy-based proteomics, we detected 117 proteins in human vitreous and elevated levels of extracellular carbonic anhydrase-I (CA-I) in vitreous from individuals with diabetic retinopathy, suggesting that retinal hemorrhage and erythrocyte lysis contribute to the diabetic vitreous proteome.  Intravitreous injection of CA-I in rats increased retinal vessel leakage and caused intraretinal edema.  CA-I-induced alkalinization of vitreous increased kallikrein activity and its generation of factor XIIa, revealing a new pathway for contact system activation.  CA-I-induced retinal edema was decreased by complement 1 inhibitor, neutralizing antibody to prekallikrein and bradykinin receptor antagonism.  Subdural infusion of CA-I in rats induced cerebral vascular permeability, suggesting that extracellular CA-I could have broad relevance to neurovascular edema.  Inhibition of extracellular CA-I and kallikrein-mediated innate inflammation could provide new therapeutic opportunities for the treatment of hemorrhage-induced retinal and cerebral edema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ-m__J9Zk9bVg90H21EOLACvtfcHk0lhpF1v-q09q0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyktbg%253D&md5=5b1f84e067258905cc21247986308abb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnm1534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1534%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DB.%2BB.%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DRook%26aufirst%3DS.%26aulast%3DFonda%26aufirst%3DS.%2BJ.%26aulast%3DSrinivasan%26aufirst%3DV.%2BJ.%26aulast%3DWojtkowski%26aufirst%3DM.%26aulast%3DFujimoto%26aufirst%3DJ.%2BG.%26aulast%3DAvery%26aufirst%3DR.%2BL.%26aulast%3DArrigg%26aufirst%3DP.%2BG.%26aulast%3DBursell%26aufirst%3DS.%2BE.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DExtracellular%2520carbonic%2520anhydrase%2520mediates%2520hemorrhagic%2520retinal%2520and%2520cerebral%2520vascular%2520permeability%2520through%2520prekallikrein%2520activation%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D181%26epage%3D188%26doi%3D10.1038%2Fnm1534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timothy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2516</span>– <span class="NLM_lpage">2525</span>, <span class="refDoi"> DOI: 10.1021/pr800112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr800112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVeitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2516-2525&author=B.+B.+Gaoauthor=X.+Chenauthor=N.+Timothyauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Characterization+of+the+vitreous+proteome+in+diabetes+without+diabetic+retinopathy+and+diabetes+with+proliferative+diabetic+retinopathy&doi=10.1021%2Fpr800112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Vitreous Proteome in Diabetes without Diabetic Retinopathy and Diabetes with Proliferative Diabetic Retinopathy</span></div><div class="casAuthors">Gao, Ben-Bo; Chen, Xiaohong; Timothy, Nigel; Aiello, Lloyd Paul; Feener, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2516-2525</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An understanding of the diabetes-induced alterations in vitreous protein compn. in the absence and in the presence of proliferative diabetic retinopathy (PDR) may provide insights into factors and mechanisms responsible for this disease.  We have performed a comprehensive proteomic anal. and comparison of vitreous samples from individuals with diabetes but without diabetic retinopathy (noDR) or with PDR and nondiabetic individuals (NDM).  Using preparative one-dimensional SDS-PAGE and nano-LC/MS/MS of 17 independent vitreous samples, we identified 252 proteins from human vitreous.  Fifty-six proteins were differentially abundant in noDR and PDR vitreous compared with NDM vitreous, including 32 proteins increased and 10 proteins decreased in PDR vitreous compared with NDM vitreous.  Comparison of noDR and PDR groups revealed increased levels of angiotensinogen and decreased levels of calsyntenin-1, interphotoreceptor retinoid-binding protein, and neuroserpin in PDR vitreous.  Biol. pathway anal. revealed that vitreous contains 30 proteins assocd. with the kallikrein-kinin, coagulation, and complement systems.  Five of them (complement C3, complement factor I, prothrombin, alpha-1-antitrypsin, and antithrombin III) were increased in PDR vitreous compared with NDM vitreous.  Factor XII was detected in PDR vitreous but not obsd. in either NDM or noDR vitreous.  PDR vitreous also had increased levels of peroxiredoxin-1 and decreased levels of extracellular superoxide dismutase, compared with noDR or NDM vitreous.  These data provide an in depth anal. of the human vitreous proteome and reveal protein alterations that are assocd. with PDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvUR5b89k5tLVg90H21EOLACvtfcHk0lhpF1v-q09q0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVeitrk%253D&md5=6b14662bae828e12147a648bb71ca341</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fpr800112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr800112g%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DB.%2BB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DTimothy%26aufirst%3DN.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520vitreous%2520proteome%2520in%2520diabetes%2520without%2520diabetic%2520retinopathy%2520and%2520diabetes%2520with%2520proliferative%2520diabetic%2520retinopathy%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2008%26volume%3D7%26spage%3D2516%26epage%3D2525%26doi%3D10.1021%2Fpr800112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3588</span>– <span class="NLM_lpage">3599</span>, <span class="refDoi"> DOI: 10.2337/db15-0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdb15-0317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=3588-3599&author=T.+Kitaauthor=A.+C.+Clermontauthor=N.+Murugesanauthor=Q.+Zhouauthor=K.+Fujisawaauthor=T.+Ishibashiauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Plasma+kallikrein-kinin+system+as+a+VEGF-independent+mediator+of+diabetic+macular+edema&doi=10.2337%2Fdb15-0317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0317%26sid%3Dliteratum%253Aachs%26aulast%3DKita%26aufirst%3DT.%26aulast%3DClermont%26aufirst%3DA.%2BC.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DFujisawa%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DT.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein-kinin%2520system%2520as%2520a%2520VEGF-independent%2520mediator%2520of%2520diabetic%2520macular%2520edema%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26spage%3D3588%26epage%3D3599%26doi%3D10.2337%2Fdb15-0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilcote, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.2337/db10-1260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdb10-1260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1590-1598&author=A.+Clermontauthor=T.+J.+Chilcoteauthor=T.+Kitaauthor=J.+Liuauthor=P.+Rivaauthor=S.+Sinhaauthor=E.+P.+Feener&title=Plasma+kallikrein+mediates+retinal+vascular+dysfunction+and+induces+retinal+thickening+in+diabetic+rats&doi=10.2337%2Fdb10-1260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2337%2Fdb10-1260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb10-1260%26sid%3Dliteratum%253Aachs%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DChilcote%26aufirst%3DT.%2BJ.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRiva%26aufirst%3DP.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520mediates%2520retinal%2520vascular%2520dysfunction%2520and%2520induces%2520retinal%2520thickening%2520in%2520diabetic%2520rats%26jtitle%3DDiabetes%26date%3D2011%26volume%3D60%26spage%3D1590%26epage%3D1598%26doi%3D10.2337%2Fdb10-1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neugebauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirois, P.</span></span> <span> </span><span class="NLM_article-title">Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2004.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.regpep.2004.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15544863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2crntlejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2005&pages=221-224&author=S.+R.+Lawsonauthor=B.+H.+Gabraauthor=B.+Gu%C3%A9rinauthor=W.+Neugebauerauthor=F.+Nantelauthor=B.+Battistiniauthor=P.+Sirois&title=Enhanced+dermal+and+retinal+vascular+permeability+in+streptozotocin-induced+type+1+diabetes+in+Wistar+rats%3A+blockade+with+a+selective+bradykinin+B1+receptor+antagonist&doi=10.1016%2Fj.regpep.2004.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist</span></div><div class="casAuthors">Lawson Sibi R; Gabra Bichoy H; Guerin Brigitte; Neugebauer Witold; Nantel Francois; Battistini Bruno; Sirois Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory peptides</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">221-4</span>
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    </div><div class="casAbstract">The vascular complications associated with type 1 diabetes are to some extent related to the dysfunction of the endothelium leading to an increased vascular permeability and plasma extravasation in the surrounding tissues.  The various micro- and macro-vascular complications of diabetes develop over time, leading to nephropathy, retinopathy and neuropathy and cardiomyopathy.  In the present study, the effect of a novel selective bradykinin B1 receptor (BKB1-R) antagonist, R-954, was investigated on the changes of vascular permeability in the skin and retina of streptozotocin (STZ)-induced type 1 diabetic rats.  Plasma extravasation increased in the skin and retina of STZ-diabetic rats after 1 week and persisted over 4 weeks following STZ injection.  Acute treatment with R-954 (2 mg/kg, bolus s.c.) highly reduced the elevated vascular permeability in both 1- and 4-week STZ-diabetic rats.  These results showed that the inducible BKB1-R subtype modulates the vascular permeability of the skin and retina of type 1 diabetic rats and suggests that BKB1-R antagonists could have a beneficial role in diabetic neuropathy and retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTF_TVSB24GPresJRIHUP1ofW6udTcc2eadqC00u0fBxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crntlejsg%253D%253D&md5=65d4eeef1c4c0c73f70542f670ac27d3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2004.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2004.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DS.%2BR.%26aulast%3DGabra%26aufirst%3DB.%2BH.%26aulast%3DGu%25C3%25A9rin%26aufirst%3DB.%26aulast%3DNeugebauer%26aufirst%3DW.%26aulast%3DNantel%26aufirst%3DF.%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DSirois%26aufirst%3DP.%26atitle%3DEnhanced%2520dermal%2520and%2520retinal%2520vascular%2520permeability%2520in%2520streptozotocin-induced%2520type%25201%2520diabetes%2520in%2520Wistar%2520rats%253A%2520blockade%2520with%2520a%2520selective%2520bradykinin%2520B1%2520receptor%2520antagonist%26jtitle%3DRegul.%2520Pept.%26date%3D2005%26volume%3D124%26spage%3D221%26epage%3D224%26doi%3D10.1016%2Fj.regpep.2004.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sénécal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotigny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span> <span> </span><span class="NLM_article-title">Ocular application of the kinin B1 receptor antagonist LF22–0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e33864</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0033864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1371%2Fjournal.pone.0033864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e33864&author=M.+Pouliotauthor=S.+Talbotauthor=J.+S%C3%A9n%C3%A9calauthor=F.+Dotignyauthor=E.+Vaucherauthor=R.+Couture&title=Ocular+application+of+the+kinin+B1+receptor+antagonist+LF22%E2%80%930542+inhibits+retinal+inflammation+and+oxidative+stress+in+streptozotocin-diabetic+rats&doi=10.1371%2Fjournal.pone.0033864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0033864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0033864%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DS.%26aulast%3DS%25C3%25A9n%25C3%25A9cal%26aufirst%3DJ.%26aulast%3DDotigny%26aufirst%3DF.%26aulast%3DVaucher%26aufirst%3DE.%26aulast%3DCouture%26aufirst%3DR.%26atitle%3DOcular%2520application%2520of%2520the%2520kinin%2520B1%2520receptor%2520antagonist%2520LF22%25E2%2580%25930542%2520inhibits%2520retinal%2520inflammation%2520and%2520oxidative%2520stress%2520in%2520streptozotocin-diabetic%2520rats%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De33864%26doi%3D10.1371%2Fjournal.pone.0033864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0ljWRZcB9X6CcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarroz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzavarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelillo-Scherrer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01548</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01548" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1151-1158&author=S.+J.+Middendorpauthor=J.+Wilbsauthor=C.+Quarrozauthor=S.+Calzavariniauthor=A.+Angelillo-Scherrerauthor=C.+Heinis&title=Peptide+macrocycle+inhibitor+of+coagulation+factor+XII+with+subnanomolar+affinity+and+high+target+selectivity&doi=10.1021%2Facs.jmedchem.6b01548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity</span></div><div class="casAuthors">Middendorp, Simon J.; Wilbs, Jonas; Quarroz, Claudia; Calzavarini, Sara; Angelillo-Scherrer, Anne; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1151-1158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathol. thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angioedema.  While several protein based inhibitors with high affinity for activated FXII (FXIIa) were developed, the generation of small mol. inhibitors has been challenging.  The authors have generated a potent and selective FXIIa inhibitor by optimizing a peptide macrocycle that was recently evolved by phage display (Ki = 0.84±0.03 nM).  A fluorine atom introduced in the para-position of phenylalanine enhanced the binding affinity as much as 10-fold.  Furthermore, the authors improved the proteolytic stability by substituting the N-terminal arginine by norarginine.  The resulting inhibitor combines high inhibitory affinity and selectivity with a good stability in plasma (Ki = 1.63±0.18 nM, >27,000-fold selectivity, t1/2 plasma = 16±4 h).  The inhibitor efficiently blocked activation of the intrinsic coagulation pathway in human blood ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtHmZYsV_bi7Vg90H21EOLACvtfcHk0ljWRZcB9X6CcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yqtw%253D%253D&md5=66f9fe274cdd51f9148f7e13f27617e4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01548%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%2BJ.%26aulast%3DWilbs%26aufirst%3DJ.%26aulast%3DQuarroz%26aufirst%3DC.%26aulast%3DCalzavarini%26aufirst%3DS.%26aulast%3DAngelillo-Scherrer%26aufirst%3DA.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520macrocycle%2520inhibitor%2520of%2520coagulation%2520factor%2520XII%2520with%2520subnanomolar%2520affinity%2520and%2520high%2520target%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1151%26epage%3D1158%26doi%3D10.1021%2Facs.jmedchem.6b01548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide ligands stabilized by small molecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1602</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+ligands+stabilized+by+small+molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0ljVbJBWrHYzPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520ligands%2520stabilized%2520by%2520small%2520molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeriswyl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fcmdc.201200071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22492508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1173-1176&author=V.+Baeriswylauthor=H.+Rapleyauthor=L.+Pollaroauthor=C.+Staceauthor=D.+Teufelauthor=E.+Walkerauthor=S.+Chenauthor=G.+Winterauthor=J.+Titeauthor=C.+Heinis&title=Bicyclic+peptides+with+optimized+ring+size+inhibit+human+plasma+kallikrein+and+its+orthologues+while+sparing+paralogous+proteases&doi=10.1002%2Fcmdc.201200071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases</span></div><div class="casAuthors">Baeriswyl, Vanessa; Rapley, Helen; Pollaro, Lisa; Stace, Catherine; Teufel, Dan; Walker, Edward; Chen, Shiyu; Winter, Greg; Tite, John; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1173-1176, S1173/1-S1173/5</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this work, we aimed at generating bicyclic peptides inhibiting both human and murine plasma kallikrein (PK) but not any paralogous proteases.  We speculated that inhibitors with the desired specificity profile could be obtained by generating binders to a surface region that is identical in PK orthologues but different in paralogues.  By comparing structural models of target and related nontarget proteases to identify conserved regions in the vicinity of the active site and by modulating the loop size of our libraries of peptide macrocycles accordingly, we succeeded in identifying potent inhibitors of human, rat and monkey plasma kallikrein that do not also inhibit related human serum proteases.  Our strategy should facilitate the evaluation of this type of peptide macrocycles in animal models, and furthermore, avoid unwanted off-target activities that would be detrimental to their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTYMUG-b7ubVg90H21EOLACvtfcHk0ljVbJBWrHYzPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D&md5=5a3177403617ce635c46b0a759a110ab</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200071%26sid%3Dliteratum%253Aachs%26aulast%3DBaeriswyl%26aufirst%3DV.%26aulast%3DRapley%26aufirst%3DH.%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DStace%26aufirst%3DC.%26aulast%3DTeufel%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DTite%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DBicyclic%2520peptides%2520with%2520optimized%2520ring%2520size%2520inhibit%2520human%2520plasma%2520kallikrein%2520and%2520its%2520orthologues%2520while%2520sparing%2520paralogous%2520proteases%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1173%26epage%3D1176%26doi%3D10.1002%2Fcmdc.201200071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuweiler, H.</span></span> <span> </span><span class="NLM_article-title">Backbone-driven collapse in unfolded protein chains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2011.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.jmb.2011.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21497607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=250-262&author=D.+P.+Teufelauthor=C.+M.+Johnsonauthor=J.+K.+Lumauthor=H.+Neuweiler&title=Backbone-driven+collapse+in+unfolded+protein+chains&doi=10.1016%2Fj.jmb.2011.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Backbone-Driven Collapse in Unfolded Protein Chains</span></div><div class="casAuthors">Teufel, Daniel P.; Johnson, Christopher M.; Lum, Jenifer K.; Neuweiler, Hannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Collapse of unfolded protein chains is an early event in folding.  It affects structural properties of intrinsically disordered proteins (IDPs), which take up a considerable fraction of the human proteome.  Collapse is generally believed to be driven by hydrophobic forces imposed by the presence of nonpolar amino acid side chains.  Contributions from backbone hydrogen bonds to protein folding and stability, however, are controversial.  To date, the exptl. dissection of side-chain and backbone contributions has not yet been achieved because both types of interactions are integral parts of protein structure.  Here, we realized this goal by applying mutagenesis and chem. modification on a set of disordered peptides and proteins.  We measured the protein dimensions and kinetics of intra-chain diffusion of modified polypeptides at the level of individual mols. using fluorescence correlation spectroscopy (FCS), thereby avoiding artifacts commonly caused by aggregation of unfolded protein material in bulk.  We found no contributions from side chains to collapse, but instead, identified backbone interactions as a source sufficient to form globules of native-like dimensions.  The presence of backbone hydrogen bonds decreased polypeptide water soly. dramatically and accelerated the nanosecond kinetics of loop closure, in agreement with recent predictions from computer simulation.  The presence of side chains, instead, slowed loop closure and modulated the dimensions of intrinsically disordered domains.  It appeared that the transient formation of backbone interactions facilitates the diffusive search for productive conformations at the early stage of folding and within intrinsically disordered proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCa-Q7pukl7bVg90H21EOLACvtfcHk0ljVbJBWrHYzPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D&md5=c8bcdbf4dbc91f7afe960d2aa7cf6024</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2011.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2011.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DLum%26aufirst%3DJ.%2BK.%26aulast%3DNeuweiler%26aufirst%3DH.%26atitle%3DBackbone-driven%2520collapse%2520in%2520unfolded%2520protein%2520chains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D409%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.jmb.2011.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tugyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iván, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecz, F.</span></span> <span> </span><span class="NLM_article-title">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.0407677102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1073%2Fpnas.0407677102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15630090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=413-418&author=R.+Tugyiauthor=K.+Urayauthor=D.+Iv%C3%A1nauthor=E.+Fellingerauthor=A.+Perkinsauthor=F.+Hudecz&title=Partial+D-amino+acid+substitution%3A+Improved+enzymatic+stability+and+preserved+Ab+recognition+of+a+MUC2+epitope+peptide&doi=10.1073%2Fpnas.0407677102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span></div><div class="casAuthors">Tugyi, Regina; Uray, Katalin; Ivan, Dora; Fellinger, Erzsebet; Perkins, Alan; Hudecz, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The stability of an immunogen against enzymic degrdn. is considered an important factor for the design of synthetic vaccines.  For our studies, we have selected an epitope from the tandem-repeat unit of the high-mol.-wt. MUC2 mucin glycoprotein, which can be underglycosylated in case of colon cancer.  In this study, we prepd. a MUC2 peptide contg. the PTGTQ epitope of a MUC2 protein backbone-specific mAb 996 and its derivs.  In these peptides, the N- and C-terminal flanking regions were systematically substituted by up to three D-amino acids.  Peptides prepd. by solid-phase synthesis were tested for their mAb 996 binding in competitive ELISA expts., and their stability was studied in serum and lysosomal prepn.  Our data show that the epitope function of peptide 15TPTPTGTQTPT25 is retained even in the presence of two D-amino acid residues at its N-terminal flanking region and up to three at its C-terminal flanking region (tpTPTGTQtpt).  Also, this partly D peptide shows high resistance against proteolytic degrdn. in dild. human serum and in lysosomal prepn.  These findings suggest that, by appropriate combination of structural modifications (namely, D-amino acid substitution) in the flanks of an Ab epitope, it is feasible to construct a synthetic antigen with preserved recognition properties and high stability against enzymic degrdn.  Peptides tPTPTGTQTpt and tpTPTGTQTpt derived from this study can be used for immunization expts. and as potential components of synthetic vaccines for tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MtlZFnf6a7Vg90H21EOLACvtfcHk0lhYVaTSIEslEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D&md5=aa80020d0dcf9d18d18775fcf77b050a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0407677102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0407677102%26sid%3Dliteratum%253Aachs%26aulast%3DTugyi%26aufirst%3DR.%26aulast%3DUray%26aufirst%3DK.%26aulast%3DIv%25C3%25A1n%26aufirst%3DD.%26aulast%3DFellinger%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DHudecz%26aufirst%3DF.%26atitle%3DPartial%2520D-amino%2520acid%2520substitution%253A%2520Improved%2520enzymatic%2520stability%2520and%2520preserved%2520Ab%2520recognition%2520of%2520a%2520MUC2%2520epitope%2520peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.0407677102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, N. R.</span></span> <span> </span><span class="NLM_article-title">Perioperative systemic haemostatic agents</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1093/bja/aeh227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1093%2Fbja%2Faeh227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=15277296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSrurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=842-858&author=A.+M.+Mahdyauthor=N.+R.+Webster&title=Perioperative+systemic+haemostatic+agents&doi=10.1093%2Fbja%2Faeh227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Perioperative systemic haemostatic agents</span></div><div class="casAuthors">Mahdy, A. M.; Webster, N. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">842-858</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Skilful surgery combined with blood-saving methods and careful management of blood coagulation will all help reduce unnecessary blood loss and transfusion requirements.  Excessive surgical bleeding causes hypovolemia, hemodynamic instability, anemia and reduced oxygen delivery to tissues, with a subsequent increase in postoperative morbidity and mortality.  The role of anesthetists in managing surgical blood loss has increased greatly in the last decade.  Position of the patient during surgery and the provision of a hypotensive anesthetic regimen were once considered the most important contributions of the anesthetist to decreasing blood loss.  Now, several pharmacol. hemostatic agents are being used by anesthetists as blood-saving agents.  After a brief discussion of the physiol. of hemostasis, this article will review the evidence for the role of such agents in reducing perioperative blood loss and transfusion requirements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZUXHdKQ09sbVg90H21EOLACvtfcHk0lhYVaTSIEslEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSrurvE&md5=5c31ac116c4b392bcc42f902ace5922a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fbja%2Faeh227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252Faeh227%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BM.%26aulast%3DWebster%26aufirst%3DN.%2BR.%26atitle%3DPerioperative%2520systemic%2520haemostatic%2520agents%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2004%26volume%3D93%26spage%3D842%26epage%3D858%26doi%3D10.1093%2Fbja%2Faeh227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, R. A.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">25411</span>– <span class="NLM_lpage">25417</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.43.25411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.270.43.25411" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=25411-25417&author=M.+S.+Dennisauthor=A.+Herzkaauthor=R.+A.+Lazarus&title=Potent+and+selective+Kunitz+domain+inhibitors+of+plasma+kallikrein+designed+by+phage+display&doi=10.1074%2Fjbc.270.43.25411"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.43.25411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.43.25411%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DHerzka%26aufirst%3DA.%26aulast%3DLazarus%26aufirst%3DR.%2BA.%26atitle%3DPotent%2520and%2520selective%2520Kunitz%2520domain%2520inhibitors%2520of%2520plasma%2520kallikrein%2520designed%2520by%2520phage%2520display%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D25411%26epage%3D25417%26doi%3D10.1074%2Fjbc.270.43.25411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Contact pathway of coagulation and inflammation</span>. <i>Thromb. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1186/s12959-015-0048-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1186%2Fs12959-015-0048-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25949215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MfhsF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=17&author=Y.+Wu&title=Contact+pathway+of+coagulation+and+inflammation&doi=10.1186%2Fs12959-015-0048-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Contact pathway of coagulation and inflammation</span></div><div class="casAuthors">Wu Yi</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17</span>
        ISSN:<span class="NLM_cas:issn">1477-9560</span>.
    </div><div class="casAbstract">The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor high molecular weight kininogen (HK).  This system has been investigated actively for more than 50 years.  The components of this system and their interactions have been elucidated from in vitro experiments, which indicates that this system is prothrombotic by activating intrinsic pathway, and proinflammatory by producing bioactive peptide bradykinin.  Although the activation of the contact system have been implicated in various types of human disease, in only a few instances is its role clearly defined.  In the last 10 years, our understanding of the contact system, particularly its biology and (patho)physiology has greatly increased through investigations using gene-modified animal models.  In this review we will describe a revitalized view of the contact system as a critical (patho)physiologic mediator of coagulation and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu8gBlm77WhAWRJ3OJdH_qfW6udTcc2eayblXB_JJNTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfhsF2jtw%253D%253D&md5=a44dd0a6efab3b58507e4252d509cbb4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs12959-015-0048-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12959-015-0048-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26atitle%3DContact%2520pathway%2520of%2520coagulation%2520and%2520inflammation%26jtitle%3DThromb.%2520J.%26date%3D2015%26volume%3D13%26spage%3D17%26doi%3D10.1186%2Fs12959-015-0048-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raber, M. N.</span></span> <span> </span><span class="NLM_article-title">Coagulation Tests</span>. In  <i>Clinical Methods: The History, Physical, and Laboratory Examinations</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, H. K.</span>, <span class="NLM_string-name">Hall, W. D.</span>, <span class="NLM_string-name">Hurst, J. W.</span></span>, Eds.; <span class="NLM_publisher-name">Butterworths</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+N.+Raberauthor=H.+K.+Walker&author=W.+D.+Hall&author=J.+W.+Hurst&title=Clinical+Methods%3A+The+History%2C+Physical%2C+and+Laboratory+Examinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRaber%26aufirst%3DM.%2BN.%26atitle%3DCoagulation%2520Tests%26btitle%3DClinical%2520Methods%253A%2520The%2520History%252C%2520Physical%252C%2520and%2520Laboratory%2520Examinations%26aulast%3DWalker%26aufirst%3DH.%2BK.%26pub%3DButterworths%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruttmann, T.</span></span> <span> </span><span class="NLM_article-title">Coagulation for the clinician</span>. <i>S. Afr. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">26</span>, 28–30, 32–37</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=24-26&issue=22&author=T.+Ruttmann&title=Coagulation+for+the+clinician"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuttmann%26aufirst%3DT.%26atitle%3DCoagulation%2520for%2520the%2520clinician%26jtitle%3DS.%2520Afr.%2520J.%2520Surg.%26date%3D2006%26volume%3D44%26issue%3D22%26spage%3D24%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, J.</span></span> <span> </span><span class="NLM_article-title">The vitreous</span>. In  <i>Adler’s Physiology of the Eye</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, W.</span></span>, Eds.; <span class="NLM_publisher-name">Mosby</span>: <span class="NLM_publisher-loc">St. Louis</span>, <span class="NLM_year">1992</span>; pp  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">347</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&pages=268-347&author=J.+Sebagauthor=W.+Hart&title=Adler%E2%80%99s+Physiology+of+the+Eye"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSebag%26aufirst%3DJ.%26atitle%3DThe%2520vitreous%26btitle%3DAdler%25E2%2580%2599s%2520Physiology%2520of%2520the%2520Eye%26aulast%3DHart%26aufirst%3DW.%26pub%3DMosby%26date%3D1992%26spage%3D268%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jobin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonjour, J. P.</span></span> <span> </span><span class="NLM_article-title">Measurement of glomerular filtration rate in conscious unrestrained rats with inulin infused by implanted osmotic pumps</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">F734</span>– <span class="NLM_lpage">F738</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.1985.248.5.F734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1152%2Fajprenal.1985.248.5.F734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1985&pages=F734-F738&author=J.+Jobinauthor=J.+P.+Bonjour&title=Measurement+of+glomerular+filtration+rate+in+conscious+unrestrained+rats+with+inulin+infused+by+implanted+osmotic+pumps&doi=10.1152%2Fajprenal.1985.248.5.F734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.1985.248.5.F734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.1985.248.5.F734%26sid%3Dliteratum%253Aachs%26aulast%3DJobin%26aufirst%3DJ.%26aulast%3DBonjour%26aufirst%3DJ.%2BP.%26atitle%3DMeasurement%2520of%2520glomerular%2520filtration%2520rate%2520in%2520conscious%2520unrestrained%2520rats%2520with%2520inulin%2520infused%2520by%2520implanted%2520osmotic%2520pumps%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1985%26volume%3D248%26spage%3DF734%26epage%3DF738%26doi%3D10.1152%2Fajprenal.1985.248.5.F734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del
Amo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtti, A.</span></span> <span> </span><span class="NLM_article-title">Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of published data</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2015.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.exer.2015.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25975234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=111-124&author=E.+M.+del%0AAmoauthor=A.+Urtti&title=Rabbit+as+an+animal+model+for+intravitreal+pharmacokinetics%3A+clinical+predictability+and+quality+of+published+data&doi=10.1016%2Fj.exer.2015.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data</span></div><div class="casAuthors">del Amo, Eva M.; Urtti, Arto</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-124</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Intravitreal administration is the method of choice in drug delivery to the retina and/or choroid.  Rabbit is the most commonly used animal species in intravitreal pharmacokinetics, but it has been criticized as being a poor model of human eye.  The critique is based on some anatomical differences, properties of the vitreous humor, and obsd. differences in drug concns. in the anterior chamber after intravitreal injections.  We have systematically analyzed all published information on intravitreal pharmacokinetics in the rabbit and human eye.  The anal. revealed major problems in the design of the pharmacokinetic studies.  In this review we provide advice for study design.  Overall, the pharmacokinetic parameters (clearance, vol. of distribution, half-life) in the human and rabbit eye have good correlation and comparable abs. values.  Therefore, reliable rabbit-to-man translation of intravitreal pharmacokinetics should be feasible.  The relevant anatomical and physiol. parameters in rabbit and man show only small differences.  Furthermore, the claimed discrepancy between drug concns. in the human and rabbit aq. humor is not supported by the data anal.  Based on the available and properly conducted pharmacokinetic studies, the differences in the vitreous structure in rabbits and human patients do not lead to significant pharmacokinetic differences.  This review is the first step towards inter-species translation of intravitreal pharmacokinetics.  More information is still needed to dissect the roles of drug delivery systems, disease states, age and ocular manipulation on the intravitreal pharmacokinetics in rabbit and man.  Anyway, the published data and the derived pharmacokinetic parameters indicate that the rabbit is a useful animal model in intravitreal pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwLXcII4mXhLVg90H21EOLACvtfcHk0lippQtnoSA6KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGnu7Y%253D&md5=c6a3e013b0e4e03f260120bfb8df055f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2015.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2015.05.003%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BAmo%26aufirst%3DE.%2BM.%26aulast%3DUrtti%26aufirst%3DA.%26atitle%3DRabbit%2520as%2520an%2520animal%2520model%2520for%2520intravitreal%2520pharmacokinetics%253A%2520clinical%2520predictability%2520and%2520quality%2520of%2520published%2520data%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2015%26volume%3D137%26spage%3D111%26epage%3D124%26doi%3D10.1016%2Fj.exer.2015.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenniston, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopacz, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrapeli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenHoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of plasma kallikrein by a highly specific active site blocking antibody</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">23596</span>– <span class="NLM_lpage">235608</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.569061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1074%2Fjbc.M114.569061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24970892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSms7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=23596-235608&author=J.+A.+Kennistonauthor=R.+R.+Faucetteauthor=D.+Martikauthor=S.+R.+Comeauauthor=A.+P.+Lindbergauthor=K.+J.+Kopaczauthor=G.+P.+Conleyauthor=J.+Chenauthor=M.+Viswanathanauthor=N.+Kastrapeliauthor=J.+Cosicauthor=S.+Masonauthor=M.+DiLeoauthor=J.+Abendrothauthor=P.+Kuzmicauthor=R.+C.+Ladnerauthor=T.+E.+Edwardsauthor=C.+TenHoorauthor=B.+A.+Adelmanauthor=A.+E.+Nixonauthor=D.+J.+Sexton&title=Inhibition+of+plasma+kallikrein+by+a+highly+specific+active+site+blocking+antibody&doi=10.1074%2Fjbc.M114.569061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody</span></div><div class="casAuthors">Kenniston, Jon A.; Faucette, Ryan R.; Martik, Diana; Comeau, Stephen R.; Lindberg, Allison P.; Kopacz, Kris J.; Conley, Gregory P.; Chen, Jie; Viswanathan, Malini; Kastrapeli, Niksa; Cosic, Janja; Mason, Shauna; Di Leo, Mike; Abendroth, Jan; Kuzmic, Petr; Ladner, Robert C.; Edwards, Thomas E.; Ten Hoor, Christopher; Adelman, Burt A.; Nixon, Andrew E.; Sexton, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">23596-23608</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasma kallikrein (pKal) proteolytically cleaves high mol. wt. kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin.  PKal activity is tightly regulated in healthy individuals by the serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibitor and consequently exhibit excessive bradykinin generation that in turn causes debilitating and potentially fatal swelling attacks.  To develop a potential therapeutic agent for HAE and other pKal-mediated disorders, the authors used phage display to discover a fully human IgG1 monoclonal antibody (DX-2930) against pKal.  In vitro expts. demonstrated that DX-2930 potently inhibits active pKal (Ki = 0.120 nm) but does not target either the zymogen (prekallikrein) or any other serine protease tested.  These findings are supported by a 2.1-Å resoln. crystal structure of pKal complexed to a DX-2930 Fab construct, which establishes that the pKal active site is fully occluded by the antibody.  DX-2930 injected s.c. into cynomolgus monkeys exhibited a long half-life (t1/2 ∼12.5 days) and blocked high mol. wt. kininogen proteolysis in activated plasma in a dose- and time-dependent manner.  Furthermore, s.c. DX-2930 reduced carrageenan-induced paw edema in rats.  A potent and long acting inhibitor of pKal activity could be an effective treatment option for pKal-mediated diseases, such as HAE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-4XVHdXBJ7Vg90H21EOLACvtfcHk0lippQtnoSA6KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSms7%252FL&md5=4bdd050b8cd5aa7e50daa04e8e260437</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.569061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.569061%26sid%3Dliteratum%253Aachs%26aulast%3DKenniston%26aufirst%3DJ.%2BA.%26aulast%3DFaucette%26aufirst%3DR.%2BR.%26aulast%3DMartik%26aufirst%3DD.%26aulast%3DComeau%26aufirst%3DS.%2BR.%26aulast%3DLindberg%26aufirst%3DA.%2BP.%26aulast%3DKopacz%26aufirst%3DK.%2BJ.%26aulast%3DConley%26aufirst%3DG.%2BP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DM.%26aulast%3DKastrapeli%26aufirst%3DN.%26aulast%3DCosic%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DDiLeo%26aufirst%3DM.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DLadner%26aufirst%3DR.%2BC.%26aulast%3DEdwards%26aufirst%3DT.%2BE.%26aulast%3DTenHoor%26aufirst%3DC.%26aulast%3DAdelman%26aufirst%3DB.%2BA.%26aulast%3DNixon%26aufirst%3DA.%2BE.%26aulast%3DSexton%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520plasma%2520kallikrein%2520by%2520a%2520highly%2520specific%2520active%2520site%2520blocking%2520antibody%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D23596%26epage%3D235608%26doi%3D10.1074%2Fjbc.M114.569061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C. J.</span></span> <span> </span><span class="NLM_article-title">Carrageenan-induced paw edema in the rat and mouse</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1385/1-59259-374-7:115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1385%2F1-59259-374-7%3A115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=12769480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3s3ks1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2003&pages=115-121&author=C.+J.+Morris&title=Carrageenan-induced+paw+edema+in+the+rat+and+mouse&doi=10.1385%2F1-59259-374-7%3A115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Carrageenan-induced paw edema in the rat and mouse</span></div><div class="casAuthors">Morris Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-21</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIeD9uSGbBLEGy1nwu7K2mfW6udTcc2eYokDtBN1K-lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s3ks1ensw%253D%253D&md5=b012018ed50b034ed911c9e0d863a3b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1385%2F1-59259-374-7%3A115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-374-7%253A115%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%2BJ.%26atitle%3DCarrageenan-induced%2520paw%2520edema%2520in%2520the%2520rat%2520and%2520mouse%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2003%26volume%3D225%26spage%3D115%26epage%3D121%26doi%3D10.1385%2F1-59259-374-7%3A115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroud, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, D. A.</span></span> <span> </span><span class="NLM_article-title">Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/path.1711040103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fpath.1711040103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=4398139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADyaE38XktFyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1971&pages=15-29&author=M.+Di%0ARosaauthor=J.+P.+Giroudauthor=D.+A.+Willoughby&title=Studies+on+the+mediators+of+the+acute+inflammatory+response+induced+in+rats+in+different+sites+by+carrageenan+and+turpentine&doi=10.1002%2Fpath.1711040103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine</span></div><div class="casAuthors">Di Rosa, M.; Giroud, J. P.; Willoughby, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-29</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    </div><div class="casAbstract">Pharmacol. expts. on carrageenan-induced edema in rats indicated that there are 3 time phases in the inflammatory response which are sequentially mediated by histamine (I) [51-45-6] and 5-hydroxytryptamine (II) [50-67-9] release, kinins, and prostaglandins.  The actions of all the mediators were dependent upon the presence of complement.  The same sequential release of the mediators I and II, kinins, and prostaglandins occurred in other types of inflammatory response in rats:  carrageenan-induced pleurisy, turpentine-induced foot edema, and turpentine-induced pleurisy.  Complement seemed to be important in all these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDBiHhmh-9yLVg90H21EOLACvtfcHk0li2jxFFo7xXDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XktFyqug%253D%253D&md5=80b5e506e0d9ca5c86aae4426dd73a96</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fpath.1711040103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1711040103%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRosa%26aufirst%3DM.%26aulast%3DGiroud%26aufirst%3DJ.%2BP.%26aulast%3DWilloughby%26aufirst%3DD.%2BA.%26atitle%3DStudies%2520on%2520the%2520mediators%2520of%2520the%2520acute%2520inflammatory%2520response%2520induced%2520in%2520rats%2520in%2520different%2520sites%2520by%2520carrageenan%2520and%2520turpentine%26jtitle%3DJ.%2520Pathol.%26date%3D1971%26volume%3D104%26spage%3D15%26epage%3D29%26doi%3D10.1002%2Fpath.1711040103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C.</span></span> <span> </span><span class="NLM_article-title">Animal models of diabetic retinopathy: summary and comparison</span>. <i>J. Diabetes Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">106594</span>, <span class="refDoi"> DOI: 10.1155/2013/106594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1155%2F2013%2F106594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24286086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2c3it1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=106594&author=A.+K.+Laiauthor=A.+C.+Lo&title=Animal+models+of+diabetic+retinopathy%3A+summary+and+comparison&doi=10.1155%2F2013%2F106594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of diabetic retinopathy: summary and comparison</span></div><div class="casAuthors">Lai Angela Ka Wai; Lo Amy C Y</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106594</span>
        ISSN:<span class="NLM_cas:issn">2314-6745</span>.
    </div><div class="casAbstract">Diabetic retinopathy (DR) is a microvascular complication associated with chronic exposure to hyperglycemia and is a major cause of blindness worldwide.  Although clinical assessment and retinal autopsy of diabetic patients provide information on the features and progression of DR, its underlying pathophysiological mechanism cannot be deduced.  In order to have a better understanding of the development of DR at the molecular and cellular levels, a variety of animal models have been developed.  They include pharmacological induction of hyperglycemia and spontaneous diabetic rodents as well as models of angiogenesis without diabetes (to compensate for the absence of proliferative DR symptoms).  In this review, we summarize the existing protocols to induce diabetes using STZ.  We also describe and compare the pathological presentations, in both morphological and functional aspects, of the currently available DR animal models.  The advantages and disadvantages of using different animals, ranging from zebrafish, rodents to other higher-order mammals, are also discussed.  Until now, there is no single model that displays all the clinical features of DR as seen in human.  Yet, with the understanding of the pathological findings in these animal models, researchers can select the most suitable models for mechanistic studies or drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm7MKbRi3Cu4JKJbLTgsvCfW6udTcc2eYokDtBN1K-lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3it1CktQ%253D%253D&md5=6580a125aa1466471a7694fd3f0ce404</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1155%2F2013%2F106594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F106594%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BK.%26aulast%3DLo%26aufirst%3DA.%2BC.%26atitle%3DAnimal%2520models%2520of%2520diabetic%2520retinopathy%253A%2520summary%2520and%2520comparison%26jtitle%3DJ.%2520Diabetes%2520Res.%26date%3D2013%26volume%3D2013%26spage%3D106594%26doi%3D10.1155%2F2013%2F106594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mas-Moruno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechenmacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span> <span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21269250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate+design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span></div><div class="casAuthors">Mas-Moruno, Carlos; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilengitide, a cyclic RGD pentapeptide, is currently in clin. phase III for treatment of glioblastomas and in phase II for several other tumors.  This drug is the first anti-angiogenic small mol. targeting the integrins αvβ3, αvβ5 and α5β1.  It was developed by us in the early 90s by a novel procedure, the spatial screening.  This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear ref. peptides), which in addn. exhibited high selectivity against the platelet receptor αIIbβ3.  This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V).  This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany).  This article describes the chem. development of Cilengitide, the biochem. background of its activity and a short review about the present clin. trials.  The pos. anti-angiogenic effects in cancer treatment can be further increased by combination with "classical" anti-cancer therapies.  Several clin. trials in this direction are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlP-_WXS6GbVg90H21EOLACvtfcHk0li2jxFFo7xXDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D&md5=694b4a2876be15ec767dcc82278a316c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate%2520design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavenonis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kritzer, J. A.</span></span> <span> </span><span class="NLM_article-title">Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1021/cb300515u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300515u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWksbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=488-499&author=J.+E.+Bockauthor=J.+Gavenonisauthor=J.+A.+Kritzer&title=Getting+in+shape%3A+controlling+peptide+bioactivity+and+bioavailability+using+conformational+constraints&doi=10.1021%2Fcb300515u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Getting in Shape: Controlling Peptide Bioactivity and Bioavailability Using Conformational Constraints</span></div><div class="casAuthors">Bock, Jonathan E.; Gavenonis, Jason; Kritzer, Joshua A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-499</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chem. biologists commonly seek out correlations between the physicochem. properties of mols. and their behavior in biol. systems.  However, a new paradigm is emerging for peptides in which conformation is recognized as the primary determinant of bioactivity and bioavailability.  This review highlights an emerging body of work that directly addresses how a peptide's conformation controls its biol. effects, cell penetration, and intestinal absorption.  Based on this work, the dream of mimicking the potency and bioavailability of natural product peptides is getting closer to reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTflF3sA9dgrVg90H21EOLACvtfcHk0lhjSDo0RaL64g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWksbjM&md5=cb95fdecb85b9588ef3c95673e59431a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcb300515u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300515u%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DGavenonis%26aufirst%3DJ.%26aulast%3DKritzer%26aufirst%3DJ.%2BA.%26atitle%3DGetting%2520in%2520shape%253A%2520controlling%2520peptide%2520bioactivity%2520and%2520bioavailability%2520using%2520conformational%2520constraints%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D488%26epage%3D499%26doi%3D10.1021%2Fcb300515u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diness, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Constraining cyclic peptides to mimic protein structure motifs</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">13020</span>– <span class="NLM_lpage">13041</span>, <span class="refDoi"> DOI: 10.1002/anie.201401058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201401058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGit77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=13020-13041&author=T.+A.+Hillauthor=N.+E.+Shepherdauthor=F.+Dinessauthor=D.+P.+Fairlie&title=Constraining+cyclic+peptides+to+mimic+protein+structure+motifs&doi=10.1002%2Fanie.201401058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Constraining Cyclic Peptides To Mimic Protein Structure Motifs</span></div><div class="casAuthors">Hill, Timothy A.; Shepherd, Nicholas E.; Diness, Frederik; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">13020-13041</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Many proteins exert their biol. activities through small exposed surface regions called epitopes that are folded peptides of well-defined three-dimensional structures.  Short synthetic peptide sequences corresponding to these bioactive protein surfaces do not form thermodynamically stable protein-like structures in water.  However, short peptides can be induced to fold into protein-like bioactive conformations (strands, helixes, turns) by cyclization, in conjunction with the use of other mol. constraints, that helps to fine-tune three-dimensional structure.  Such constrained cyclic peptides can have protein-like biol. activities and potencies, enabling their uses as biol. probes and leads to therapeutics, diagnostics and vaccines.  This Review highlights examples of cyclic peptides that mimic three-dimensional structures of strand, turn or helical segments of peptides and proteins, and identifies some addnl. restraints incorporated into natural product cyclic peptides and synthetic macrocyclic peptidomimetics that refine peptide structure and confer biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhn7uR358YLVg90H21EOLACvtfcHk0lhjSDo0RaL64g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGit77K&md5=77180acba388f5c2a0af461ce965b82a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201401058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201401058%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DT.%2BA.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DDiness%26aufirst%3DF.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DConstraining%2520cyclic%2520peptides%2520to%2520mimic%2520protein%2520structure%2520motifs%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D13020%26epage%3D13041%26doi%3D10.1002%2Fanie.201401058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelay-Gimeno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, T. N.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8896</span>– <span class="NLM_lpage">8927</span>, <span class="refDoi"> DOI: 10.1002/anie.201412070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201412070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=26119925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8896-8927&author=M.+Pelay-Gimenoauthor=A.+Glasauthor=O.+Kochauthor=T.+N.+Grossmann&title=Structure-based+design+of+inhibitors+of+protein-protein+interactions%3A+mimicking+peptide+binding+epitopes&doi=10.1002%2Fanie.201412070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes</span></div><div class="casAuthors">Pelay-Gimeno, Marta; Glas, Adrian; Koch, Oliver; Grossmann, Tom N.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8896-8927</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions (PPIs) are involved at all levels of cellular organization, thus making the development of PPI inhibitors extremely valuable.  The identification of selective inhibitors is challenging because of the shallow and extended nature of PPI interfaces.  Inhibitors can be obtained by mimicking peptide binding epitopes in their bioactive conformation.  For this purpose, several strategies have been evolved to enable a projection of side chain functionalities in analogy to peptide secondary structures, thereby yielding mols. that are generally referred to as peptidomimetics.  Herein, we introduce a new classification of peptidomimetics (classes A-D) that enables a clear assignment of available approaches.  Based on this classification, the Review summarizes strategies that have been applied for the structure-based design of PPI inhibitors through stabilizing or mimicking turns, β-sheets, and helixes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPTEmZpatXbrVg90H21EOLACvtfcHk0lhjSDo0RaL64g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOmu7rM&md5=447c84aab6275b1057fda9a610918f2b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201412070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201412070%26sid%3Dliteratum%253Aachs%26aulast%3DPelay-Gimeno%26aufirst%3DM.%26aulast%3DGlas%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGrossmann%26aufirst%3DT.%2BN.%26atitle%3DStructure-based%2520design%2520of%2520inhibitors%2520of%2520protein-protein%2520interactions%253A%2520mimicking%2520peptide%2520binding%2520epitopes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8896%26epage%3D8927%26doi%3D10.1002%2Fanie.201412070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bianco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Direct inhibition of the NOTCH transcription factor complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature08543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1038%2Fnature08543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=19907488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSjsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=182-188&author=R.+E.+Moelleringauthor=M.+Cornejoauthor=T.+N.+Davisauthor=C.+Del+Biancoauthor=J.+C.+Asterauthor=S.+C.+Blacklowauthor=A.+L.+Kungauthor=D.+G.+Gillilandauthor=G.+L.+Verdineauthor=J.+E.+Bradner&title=Direct+inhibition+of+the+NOTCH+transcription+factor+complex&doi=10.1038%2Fnature08543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Direct inhibition of the NOTCH transcription factor complex</span></div><div class="casAuthors">Moellering, Raymond E.; Cornejo, Melanie; Davis, Tina N.; Del Bianco, Cristina; Aster, Jon C.; Blacklow, Stephen C.; Kung, Andrew L.; Gilliland, D. Gary; Verdine, Gregory L.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">182-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Direct inhibition of transcription factor complexes remains a central challenge in the discipline of ligand discovery.  In general, these proteins lack surface involutions suitable for high-affinity binding by small mols.  Here the authors report the design of synthetic, cell-permeable, stabilized α-helical peptides that target a crit. protein-protein interface in the NOTCH transactivation complex.  The authors demonstrate that direct, high-affinity binding of the hydrocarbon-stapled peptide SAHM1 prevents assembly of the active transcriptional complex.  Inappropriate NOTCH activation is directly implicated in the pathogenesis of several disease states, including T-cell acute lymphoblastic leukemia (T-ALL).  The treatment of leukemic cells with SAHM1 results in genome-wide suppression of NOTCH-activated genes.  Direct antagonism of the NOTCH transcriptional program causes potent, NOTCH-specific anti-proliferative effects in cultured cells and in a mouse model of NOTCH1-driven T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hyuFJHX0T7Vg90H21EOLACvtfcHk0lgiXq_2X-kPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSjsr3F&md5=a12f19dd03303fd054e3052d7bbffd47</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature08543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08543%26sid%3Dliteratum%253Aachs%26aulast%3DMoellering%26aufirst%3DR.%2BE.%26aulast%3DCornejo%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DT.%2BN.%26aulast%3DDel%2BBianco%26aufirst%3DC.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDirect%2520inhibition%2520of%2520the%2520NOTCH%2520transcription%2520factor%2520complex%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D182%26epage%3D188%26doi%3D10.1038%2Fnature08543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1021/jm400887j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400887j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGnurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=278-295&author=F.+Giordanettoauthor=J.+Kihlberg&title=Macrocyclic+drugs+and+clinical+candidates%3A+what+can+medicinal+chemists+learn+from+their+properties%3F&doi=10.1021%2Fjm400887j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?</span></div><div class="casAuthors">Giordanetto, Fabrizio; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles are ideal in efforts to tackle difficult targets, but our understanding of what makes them cell permeable and orally bioavailable is limited.  Anal. of approx. 100 macrocyclic drugs and clin. candidates revealed that macrocycles are predominantly used for infectious disease and in oncol. and that most belong to the macrolide or cyclic peptide class.  A significant no. (N = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at mol. wts. up to and above 1 kDa and polar surface areas ranging toward 250 Å2.  Moreover, insight from a group of de novo designed oral macrocycles in clin. studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery.  However, the no. of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaeM2DXwvmiLVg90H21EOLACvtfcHk0lgiXq_2X-kPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGnurjI&md5=a3e1743bd5ba34f73d8e78f8cb1bee5f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm400887j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400887j%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DMacrocyclic%2520drugs%2520and%2520clinical%2520candidates%253A%2520what%2520can%2520medicinal%2520chemists%2520learn%2520from%2520their%2520properties%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D278%26epage%3D295%26doi%3D10.1021%2Fjm400887j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyaya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clippinger, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7602</span>– <span class="NLM_lpage">7606</span>, <span class="refDoi"> DOI: 10.1002/anie.201502763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2Fanie.201502763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=7602-7606&author=P.+Upadhyayaauthor=Z.+Qianauthor=N.+G.+Selnerauthor=S.+R.+Clippingerauthor=Z.+Wuauthor=R.+Briesewitzauthor=D.+Pei&title=Inhibition+of+Ras+signaling+by+blocking+Ras-effector+interactions+with+cyclic+peptides&doi=10.1002%2Fanie.201502763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras Signaling by Blocking Ras-Effector Interactions with Cyclic Peptides</span></div><div class="casAuthors">Upadhyaya, Punit; Qian, Ziqing; Selner, Nicholas G.; Clippinger, Sarah R.; Wu, Zhengrong; Briesewitz, Roger; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7602-7606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ras genes are frequently activated in human cancers, but the mutant Ras proteins remain largely "undruggable" through the conventional small-mol. approach owing to the absence of any obvious binding pockets on their surfaces.  By screening a combinatorial peptide library, followed by structure-activity relationship (SAR) anal., we discovered a family of cyclic peptides possessing both Ras-binding and cell-penetrating properties.  These cell-permeable cyclic peptides inhibit Ras signaling by binding to Ras-GTP and blocking its interaction with downstream proteins and they induce apoptosis of cancer cells.  Our results demonstrate the feasibility of developing cyclic peptides for the inhibition of intracellular protein-protein interactions and of direct Ras inhibitors as a novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs7bDEvBhzUbVg90H21EOLACvtfcHk0lgiXq_2X-kPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSrtrw%253D&md5=ad761df9481ab6b206b85ea63c1d1f29</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fanie.201502763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201502763%26sid%3Dliteratum%253Aachs%26aulast%3DUpadhyaya%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSelner%26aufirst%3DN.%2BG.%26aulast%3DClippinger%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBriesewitz%26aufirst%3DR.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Ras%2520signaling%2520by%2520blocking%2520Ras-effector%2520interactions%2520with%2520cyclic%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D7602%26epage%3D7606%26doi%3D10.1002%2Fanie.201502763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, A.</span>; <span class="NLM_string-name">Roskos, L.</span>; <span class="NLM_string-name">Klakamp, S.</span>; <span class="NLM_string-name">Liang, M.</span>; <span class="NLM_string-name">Arends, R.</span>; <span class="NLM_string-name">Green, L.</span></span> <span> </span><span class="NLM_article-title">Antibody Affinity</span>. In  <i>Handbook of Therapeutic Antibodies</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dübel, S.</span>, <span class="NLM_string-name">Reichert, J. M.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2014</span>; DOI: <span class="refDoi"> DOI: 10.1002/9783527682423.ch6</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1002%2F9783527682423.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Frenzel&author=L.+Roskos&author=S.+Klakamp&author=M.+Liang&author=R.+Arends&author=L.+Greenauthor=S.+D%C3%BCbel&author=J.+M.+Reichert&title=Handbook+of+Therapeutic+Antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2F9783527682423.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527682423.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DA.%26atitle%3DAntibody%2520Affinity%26btitle%3DHandbook%2520of%2520Therapeutic%2520Antibodies%26aulast%3DD%25C3%25BCbel%26aufirst%3DS.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2014%26doi%3D10.1002%2F9783527682423.ch6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span> <span> </span><span class="NLM_article-title">PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis</span>. <i>Cardiovasc. Hematol. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.2174/187152512800388939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2174%2F187152512800388939" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=154-166&author=D.+Kolteauthor=J.+W.+Bryantauthor=G.+W.+Gibsonauthor=J.+Wangauthor=Z.+Shariat-Madar&title=PF-04886847+%28an+inhibitor+of+plasma+kallikrein%29+attenuates+inflammatory+mediators+and+activation+of+blood+coagulation+in+rat+model+of+lipopolysaccharide+%28LPS%29-induced+sepsis&doi=10.2174%2F187152512800388939"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F187152512800388939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152512800388939%26sid%3Dliteratum%253Aachs%26aulast%3DKolte%26aufirst%3DD.%26aulast%3DBryant%26aufirst%3DJ.%2BW.%26aulast%3DGibson%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShariat-Madar%26aufirst%3DZ.%26atitle%3DPF-04886847%2520%2528an%2520inhibitor%2520of%2520plasma%2520kallikrein%2529%2520attenuates%2520inflammatory%2520mediators%2520and%2520activation%2520of%2520blood%2520coagulation%2520in%2520rat%2520model%2520of%2520lipopolysaccharide%2520%2528LPS%2529-induced%2520sepsis%26jtitle%3DCardiovasc.%2520Hematol.%2520Agents%2520Med.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D154%26epage%3D166%26doi%3D10.2174%2F187152512800388939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holsworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariat-Madar, Z.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1649</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01170.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fj.1476-5381.2010.01170.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=21175583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1639-1649&author=D.+Kolteauthor=J.+Bryantauthor=D.+Holsworthauthor=J.+Wangauthor=P.+Akbariauthor=G.+Gibsonauthor=Z.+Shariat-Madar&title=Biochemical+characterization+of+a+novel+high-affinity+and+specific+plasma+kallikrein+inhibitor&doi=10.1111%2Fj.1476-5381.2010.01170.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor</span></div><div class="casAuthors">Kolte, D.; Bryant, J. W.; Holsworth, D.; Wang, J.; Akbari, P.; Gibson, G. W.; Shariat-Madar, Z.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1639-1649</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Kallikrein acts on high mol. wt. kininogen (HK) to generate HKa (cleaved HK) and bradykinin (BK).  BK exerts its effects by binding to B2 receptors.  The activation of B2 receptors leads to the formation of tissue plasminogen activator, nitric oxide (NO) and prostacyclin (PGI2).  An elevated kallikrein-dependent pathway has been linked to cardiovascular disease risk.  This study investigated whether our the plasma kallikrein inhibitor PF-04886847 abolishes kallikrein-mediated generation of BK from HK and subsequent BK-induced NO and PGI2 formation, thereby influencing endothelial pathophysiol. during chronic inflammatory diseases.  Kinetic anal. was initially used to det. the potency of PF-04886847.  Biochem. ligand binding assays, immunol. methods and calcium flux studies were used to det. the selectivity of the kallikrein inhibitor.  In addn., the effect of PF-04886847 on BK-induced relaxation of the rat aortic ring was detd. in a model of lipopolysaccharide-induced tissue inflammation.  Evidence was obtained in vitro and in situ, indicating that PF-04886847 is a potent and specific inhibitor of plasma kallikrein.  PF-04886847 efficiently blocked calcium influx as well as NO and PGI2 formation mediated through the BK-stimulated B2 receptor signaling pathway.  PF-04886847 blocked kallikrein-induced endothelial-dependent relaxation of isolated rat aortic rings pre-contracted with phenylephrine.  PF-04886847 was shown to be the most potent small mol. inhibitor of plasma kallikrein yet described; it inhibited kallikrein in isolated aortic rings and cultured endothelial cells.  Overall, our results indicate that PF-04886847 would be useful for the treatment of kallikrein-mediated inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeQrmlqfpu9bVg90H21EOLACvtfcHk0ljVwU5Mul-WUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lurg%253D&md5=4140a9f24f3bd60663bfac5e552f3da6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01170.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01170.x%26sid%3Dliteratum%253Aachs%26aulast%3DKolte%26aufirst%3DD.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DHolsworth%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAkbari%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DG.%26aulast%3DShariat-Madar%26aufirst%3DZ.%26atitle%3DBiochemical%2520characterization%2520of%2520a%2520novel%2520high-affinity%2520and%2520specific%2520plasma%2520kallikrein%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1639%26epage%3D1649%26doi%3D10.1111%2Fj.1476-5381.2010.01170.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakri, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravitreal bevacizumab (Avastin)</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.ophtha.2007.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ophtha.2007.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=17467524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2s3lvVyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=855-859&author=S.+J.+Bakriauthor=M.+R.+Snyderauthor=J.+M.+Reidauthor=J.+S.+Pulidoauthor=R.+J.+Singh&title=Pharmacokinetics+of+intravitreal+bevacizumab+%28Avastin%29&doi=10.1016%2Fj.ophtha.2007.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravitreal bevacizumab (Avastin)</span></div><div class="casAuthors">Bakri Sophie J; Snyder Melissa R; Reid Joel M; Pulido Jose S; Singh Ravinder J</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">855-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin).  DESIGN:  Experimental animal study.  PARTICIPANTS:  Twenty Dutch-belted rabbits.  METHODS:  One eye of each of 20 rabbits was injected with 1.25 mg of intravitreal bevacizumab.  Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15, and 29.  Bevacizumab concentrations were measured in aqueous fluid, whole vitreous, and serum.  MAIN OUTCOME MEASURES:  Bevacizumab concentrations in the aqueous, vitreous, and serum.  RESULTS:  Whereas vitreous concentrations of bevacizumab declined in a monoexponential fashion with a half-life of 4.32 days, concentrations of >10 microg/ml bevacizumab were maintained in the vitreous humor for 30 days.  Bevacizumab concentrations in the aqueous humor of the injected eye reached a peak concentration of 37.7 microg/ml 3 days after drug administration.  A maximum serum concentration of 3.3 mug/ml was achieved 8 days after intravitreal injection and the concentration fell below 1 microg/ml 29 days after injection.  Elimination of bevacizumab from the aqueous humor and serum paralleled that found in the vitreous humor, with half-life values of 4.88 days and 6.86 days, respectively.  Very low concentrations of bevacizumab were detected in the fellow uninjected eye.  Concentrations of bevacizumab in the vitreous of the fellow eye varied incrementally, from 0.35 ng/ml at 1 day to 11.17 ng/ml at 4 weeks.  Concentrations of bevacizumab in the aqueous humor of the fellow eye reached their peak at 1 week, at 29.4 ng/ml, and declined to 4.56 ng/ml at 4 weeks.  CONCLUSION:  The vitreous half-life of 1.25 mg intravitreal bevacizumab is 4.32 days in a rabbit eye.  Very small amounts of bevacizumab were detected in the serum and in the fellow uninjected eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXZWkaQXyEAcjl5L8hwNX0fW6udTcc2ebU9_ejMHoXiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3lvVyhug%253D%253D&md5=682a220ca192f7a738ce5d3c8c78f651</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2007.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2007.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DBakri%26aufirst%3DS.%2BJ.%26aulast%3DSnyder%26aufirst%3DM.%2BR.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DPulido%26aufirst%3DJ.%2BS.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetics%2520of%2520intravitreal%2520bevacizumab%2520%2528Avastin%2529%26jtitle%3DOphthalmology%26date%3D2007%26volume%3D114%26spage%3D855%26epage%3D859%26doi%3D10.1016%2Fj.ophtha.2007.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakri, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzat, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of intravitreal ranibizumab (Lucentis)</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2179</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.ophtha.2007.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ophtha.2007.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=18054637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2sjisV2rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=2179-2182&author=S.+J.+Bakriauthor=M.+R.+Snyderauthor=J.+M.+Reidauthor=J.+S.+Pulidoauthor=M.+K.+Ezzatauthor=R.+J.+Singh&title=Pharmacokinetics+of+intravitreal+ranibizumab+%28Lucentis%29&doi=10.1016%2Fj.ophtha.2007.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of intravitreal ranibizumab (Lucentis)</span></div><div class="casAuthors">Bakri Sophie J; Snyder Melissa R; Reid Joel M; Pulido Jose S; Ezzat Mohamed K; Singh Ravinder J</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2179-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To describe the pharmacokinetics of 0.5 mg of intravitreal ranibizumab (Lucentis) and to compare it with that of 1.25 mg of intravitreal bevacizumab (Avastin), using the same rabbit model.  DESIGN:  Experimental animal study.  PARTICIPANTS:  Twenty-eight Dutch-belted rabbits.  METHODS:  One eye of each of 20 rabbits was injected with 0.5 mg of intravitreal ranibizumab.  Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15, and 29.  Ranibizumab concentrations were measured in aqueous fluid, whole vitreous, and serum.  A further 8 rabbits were used to measure serum and fellow ranibizumab at additional time points of 3 and 8 hours.  MAIN OUTCOME MEASURES:  Ranibizumab concentrations in the aqueous, vitreous, and serum.  RESULTS:  Although vitreous concentrations of ranibizumab declined in a monoexponential fashion with a half-life of 2.88 days, concentrations of >0.1 microg/ml ranibizumab were maintained in the vitreous humor for 29 days.  Ranibizumab concentrations in the aqueous humor of the injected eye reached a peak concentration of 17.9 microg/ml, 3 days after drug administration.  Elimination of ranibizumab from the aqueous humor paralleled that found in the vitreous humor, with a half-life value of 2.84 days.  No ranibizumab was detected in the serum or the fellow eye.  CONCLUSION:  In the rabbit, the vitreous half-life of 0.5-mg intravitreal ranibizumab is 2.88 days, shorter than the half-life of 1.25-mg intravitreal bevacizumab of 4.32 days.  No ranibizumab was detected in the serum or the fellow uninjected eye; whereas small amounts of intravitreal bevacizumab have been detected in the serum and fellow uninjected eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRjr64usV5p4YPsCkJIw00fW6udTcc2ebU9_ejMHoXiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjisV2rtA%253D%253D&md5=aaedf8b24518dafc2e4a34cd5864f009</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2007.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2007.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DBakri%26aufirst%3DS.%2BJ.%26aulast%3DSnyder%26aufirst%3DM.%2BR.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DPulido%26aufirst%3DJ.%2BS.%26aulast%3DEzzat%26aufirst%3DM.%2BK.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetics%2520of%2520intravitreal%2520ranibizumab%2520%2528Lucentis%2529%26jtitle%3DOphthalmology%26date%3D2007%26volume%3D114%26spage%3D2179%26epage%3D2182%26doi%3D10.1016%2Fj.ophtha.2007.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampol, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoszyk, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold-Bush, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieramici, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R. W.</span></span> <span> </span><span class="NLM_article-title">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1414264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1056%2FNEJMoa1414264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25692915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFaiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1193-1203&author=J.+A.+Wellsauthor=A.+R.+Glassmanauthor=A.+R.+Ayalaauthor=L.+M.+Jampolauthor=L.+P.+Aielloauthor=A.+N.+Antoszykauthor=B.+Arnold-Bushauthor=C.+W.+Bakerauthor=N.+M.+Bresslerauthor=D.+J.+Browningauthor=M.+J.+Elmanauthor=F.+L.+Ferrisauthor=S.+M.+Friedmanauthor=M.+Meliaauthor=D.+J.+Pieramiciauthor=J.+K.+Sunauthor=R.+W.+Beck&title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema&doi=10.1056%2FNEJMoa1414264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema</span></div><div class="casAuthors">Wells, John A.; Glassman, Adam R.; Ayala, Allison R.; Jampol, Lee M.; Aiello, Lloyd Paul; Antoszyk, Andrew N.; Arnold-Bush, Bambi; Baker, Carl W.; Bressler, Neil M.; Browning, David J.; Elman, Michael J.; Ferris, Frederick L.; Friedman, Scott M.; Melia, Michele; Pieramici, Dante J.; Sun, Jennifer K.; Beck, Roy W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1193-1203</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.  At 89 clin. sites, we randomly assigned 660 adults (mean age, 61 ± 10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants).  The study drugs were administered as often as every 4 wk, according to a protocol-specified algorithm.  The primary outcome was the mean change in visual acuity at 1 yr.  From baseline to 1 yr, the mean visual-acuity letter score (range, 0 to 100, with higher scores indicating better visual acuity; a score of 85 is approx. 20/20) improved by 13.3 with aflibercept, by 9.7 with bevacizumab, and by 11.2 with ranibizumab.  Although the improvement was greater with aflibercept than with the other two drugs (P<0.001 for aflibercept vs. bevacizumab and P = 0.03 for aflibercept vs. ranibizumab), it was not clin. meaningful, because the difference was driven by the eyes with worse visual acuity at baseline (P<0.001 for interaction).  When the initial visual-acuity letter score was 78 to 69 (equiv. to approx. 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with aflibercept, 7.5 with bevacizumab, and 8.3 with ranibizumab (P>0.50 for each pairwise comparison).  When the initial letter score was less than 69 (approx. 20/50 or worse), the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab (P<0.001 for aflibercept vs. bevacizumab, P = 0.003 for aflibercept vs. ranibizumab, and P = 0.21 for ranibizumab vs. bevacizumab).  There were no significant differences among the study groups in the rates of serious adverse events (P = 0.40), hospitalization (P = 0.51), death (P = 0.72), or major cardiovascular events (P = 0.56).  Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity.  When the initial visual-acuity loss was mild, there were no apparent differences, on av., among study groups.  At worse levels of initial visual acuity, aflibercept was more effective at improving vision.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2NCewqa7M7Vg90H21EOLACvtfcHk0lhFp2a74QgAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFaiu74%253D&md5=1f9154feae8fd36161a05f07fb7881bc</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1414264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1414264%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DGlassman%26aufirst%3DA.%2BR.%26aulast%3DAyala%26aufirst%3DA.%2BR.%26aulast%3DJampol%26aufirst%3DL.%2BM.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DAntoszyk%26aufirst%3DA.%2BN.%26aulast%3DArnold-Bush%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DC.%2BW.%26aulast%3DBressler%26aufirst%3DN.%2BM.%26aulast%3DBrowning%26aufirst%3DD.%2BJ.%26aulast%3DElman%26aufirst%3DM.%2BJ.%26aulast%3DFerris%26aufirst%3DF.%2BL.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DMelia%26aufirst%3DM.%26aulast%3DPieramici%26aufirst%3DD.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%2BK.%26aulast%3DBeck%26aufirst%3DR.%2BW.%26atitle%3DAflibercept%252C%2520bevacizumab%252C%2520or%2520ranibizumab%2520for%2520diabetic%2520macular%2520edema%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1193%26epage%3D1203%26doi%3D10.1056%2FNEJMoa1414264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Geniez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walshe, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darland, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span> <span> </span><span class="NLM_article-title">Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e3554</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0003554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1371%2Fjournal.pone.0003554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e3554&author=M.+Saint-Geniezauthor=A.+S.+Maharajauthor=T.+E.+Walsheauthor=B.+A.+Tuckerauthor=E.+Sekiyamaauthor=T.+Kuriharaauthor=D.+C.+Darlandauthor=M.+J.+Youngauthor=P.+A.+D%E2%80%99Amore&title=Endogenous+VEGF+is+required+for+visual+function%3A+evidence+for+a+survival+role+on+muller+cells+and+photoreceptors&doi=10.1371%2Fjournal.pone.0003554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0003554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0003554%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DMaharaj%26aufirst%3DA.%2BS.%26aulast%3DWalshe%26aufirst%3DT.%2BE.%26aulast%3DTucker%26aufirst%3DB.%2BA.%26aulast%3DSekiyama%26aufirst%3DE.%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DDarland%26aufirst%3DD.%2BC.%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DEndogenous%2520VEGF%2520is%2520required%2520for%2520visual%2520function%253A%2520evidence%2520for%2520a%2520survival%2520role%2520on%2520muller%2520cells%2520and%2520photoreceptors%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De3554%26doi%3D10.1371%2Fjournal.pone.0003554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Geniez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span> <span> </span><span class="NLM_article-title">An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18751</span>– <span class="NLM_lpage">18756</span>, <span class="refDoi"> DOI: 10.1073/pnas.0905010106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1073%2Fpnas.0905010106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18751-18756&author=M.+Saint-Geniezauthor=T.+Kuriharaauthor=E.+Sekiyamaauthor=A.+E.+Maldonadoauthor=P.+A.+D%E2%80%99Amore&title=An+essential+role+for+RPE-derived+soluble+VEGF+in+the+maintenance+of+the+choriocapillaris&doi=10.1073%2Fpnas.0905010106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0905010106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0905010106%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Geniez%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DSekiyama%26aufirst%3DE.%26aulast%3DMaldonado%26aufirst%3DA.%2BE.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26atitle%3DAn%2520essential%2520role%2520for%2520RPE-derived%2520soluble%2520VEGF%2520in%2520the%2520maintenance%2520of%2520the%2520choriocapillaris%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D18751%26epage%3D18756%26doi%3D10.1073%2Fpnas.0905010106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westenskow, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span> <span> </span><span class="NLM_article-title">Targeted deletion of Vegfa in adult mice induces vision loss</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">4213</span>– <span class="NLM_lpage">4217</span>, <span class="refDoi"> DOI: 10.1172/JCI65157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1172%2FJCI65157" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4213-4217&author=T.+Kuriharaauthor=P.+D.+Westenskowauthor=S.+Bravoauthor=E.+Aguilarauthor=M.+Friedlander&title=Targeted+deletion+of+Vegfa+in+adult+mice+induces+vision+loss&doi=10.1172%2FJCI65157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1172%2FJCI65157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65157%26sid%3Dliteratum%253Aachs%26aulast%3DKurihara%26aufirst%3DT.%26aulast%3DWestenskow%26aufirst%3DP.%2BD.%26aulast%3DBravo%26aufirst%3DS.%26aulast%3DAguilar%26aufirst%3DE.%26aulast%3DFriedlander%26aufirst%3DM.%26atitle%3DTargeted%2520deletion%2520of%2520Vegfa%2520in%2520adult%2520mice%2520induces%2520vision%2520loss%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4213%26epage%3D4217%26doi%3D10.1172%2FJCI65157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. K.</span></span> <span> </span><span class="NLM_article-title">Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1762</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2014.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.ajpath.2014.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=24709590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFalurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2014&pages=1752-1762&author=H.+Y.+Parkauthor=J.+H.+Kimauthor=C.+K.+Park&title=Neuronal+cell+death+in+the+inner+retina+and+the+influence+of+vascular+endothelial+growth+factor+inhibition+in+a+diabetic+rat+model&doi=10.1016%2Fj.ajpath.2014.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Cell Death in the Inner Retina and the Influence of Vascular Endothelial Growth Factor Inhibition in a Diabetic Rat Model</span></div><div class="casAuthors">Park, Hae-Young Lopilly; Kim, Jie Hyun; Park, Chan Kee</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1752-1762</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To inhibit vascular changes in diabetic retinopathy, inhibiting vascular endothelial growth factor (VEGF) has become a mainstay of the treatment of diabetic retinopathy.  However, its effects on neuronal cells remain to be elucidated.  We aimed to evaluate the effect of VEGF inhibition on neuronal cells in a streptozotocin-induced diabetic rat retina.  VEGF inhibition was performed by intravitreal VEGF-A antibody injection.  After anti-VEGF treatment, apoptosis in retinal ganglion cells (RGCs) increased, and novel apoptosis in amacrine and bipolar cells of the inner nuclear layer was obsd. by TUNEL staining.  Phosphorylated Akt expression was significantly higher in RGCs but was decreased in neuronal cells of the inner nuclear layer after anti-VEGF treatment by Western blot anal. and immunohistochem. staining.  These results demonstrate that VEGF inhibition significantly increased RGC apoptosis and neuronal cell apoptosis in the inner nuclear layer of a diabetic retina, which seems to consist primarily of amacrine and bipolar cells.  The phosphorylated Akt pathway, which plays a neuroprotective role via VEGF, was significantly affected by VEGF inhibition in the inner nuclear layer, suggesting that neurotrophic factor deprivation is the main mechanism for neuronal cell death after inhibiting VEGF.  The results of this study show that inhibiting VEGF may have detrimental effects on the apoptosis of neuronal cells in the inner layers of the diabetic retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1GWuYmut7WrVg90H21EOLACvtfcHk0lhFp2a74QgAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFalurk%253D&md5=6b215a525a52626b617a38e275eeb440</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2014.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2014.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BK.%26atitle%3DNeuronal%2520cell%2520death%2520in%2520the%2520inner%2520retina%2520and%2520the%2520influence%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520inhibition%2520in%2520a%2520diabetic%2520rat%2520model%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2014%26volume%3D184%26spage%3D1752%26epage%3D1762%26doi%3D10.1016%2Fj.ajpath.2014.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domigan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antanesian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Happel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziyad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Collado, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Bliek, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potente, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iruela-Arispe, M. L.</span></span> <span> </span><span class="NLM_article-title">Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2236</span>– <span class="NLM_lpage">2248</span>, <span class="refDoi"> DOI: 10.1242/jcs.163774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1242%2Fjcs.163774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=25956888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eiu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=2236-2248&author=C.+K.+Domiganauthor=C.+M.+Warrenauthor=V.+Antanesianauthor=K.+Happelauthor=S.+Ziyadauthor=S.+Leeauthor=A.+Krallauthor=L.+Duanauthor=A.+X.+Torres-Colladoauthor=L.+W.+Castellaniauthor=D.+Elashoffauthor=H.+R.+Christofkauthor=A.+M.+van+der+Bliekauthor=M.+Potenteauthor=M.+L.+Iruela-Arispe&title=Autocrine+VEGF+maintains+endothelial+survival+through+regulation+of+metabolism+and+autophagy&doi=10.1242%2Fjcs.163774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy</span></div><div class="casAuthors">Domigan, Courtney K.; Warren, Carmen M.; Antanesian, Vaspour; Happel, Katharina; Ziyad, Safiyyah; Lee, Sunyoung; Krall, Abigail; Duan, Lewei; Torres-Collado, Antoni X.; Castellani, Lawrence W.; Elashoff, David; Christofk, Heather R.; van der Bliek, Alexander M.; Potente, Michael; Iruela-Arispe, M. Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2236-2248</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Autocrine VEGF is necessary for endothelial survival, although the cellular mechanisms supporting this function are unknown.  Here, we show that - even after full differentiation and maturation - continuous expression of VEGF by endothelial cells is needed to sustain vascular integrity and cellular viability.  Depletion of VEGF from the endothelium results in mitochondria fragmentation and suppression of glucose metab., leading to increased autophagy that contributes to cell death.  Gene-expression profiling showed that endothelial VEGF contributes to the regulation of cell cycle and mitochondrial gene clusters, as well as several - but not all - targets of the transcription factor FOXO1.  Indeed, VEGF-deficient endothelium in vitro and in vivo showed increased levels of FOXO1 protein in the nucleus and cytoplasm.  Silencing of FOXO1 in VEGF-depleted cells reversed expression profiles of several of the gene clusters that were de-regulated in VEGF knockdown, and rescued both cell death and autophagy phenotypes.  Our data suggest that endothelial VEGF maintains vascular homeostasis through regulation of FOXO1 levels, thereby ensuring physiol. metab. and endothelial cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1WJch7FrCdLVg90H21EOLACvtfcHk0lh5pVmK1w4hBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eiu7jL&md5=e2f9b892f744ac1c1ea4d25ad6a2c8a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1242%2Fjcs.163774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.163774%26sid%3Dliteratum%253Aachs%26aulast%3DDomigan%26aufirst%3DC.%2BK.%26aulast%3DWarren%26aufirst%3DC.%2BM.%26aulast%3DAntanesian%26aufirst%3DV.%26aulast%3DHappel%26aufirst%3DK.%26aulast%3DZiyad%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKrall%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DTorres-Collado%26aufirst%3DA.%2BX.%26aulast%3DCastellani%26aufirst%3DL.%2BW.%26aulast%3DElashoff%26aufirst%3DD.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3Dvan%2Bder%2BBliek%26aufirst%3DA.%2BM.%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DIruela-Arispe%26aufirst%3DM.%2BL.%26atitle%3DAutocrine%2520VEGF%2520maintains%2520endothelial%2520survival%2520through%2520regulation%2520of%2520metabolism%2520and%2520autophagy%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26spage%3D2236%26epage%3D2248%26doi%3D10.1242%2Fjcs.163774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushbrooke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feener, E. P.</span></span> <span> </span><span class="NLM_article-title">Plasma kallikrein mediates vascular endothelial growth factor-induced retinal dysfunction and thickening</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2399</span>, <span class="refDoi"> DOI: 10.1167/iovs.15-18272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1167%2Fiovs.15-18272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2390-2399&author=A.+Clermontauthor=N.+Murugesanauthor=Q.+Zhouauthor=T.+Kitaauthor=P.+A.+Robsonauthor=L.+J.+Rushbrookeauthor=D.+M.+Evansauthor=L.+P.+Aielloauthor=E.+P.+Feener&title=Plasma+kallikrein+mediates+vascular+endothelial+growth+factor-induced+retinal+dysfunction+and+thickening&doi=10.1167%2Fiovs.15-18272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1167%2Fiovs.15-18272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.15-18272%26sid%3Dliteratum%253Aachs%26aulast%3DClermont%26aufirst%3DA.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRushbrooke%26aufirst%3DL.%2BJ.%26aulast%3DEvans%26aufirst%3DD.%2BM.%26aulast%3DAiello%26aufirst%3DL.%2BP.%26aulast%3DFeener%26aufirst%3DE.%2BP.%26atitle%3DPlasma%2520kallikrein%2520mediates%2520vascular%2520endothelial%2520growth%2520factor-induced%2520retinal%2520dysfunction%2520and%2520thickening%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2016%26volume%3D57%26spage%3D2390%26epage%3D2399%26doi%3D10.1167%2Fiovs.15-18272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span> <span> </span><span class="NLM_article-title">Solid phase synthesis of peptides containing the CH2NH peptide bond isostere</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/0196-9781(87)90174-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2F0196-9781%2887%2990174-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1987&pages=119-121&author=Y.+Sasakiauthor=D.+H.+Coy&title=Solid+phase+synthesis+of+peptides+containing+the+CH2NH+peptide+bond+isostere&doi=10.1016%2F0196-9781%2887%2990174-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0196-9781%2887%2990174-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0196-9781%252887%252990174-4%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DSolid%2520phase%2520synthesis%2520of%2520peptides%2520containing%2520the%2520CH2NH%2520peptide%2520bond%2520isostere%26jtitle%3DPeptides%26date%3D1987%26volume%3D8%26spage%3D119%26epage%3D121%26doi%3D10.1016%2F0196-9781%2887%2990174-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noppen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonteyn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waelkens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Smet, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhove, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inactivation of ocriplasmin in porcine vitreous</span>. <i>Biophys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165–166</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.bpc.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1016%2Fj.bpc.2012.03.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165%E2%80%93166&publication_year=2012&pages=30-38&author=F.+Aertsauthor=B.+Noppenauthor=L.+Fonteynauthor=R.+Deruaauthor=E.+Waelkensauthor=M.+D.+de+Smetauthor=M.+Vanhove&title=Mechanism+of+inactivation+of+ocriplasmin+in+porcine+vitreous&doi=10.1016%2Fj.bpc.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bpc.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpc.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DAerts%26aufirst%3DF.%26aulast%3DNoppen%26aufirst%3DB.%26aulast%3DFonteyn%26aufirst%3DL.%26aulast%3DDerua%26aufirst%3DR.%26aulast%3DWaelkens%26aufirst%3DE.%26aulast%3Dde%2BSmet%26aufirst%3DM.%2BD.%26aulast%3DVanhove%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520inactivation%2520of%2520ocriplasmin%2520in%2520porcine%2520vitreous%26jtitle%3DBiophys.%2520Chem.%26date%3D2012%26volume%3D165%25E2%2580%2593166%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.bpc.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M. W.</span></span> <span> </span><span class="NLM_article-title">Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1136/bjophthalmol-2011-300654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1136%2Fbjophthalmol-2011-300654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=22446028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38vptlartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2012&pages=1157-1158&author=M.+W.+Stewart&title=Aflibercept+%28VEGF+Trap-eye%29%3A+the+newest+anti-VEGF+drug&doi=10.1136%2Fbjophthalmol-2011-300654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug</span></div><div class="casAuthors">Stewart Michael W</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROCnGRd9t_6LGbPKh4T9eAfW6udTcc2ebiqTTOKz7z97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vptlartg%253D%253D&md5=2f6d06f34014117529ebffea0f35ec8e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1136%2Fbjophthalmol-2011-300654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjophthalmol-2011-300654%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DM.%2BW.%26atitle%3DAflibercept%2520%2528VEGF%2520Trap-eye%2529%253A%2520the%2520newest%2520anti-VEGF%2520drug%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2012%26volume%3D96%26spage%3D1157%26epage%3D1158%26doi%3D10.1136%2Fbjophthalmol-2011-300654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qaum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joussen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassessian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamis, A. P.</span></span> <span> </span><span class="NLM_article-title">VEGF-initiated blood-retinal barrier breakdown in early diabetes</span>. <i>Invest. Ophthalmol. Vis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=2408-2413&author=T.+Qaumauthor=Q.+Xuauthor=A.+M.+Joussenauthor=M.+W.+Clemensauthor=W.+Qinauthor=K.+Miyamotoauthor=H.+Hassessianauthor=S.+J.+Wiegandauthor=J.+Rudgeauthor=G.+D.+Yancopoulosauthor=A.+P.+Adamis&title=VEGF-initiated+blood-retinal+barrier+breakdown+in+early+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQaum%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJoussen%26aufirst%3DA.%2BM.%26aulast%3DClemens%26aufirst%3DM.%2BW.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DMiyamoto%26aufirst%3DK.%26aulast%3DHassessian%26aufirst%3DH.%26aulast%3DWiegand%26aufirst%3DS.%2BJ.%26aulast%3DRudge%26aufirst%3DJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DAdamis%26aufirst%3DA.%2BP.%26atitle%3DVEGF-initiated%2520blood-retinal%2520barrier%2520breakdown%2520in%2520early%2520diabetes%26jtitle%3DInvest.%2520Ophthalmol.%2520Vis.%2520Sci.%26date%3D2001%26volume%3D42%26spage%3D2408%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, S. J.</span></span> <span> </span><span class="NLM_article-title">Systemic administration of VEGF trap suppresses vascular leak and leukostasis in the retinas of diabetic rats</span>. <i>Invest. Ophthalmol. Vis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=446&author=J.+Caoauthor=H.+Songauthor=R.+A.+Renardauthor=Y.+Liuauthor=G.+D.+Yancopoulosauthor=S.+J.+Wiegand&title=Systemic+administration+of+VEGF+trap+suppresses+vascular+leak+and+leukostasis+in+the+retinas+of+diabetic+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DRenard%26aufirst%3DR.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DWiegand%26aufirst%3DS.%2BJ.%26atitle%3DSystemic%2520administration%2520of%2520VEGF%2520trap%2520suppresses%2520vascular%2520leak%2520and%2520leukostasis%2520in%2520the%2520retinas%2520of%2520diabetic%2520rats%26jtitle%3DInvest.%2520Ophthalmol.%2520Vis.%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. W.</span></span> <span> </span><span class="NLM_article-title">Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1953</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.2337/diabetes.47.12.1953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2337%2Fdiabetes.47.12.1953" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1998&pages=1953-1959&author=D.+A.+Antonettiauthor=A.+J.+Barberauthor=S.+Khinauthor=E.+Liethauthor=J.+M.+Tarbellauthor=T.+W.+Gardner&title=Vascular+permeability+in+experimental+diabetes+is+associated+with+reduced+endothelial+occludin+content%3A+vascular+endothelial+growth+factor+decreases+occludin+in+retinal+endothelial+cells.+Penn+State+Retina+Research+Group&doi=10.2337%2Fdiabetes.47.12.1953"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.47.12.1953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.47.12.1953%26sid%3Dliteratum%253Aachs%26aulast%3DAntonetti%26aufirst%3DD.%2BA.%26aulast%3DBarber%26aufirst%3DA.%2BJ.%26aulast%3DKhin%26aufirst%3DS.%26aulast%3DLieth%26aufirst%3DE.%26aulast%3DTarbell%26aufirst%3DJ.%2BM.%26aulast%3DGardner%26aufirst%3DT.%2BW.%26atitle%3DVascular%2520permeability%2520in%2520experimental%2520diabetes%2520is%2520associated%2520with%2520reduced%2520endothelial%2520occludin%2520content%253A%2520vascular%2520endothelial%2520growth%2520factor%2520decreases%2520occludin%2520in%2520retinal%2520endothelial%2520cells.%2520Penn%2520State%2520Retina%2520Research%2520Group%26jtitle%3DDiabetes%26date%3D1998%26volume%3D47%26spage%3D1953%26epage%3D1959%26doi%3D10.2337%2Fdiabetes.47.12.1953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2010.090398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.2353%2Fajpath.2010.090398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=20110406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2010&pages=1517-1524&author=J.+H.+Kimauthor=J.+H.+Kimauthor=H.+O.+Junauthor=Y.+S.+Yuauthor=K.+W.+Kim&title=Inhibition+of+protein+kinase+C+delta+attenuates+blood-retinal+barrier+breakdown+in+diabetic+retinopathy&doi=10.2353%2Fajpath.2010.090398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein kinase C δ attenuates blood-retinal barrier breakdown in diabetic retinopathy</span></div><div class="casAuthors">Kim, Jeong-Hun; Kim, Jin Hyoung; Jun, Hyoung-Oh; Yu, Young Suk; Kim, Kyu-Won</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1517-1524</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Vision loss in diabetic retinopathy is due to macular edema characterized by increased vascular permeability, which involves phosphorylation assocd. with activation of protein kinase C (PKC) isoforms.  Herein, we demonstrated PKC δ inhibition could prevent blood-retinal barrier breakdown in diabetic retinopathy.  Increased vascular permeability of diabetic retina was accompanied by a decrease of zonula occludens (ZO)-1 and ZO-2 expression.  In diabetic retina and advanced glycation end product-treated human retinal microvascular endothelial cells, vascular leakage and loss of ZO-1 and ZO-2 on retinal vessels were effectively restored or prevented with treatment of rottlerin, transfection of PKC-δ-DN, or siRNA for PKC δ.  Interestingly, PKC δ translocated from cytosol to membrane in advanced glycation end product-treated human retinal microvascular endothelial cells, which was blocked by PKC δ inhibition.  Taken together, PKC δ activation, related to its subcellular translocation, is involved in vascular permeability in response to diabetes, and inhibition of PKC δ effectively restores loss of tight junction proteins in retinal vessels.  Therefore, we suggest that inhibition of PKC δ could be an alternative treatment to blood-retinal barrier breakdown in diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZg-BNmQhE_7Vg90H21EOLACvtfcHk0liQgDVPVCgnsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOitr8%253D&md5=0446f56ed5a21e8cc4d5dca1940a1ac1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.090398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.090398%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DJun%26aufirst%3DH.%2BO.%26aulast%3DYu%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BW.%26atitle%3DInhibition%2520of%2520protein%2520kinase%2520C%2520delta%2520attenuates%2520blood-retinal%2520barrier%2520breakdown%2520in%2520diabetic%2520retinopathy%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D176%26spage%3D1517%26epage%3D1524%26doi%3D10.2353%2Fajpath.2010.090398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, G. J.</span></span> <span> </span><span class="NLM_article-title">Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">e31</span>– <span class="NLM_lpage">e37</span>, <span class="refDoi"> DOI: 10.1111/j.1755-3768.2011.02243.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1111%2Fj.1755-3768.2011.02243.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=e31-e37&author=Y.+H.+Kimauthor=Y.+S.+Kimauthor=G.+S.+Rohauthor=W.+S.+Choiauthor=G.+J.+Cho&title=Resveratrol+blocks+diabetes-induced+early+vascular+lesions+and+vascular+endothelial+growth+factor+induction+in+mouse+retinas&doi=10.1111%2Fj.1755-3768.2011.02243.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2011.02243.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2011.02243.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DRoh%26aufirst%3DG.%2BS.%26aulast%3DChoi%26aufirst%3DW.%2BS.%26aulast%3DCho%26aufirst%3DG.%2BJ.%26atitle%3DResveratrol%2520blocks%2520diabetes-induced%2520early%2520vascular%2520lesions%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520induction%2520in%2520mouse%2520retinas%26jtitle%3DActa%2520Ophthalmol.%26date%3D2012%26volume%3D90%26spage%3De31%26epage%3De37%26doi%3D10.1111%2Fj.1755-3768.2011.02243.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollanders, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hove, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergen, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandewalle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Pelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moons, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalmans, I.</span></span> <span> </span><span class="NLM_article-title">AMA0428, a potent rock inhibitor, attenuates early and late experimental diabetic retinopathy</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1080/02713683.2016.1183030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=10.1080%2F02713683.2016.1183030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=27399806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2nt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=260-272&author=K.+Hollandersauthor=I.+Van+Hoveauthor=J.+Sergeysauthor=T.+V.+Bergenauthor=E.+Lefevereauthor=N.+Kindtauthor=K.+Castermansauthor=E.+Vandewalleauthor=J.+van+Peltauthor=L.+Moonsauthor=I.+Stalmans&title=AMA0428%2C+a+potent+rock+inhibitor%2C+attenuates+early+and+late+experimental+diabetic+retinopathy&doi=10.1080%2F02713683.2016.1183030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy</span></div><div class="casAuthors">Hollanders, Karolien; Van Hove, Inge; Sergeys, Jurgen; Van Bergen, Tine; Lefevere, Evy; Kindt, Nele; Castermans, Karolien; Vandewalle, Evelien; van Pelt, Jos; Moons, Lieve; Stalmans, Ingeborg</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-272</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Purpose: Diabetic retinopathy (DR) is characterized by an early stage of inflammation and vessel leakage, and an advanced vasoproliferative stage.  Also, neurodegeneration might play an important role in disease pathogenesis.  The aim of this study was to investigate the effect of the Rho kinase (ROCK) inhibitor, AMA0428, on these processes.  Methods: The response to ROCK inhibition by AMA0428 (1 μg) was studied in vivo using the murine model for streptozotocin (STZ)-induced diabetes, focusing on early non-proliferative DR features and the oxygen-induced retinopathy (OIR) model to investigate proliferative DR.  Intravitreal (IVT) administration of AMA0428 was compared with murine anti-VEGF-R2 antibody (DC101, 6.2 μg) and placebo (H2O/PEG; 1C8).  Outcome was assessed by analyzing leukostasis using fluorescein isothiocyanate coupled Con A (FITC-ConA) and vessel leakage (bovine serum albumin conjugated with fluorescein isothiocyanate; FITC-BSA)/neovascularization and neurodegeneration by immunohistol. approaches (hematoxylin and eosin (H&E), terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL), Brn3a).  ELISA and Western blotting were employed to unravel the consequences of ROCK inhibition (1 μM AMA0428) on myosin phosphatase target protein (MYPT)-1 phosphorylation, endothelial nitric oxide synthase (eNOS) phosphorylation, and vascular endothelial growth factor (VEGF) levels in retinas of diabetic mice, on NF-κβ activity and ICAM-1 expression in endothelial cells (ECs).  Results: In vivo, AMA0428 significantly reduced vessel leakage and neovascularization, resp., in the STZ and OIR model, comparable to DC101 therapy.  Addnl., the ROCK inhibitor decreased neurodegeneration in both models and inhibited leukostasis by 30% (p < 0.05) in the STZ model (p < 0.05), while DC101 had no pos. effect on the outcome of these latter processes.  ROCK activity was upregulated in the diabetic retina and AMA0428 administration resulted in decreased phospho-MYPT-1, enhanced phospho-eNOS, and reduced VEGF levels.  In vitro, AMA0428 interfered with NF-κβ activity, thereby inhibiting ICAM-1 expression in ECs.  Conclusions: Targeting ROCK with AMA0428 effectively attenuated outcome in an early DR model (STZ) and a late vasoproliferative retinopathy model (OIR).  These findings make AMA0428 a promising candidate with an addnl. anti-inflammatory and neuroprotective benefit for DR patients, as compared with anti-VEGF treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtA6vdZwMgVLVg90H21EOLACvtfcHk0liSlDuA2E6WLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2nt7rK&md5=db46391819b768b0e93c52306f80f09d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F02713683.2016.1183030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02713683.2016.1183030%26sid%3Dliteratum%253Aachs%26aulast%3DHollanders%26aufirst%3DK.%26aulast%3DVan%2BHove%26aufirst%3DI.%26aulast%3DSergeys%26aufirst%3DJ.%26aulast%3DBergen%26aufirst%3DT.%2BV.%26aulast%3DLefevere%26aufirst%3DE.%26aulast%3DKindt%26aufirst%3DN.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DVandewalle%26aufirst%3DE.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26aulast%3DMoons%26aufirst%3DL.%26aulast%3DStalmans%26aufirst%3DI.%26atitle%3DAMA0428%252C%2520a%2520potent%2520rock%2520inhibitor%252C%2520attenuates%2520early%2520and%2520late%2520experimental%2520diabetic%2520retinopathy%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2017%26volume%3D42%26spage%3D260%26epage%3D272%26doi%3D10.1080%2F02713683.2016.1183030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i46"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01625">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_37406"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01625">10.1021/acs.jmedchem.7b01625</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figure of comparative plasma stability of <b>2b</b> and <b>2d</b>, table of bicyclic peptide names and their corresponding sequences (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_001.pdf">jm7b01625_si_001.pdf (151.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01625/suppl_file/jm7b01625_si_002.csv">jm7b01625_si_002.csv (0.99 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01625&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01625" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01625" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994ec158333da0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
